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ABSTRACT OF DISSERTATION 
  
A LIFE SPAN APPROACH TO THE RELATIONSHIP BETWEEN CHOLESTEROL, LATE 
ONSET ALZHEIMER’S DISEASE, AND COGNITIVE FUNCTIONING  
AMONG OLDER ADULTS 
 
There is evidence that cholesterol presents an important risk factor for Alzheimer’s disease (AD), 
but the direction of this relationship is modified by age.  High cholesterol during midlife and low 
cholesterol during late life are both associated with an increased risk for AD.   This dissertation 
research engaged a life span approach to study the relationship between cholesterol, AD and 
cognitive functioning among older adults.  The purpose of this research was to determine if 
trajectories of cholesterol from midlife through late life differ according to AD status and if these 
trajectories are associated with cognitive functioning during old age. 
 
This research employed a secondary analysis of cognitive, phenotypic and genetic data collected 
from subjects of the Framingham Heart Study (FHS) Original and Offspring Cohorts.  Aim One 
involved creating three summary scores of the FHS neuropsychological battery.  ROC analysis 
was used to determine which score best differentiated between cognitively normal, impaired and 
dementia subjects.  Aim Two used generalized additive mixed models to examine trajectories of 
total, HDL and total/HDL cholesterol ratio according to AD status in the Original Cohort.  Aim 
Three used mixed-effects models to examine the relationship between subject-specific trajectories 
of total cholesterol and cognition during old age.   
 
Aim One determined that a summary score that provided equal weight to each assessment in the 
FHS neuropsychological battery best differentiates between subjects classified as cognitively 
normal, cognitively impaired and dementia.  The findings from Aim Two indicated that there are 
subtle differences in the longitudinal trajectories of total, HDL and total/HDL ratio according to 
AD status.  The findings from Aim Three provide limited evidence for a relationship between 
subject-specific trajectories of total cholesterol and cognitive functioning later in life.  Older 
adults in the highest quartile for cognitive functioning had lower total cholesterol at 
approximately 55 years of age, but there were no differences in the mean trajectories of total 
cholesterol according to cognitive functioning later in life. 
 
The findings from this research suggest that older adults with high cognitive functioning have 
lower total cholesterol during midlife, but life span cholesterol trajectories do not appear to be 
associated with AD status or cognitive function.  
 
KEYWORDS: Life span, Cholesterol, Alzheimer’s Disease, Cognition, Older Adults  
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Chapter One: Introduction and Background 
 
On November 25, 1901, a 51-year-old woman named Auguste D was admitted to a 
German hospital with symptoms of impaired comprehension, memory, language and 
psychosocial skills, along with unpredictable behavior, paranoia and hallucinations (Maurer, 
Volk, & Gerbaldo, 1997).  An autopsy following her death in 1906 revealed that her brain was 
filled with abnormal proteins that had aggregated into plaques and tangles.  Auguste D’s 
physician from 1901 until her death was Dr. Alois Alzheimer, a psychiatrist and neuropathologist 
who documented the progression of her disease and, postmortem, observed the plaques and 
tangles in her brain.   
Over a century has passed since Alois Alzheimer first described the clinical and 
neuropathological characteristics of what would become known as Alzheimer’s disease (AD).  
Alzheimer’s initial reports, at first, attracted limited interest within the scientific community, but 
the past fifty years have included landmark discoveries on the biological underpinnings of AD, 
clinical and neuropathological characteristics of the disease, potential treatments, and genetic and 
environmental risk factors for AD.  These discoveries coincided with population aging and 
influential social and political events, such as the National Alzheimer’s Project Act (United States 
National Plan to Address Alzheimer's Disease, 2012), which have collectively contributed to 
increased public awareness of AD. 
Alzheimer’s disease is a complex disease with genetic, physiological, behavioral, social, 
and cultural factors all apparently contributing to the onset and progression of the disease.  
Declines in memory and difficulty recalling recently learned information are among the earliest 
observable symptoms of AD (Perry & Hodges, 1999).  However, biomarkers that signal changes 
in biological processes that likely play a causal role in the development of AD begin to deviate 
from normal many years before the onset of cognitive symptoms (Jack et al., 2013). The declines 
in memory and other cognitive domains, such as language and decision making, are followed by 
declines in physical functioning and behavioral changes (Mega, Cummings, Fiorello, & 
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Gornbein, 1996) that substantially reduce a person’s quality of life.  Older adults in the advanced 
stages of AD require assistance from family members or professional caregivers to perform 
routine activities such as bathing, eating, and dressing.  The increasing dependence on caregivers 
as the disease progresses has a substantial impact on the health of the individual who is providing 
care, and family caregivers are at an increased risk for depression (Pinquart & Sorensen, 2003), 
anxiety (Mahoney, Regan, Katona, & Livingston, 2005) and chronic stress (Russo, Vitaliano, 
Brewer, Katon, & Becker, 1995).  Alzheimer’s disease also has a significant impact at the societal 
level.  The estimated financial value of care provided by family members in 2010 for the U.S. 
was $202.6 billion (Thies & Bleiler, 2011) and the estimated total health care costs in 2010 for 
persons diagnosed with AD was between $157 billion and $215 billion (Hurd, Martorell, 
Delavande, Mullen, & Langa, 2013).          
The overall poor health of middle aged adults in the United States has received 
considerable media attention because the resources that are required to treat and manage chronic 
conditions, such as diabetes, hypertension and high cholesterol, have placed considerable strain 
on our healthcare system.  Medical advances have increased the life expectancy of people with 
chronic vascular conditions, but this may have significant implications during old age because 
poor vascular health during middle age has been linked with an increased risk for AD (Duron & 
Hanon, 2008).  Cholesterol is a marker and risk indicator for cardiovascular disease (Anderson, 
Odell, Wilson, & Kannel, 1991; Castelli et al., 1986), but cholesterol may also be an important 
risk factor for AD.  There is increasing evidence that supports the hypothesis that cholesterol is an 
important risk factor for AD.  Observational studies indicate that high cholesterol during midlife1 
increases the risk for AD (Kivipelto et al., 2001; Solomon, Kivipelto, Wolozin, Zhou, & 
Whitmer, 2009) and several genes involved in cholesterol transport and metabolism are 
                                                        
1 Midlife is typically defined as between the ages of 35 and 55 and late life is often defined as 
older than 65 years of age, but these definitions vary slightly from study to study.  The definitions 
of midlife and late life that will be used in the dissertation research are described in more detail in 
chapter three. 
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associated with AD, most notably the apolipoprotein E (APOE) gene (Corder et al., 1993; Crean 
et al., 2011; Olgiati, Politis, Papadimitriou, De Ronchi, & Serretti, 2011).  However, low 
cholesterol during late life and a decline in cholesterol from midlife to late life are both associated 
with an increased risk for AD (Reitz, Tang, Luchsinger, & Mayeux, 2004; Siest et al., 2000; 
Stewart, White, Xue, & Launer, 2007).  These seemingly conflicting findings suggest an age 
dependent relationship between cholesterol and AD.  This relationship can be further explored by 
examining longitudinal trajectories of cholesterol from midlife through late life. 
The remainder of this chapter first presents a broad overview of the modern history of 
AD research.  This review is meant to provide readers who are not familiar with AD research 
with sufficient background knowledge to appreciate the purpose and significance of this 
dissertation research.  This review includes a summary of landmark scientific discoveries that 
have shaped the current scientific understanding of AD, important social and political events that 
have increased the public awareness of AD, as well as research on the etiology, treatment and 
prevention of AD.  This chapter then introduces the life span research perspective, which served 
as the conceptual framework for the dissertation research, and summarizes the dissertation 
research by outlining the organization of the subsequent chapters of this dissertation.    
Alzheimer’s Disease Research: A Brief Historical Review 
 
 By the start of the 20th century, the term dementia was fairly well established in the 
scientific literature and several case reports of patients with the cognitive, behavioral, and 
neuropathological characteristics associated with dementia had been described (Berrios, 1990).  
The term Alzheimer’s disease, first used by Alois Alzheimer’s mentor Emil Kraepelin, would 
suggest that Alois Alzheimer had discovered a new disease.  However, Alzheimer did not make 
this claim and there is debate as to if Kraepelin chose the term for purely scientific reasons and 
believed Alzheimer’s had in fact identified a new disease or if there were personal motivations 
behind his decision [see Berrios (1990)] for a historical review of Kraepelin’s potential 
motivations for crediting Alois Alzheimer with discovering a new disease).  What made Auguste 
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D a unique case were the combination of clinical and neuropathological characteristics and the 
unusually young age of onset (Berrios, 1990).   
Alzheimer’s disease has been subdivided into early and late onset based on the age of 
diagnosis.  Early onset AD refers to cases that are diagnosed before 65 years of age, whereas late 
onset AD refers to cases that are diagnosed after 65 years of age or older.  Mutations in the APP 
(Nilsberth et al., 2001), PSEN1 (Uttner et al., 2010), and PSEN2 (Marchani et al., 2010) genes are 
known causes of early onset AD.  These genetic mutations are rare and early onset AD accounts 
for less than 5% of all cases of AD (Hebert, Scherr, Bienias, Bennett, & Evans, 2003).  Unlike 
early onset AD, there is no single gene or set of genes that ensures a person will develop late 
onset AD, but the APOE e4 allele is a genetic risk factor that has consistently been observed to 
increase the risk for AD (Bertram, McQueen, Mullin, Blacker, & Tanzi, 2007).  Auguste D’s 
young age of onset makes it likely that she had early onset AD, but there is no definitive evidence 
that Auguste D carried a genetic mutation for early onset AD.  In 2010, Yu et al. (2010) identified 
a modern-day German family residing in the Hesse region of Germany, the same region that 
Auguste D lived, with a family history of early onset AD and who carried a mutation in the 
PSEN2 gene.  This circumstantial evidence, along with the cognitive and neuropathological 
characteristics and the relatively young age in which her symptoms were observed, make it 
possible that Auguste D had early onset AD.   
 Relatively little research on AD was conducted in the decades following the initial 
discoveries by Alois Alzheimer in the early 1900s.  This was due largely in part to the limited 
funding for AD research and a lack of scientific interest in AD and aging research in general prior 
to the 1970s (Hodges, 2006; Morley, 2004).  The 1970s and 1980s marked a significant change in 
the scientific interest and public awareness of AD in possible response to the founding of the 
National Institute on Aging (NIA), the Alzheimer’s Association, and Alzheimer’s Disease 
Centers (ADC) at select academic institutions in the United States.  The NIA was founded in 
1974 with the purpose of studying the biological mechanisms of aging and aging related diseases 
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(Morley, 2004).  Soon after, in 1980, the Alzheimer’s Association was founded with support from 
the NIA.  The Alzheimer’s Association was started in an effort to compliment the mission of the 
NIA by focusing research on AD, educating the public about AD and giving support to families 
who were providing care for someone with AD.  Finally, in 1984 the NIA granted funding to 
Harvard University, Johns Hopkins University, Mount Sinai Medical School, the University of 
California San Diego and the University of Southern California to allow each institute to start an 
ADC.  One year later, five more institutions, which included Duke University, the University of 
Kentucky, Washington University at St. Louis, the University of Pittsburgh, and the University of 
Washington, were provided funding for ADCs.  There are currently twenty-nine ADCs in the 
United States and these Centers conduct focused research on understanding the etiology, 
progression, prevention and treatment of AD and other neurodegenerative diseases.  These 
Centers also make significant contributions to their respective communities by providing patients 
and their families with educational resources about dementia, family and patient support groups, 
and other resources (additional information can be accessed at the Alzheimer’s Disease Education 
and Referral Center http://www.nia.nih.gov/alzheimers).     
 The substantial increase in funding for research brought on by the founding of the NIA, 
Alzheimer’s Association, and ADCs, as well as an expected increase in dementia prevalence 
(Plum, 1979), all contributed to significant scientific discoveries in the 1970s and 1980s that have 
advanced scientific understanding of the biological underpinnings of AD.  Extensive research in 
the 1980s focused on determining the biological processes that allow humans to form new 
memories, and how these processes may be altered in older adults diagnosed with AD.  One of 
the most significant discoveries was reported in 1974 by Drachman & Levit, who determined that 
a chemical in the brain called acetylcholine plays an important role in the formation and retrieval 
of memories (Drachman & Leavitt, 1974).  In their study, Drachman & Leavitt examined healthy 
adults to determine if blocking acetylcholine in the brain impairs a person’s ability to form and 
retrieve recently learned information.  Healthy adults who received a drug that blocked 
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acetylcholine performed worse on a series of memory tests compared to those who did not 
receive the drug.  Furthermore, the memory performance of subjects who received the drug were 
consistent with the memory performance of older adults who received the same series of memory 
tests (Drachman & Leavitt, 1974).  These findings provided strong evidence that acetylcholine 
plays a crucial role in the formation and retrieval of memories and that a decrease in acetylcholine 
may contribute to the decline in memory that is observed to occur with age (Bartus, Dean, Beer, 
& Lippa, 1982).   Subsequent research revealed that the brains of older adults diagnosed with AD 
have significantly fewer neurons that produce and release acetylcholine compared to older adults 
without dementia (Lehericy et al., 1993; Whitehouse et al., 1982; Wright, Geula, & Mesulam, 
1993).  Collectively, these findings made acetylcholine an early target for drugs designed to treat 
patients with AD.  Early therapeutic treatments for AD were designed to target the decrease in 
acetylcholine by inhibiting the activity of the enzyme acetylcholinesterase, which breaks down 
acetylcholine (Soreq & Seidman, 2001).  Drugs that target this enzyme are called 
acetylcholinesterase inhibitors (AChEI).  This class of drugs makes up the majority of therapeutic 
treatments for AD that are currently approved by the Food and Drug Administration (FDA).  An 
example of an AChEI is tacrine, which was the first AD drug to enter large scale clinical trials in 
the United States (Summers, Majovski, Marsh, Tachiki, & Kling, 1986) and was the first 
pharmaceutical treatment to be approved by the FDA for the symptomatic treatment of mild to 
moderate AD (Summers, 2006).  There are currently five medications approved by the FDA that 
treat the symptoms of AD (Table 1.1).  Four of these medications (donepezil, galantamine, 
rivastigmine, and tacrine) are acetylcholinesterase inhibitors.     
The medication memantine targets a different chemical in the brain called glutamate.  
Glutamate plays an integral role in learning and memory (Riedel, Platt, & Micheau, 2003), but 
the presence of too much glutamate is harmful to neurons (Choi, 1992).  Under normal 
physiological conditions, glutamate and another chemical in the brain called glycine open a 
structure called an ion channel by binding to specific receptors on the channel.  Once the ion 
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channel has been opened, calcium and sodium are able to enter into the neuron.  The flow of 
sodium and calcium into the neuron is stopped once glycine and glutamate are removed from 
their receptors on the ion channel (Figure 1.1).  Neurons may become damaged in the presence of 
too much glutamate because the ion channels remain open for an extended period of time, which 
allows for calcium and sodium to over-stimulate the neuron.  This over-stimulation increases 
activity of specialized enzymes that breakdown structural proteins within a neuron and production 
of free radicals that break down the cell membrane, which ultimately leads to early death of 
neurons (Choi, 1988).  Memantine limits the amount of calcium and sodium that enters into the 
neuron by creating a physical barrier inside the ion channel (Figure 1.2).  Memantine has been 
shown to temporarily improve physical and cognitive functioning of patients diagnosed with 
severe AD (Reisberg et al., 2003; Winblad & Poritis, 1999).  Until recently, memantine was the 
only FDA approved medication for older adults in the advanced stages of AD (Cosman, Boyle, & 
Porsteinsson, 2007), but high doses of donepezil and rivastigmine have both shown efficacy for 
severe AD (Farlow, Grossberg, Sadowsky, Meng, & Somogyi, 2013; Farlow et al., 2010). 
Understanding Plaques and Tangles  
  
Alois Alzheimer described the characteristic plaques and tangles in 1906, but it was not 
until eighty years later that scientists were able to determine the composition of these two 
hallmark pathologies of AD.  In 1984, Glenner & Wong reported that they were able to 
successfully isolate and identify the amyloid beta (Aβ) protein, which aggregates to form neuritic 
plaques in the brain (Glenner & Wong, 1984).  Insoluble Aβ2 is produced when the amyloid 
precursor protein (APP) is cut sequentially by the enzymes β-secretase and γ-secretase (Pike et 
al., 2007).  In AD, there is an increase in β-secretase activity, which leads to an over production 
of insoluble Aβ in the brain.  These proteins stick together to form neuritic plaque (Sinha et al., 
1999), which is hypothesized to play a direct role in the decline in cognitive functioning 
                                                        
2 A soluble form of Aβ that does not aggregate into neuritic plaques is produced when APP is cut 
by α-secretase and γ-secretase.  
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consistent with AD because the build up of neuritic plaque disrupts neuronal function and leads, 
ultimately, to cell death (Geula et al., 1998). 
Soon after it was determined that neuritic plaques form from the aggregation of Aβ, 
scientists successfully identified the protein that makes up neurofibrillary tangles.  Several 
research groups published findings between 1986 and 1989 that indicated neurofibrillary tangles 
as comprised mostly of the protein tau (Grundke-Iqbal et al., 1986; Kosik, Joachim, & Selkoe, 
1986; J. G. Wood, Mirra, Pollock, & Binder, 1986).  Tau is an important protein that maintains 
the structural integrity of microtubules (Weingarten, Lockwood, Hwo, & Kirschner, 1975).  In 
AD, tau becomes saturated with the chemical phosphate in a process called phosphorylation 
(Goode, Drubin, & Barnes, 2000).  This causes tau to dissociate from microtubules (Ballatore, 
Lee, & Trojanowski, 2007) and bind together to form neurofibrillary tangles inside of neurons 
(Santa-Maria et al., 2012).  Microtubules are involved in the transportation of nutrients, 
molecules, and other materials within neurons (Goode et al., 2000) and neurons are unable to 
maintain normal physiological functioning once microtubules lose their structural integrity. 
Do Plaques and Tangles Cause Alzheimer’s Disease?   
 
Neuritic plaques and neurofibrillary tangles must both be present along with cognitive 
impairment to warrant a diagnosis of AD (Murayama & Saito, 2004).  However, there is debate 
among scientists as to if an abnormality in Aβ or tau is the primary cause of AD.  The amyloid 
cascade hypothesis proposes that changes in the processing of APP triggers the initial deposition 
of neuritic plaques and subsequent deposition of neurofibrillary tangles that both contribute to the 
loss of neurons in the brain and, ultimately, cognitive decline (Hardy & Higgins, 1992).  There is 
a large body of research that has produced evidence supporting the amyloid cascade hypothesis.  
First, mutations in genes that regulate the processing of APP are associated with early onset AD 
(Nilsberth et al., 2001; Rogaev et al., 1995; Sherrington et al., 1995).  Second, changes in the 
processing of APP and the accumulation of Aβ both occur before tau becomes phosphorylated 
and forms neurofibrillary tangles (Jack, Vemuri, et al., 2011; Jack et al., 2012).  Finally, there is 
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evidence that the presence of Aβ in the brain directly contributes to the phosphorylation of tau 
and subsequent formation of neurofibrillary tangles (Gotz, Schild, Hoerndli, & Pennanen, 2004; 
M. E. King et al., 2006), but the biological mechanisms that drive this relationship are not well 
understood (Armstrong, 2011; Ittner & Gotz, 2011).  The evidence for the amyloid cascade 
hypothesis has made Aβ and neuritic plaque a primary target of pharmaceutical treatments and 
preventions.    
Despite the strong support for the amyloid cascade hypothesis, there are important 
limitations that suggest the accumulation of Aβ may not be the primary cause of AD.  First, the 
severity of neuritic plaque accumulation in the brain is not a strong predictor of the degree of 
cognitive impairment among older adults diagnosed with AD (Giannakopoulos et al., 2003).  
Furthermore, it has been reported that in some instances older adults who exhibit normal 
cognitive functioning have Aβ accumulation in the brain consistent with AD (Bennett et al., 
2006; Knopman et al., 2003), while other investigators have reported severe cognitive impairment 
despite relatively low plaque accumulation among the oldest old3 (Haroutunian et al., 2008).  The 
second major limitation of the amyloid cascade hypothesis is that several therapies meant to 
decrease the amount of Aβ produced in the brain and prevent neuritic plaques from forming have 
not been shown to reverse or halt the progression of AD symptoms (Green et al., 2009; Siemers et 
al., 2010; Wilcock et al., 2008).  
An alternative explanation to the amyloid cascade hypothesis is that structural changes to 
tau and subsequent formation of neurofibrillary tangles is the primary cause of AD (Parihar & 
Hemnani, 2004).  This hypothesis has been referred to as the tau and tangle hypothesis (Mudher 
& Lovestone, 2002).  The tau and tangle hypothesis has received considerably less support from 
the scientific community compared to the amyloid cascade hypothesis, but tau plays an important 
role in the development of AD.  During the early stages of AD, neurofibrillary tangles begin to 
accumulate in regions of the brain involved in memory (Arriagada, Growdon, Hedley-Whyte, & 
                                                        
3 Oldest old was defined by Haroutunian et al. (2008) as subjects greater than 90 years of age.  
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Hyman, 1992; E. Braak, Braak, & Mandelkow, 1994) and spread to other regions of the brain as 
the disease progresses (H. Braak & Braak, 1991, 1995).  One of the strongest pieces of evidence 
for the tau and tangle hypothesis is there is a much stronger relationship between the severity of 
cognitive impairment and accumulation of neurofibrillary tangles compared to the amount of 
neuritic plaque in the brain (Arriagada et al., 1992; Ghoshal et al., 2002; Guillozet, Weintraub, 
Mash, & Mesulam, 2003; Mitchell et al., 2002; Nagy et al., 1995).  The tau and tangle hypothesis 
is not without its limitations; most notably that genetic mutations to the tau protein do not lead to 
AD.  Instead, genetic mutations in tau are known to cause frontotemporal dementia, which is 
characterized by damage to the frontal and temporal lobes of the brain and severe changes to 
personality, behavior, and language (McKhann et al., 2001). 
Causal relationships between the accumulation of neuritic plaques and neurofibrillary 
tangles and onset of cognitive and behavioral symptoms of AD have been difficult to establish 
and disappointing findings from clinical studies that have employed therapies that remove 
neuritic plaques and neurofibrillary tangles among older adults who are in the mild to moderate 
stages of AD have motivated criticism towards some AD hypotheses.  The collective strengths 
and limitations of both the amyloid cascade and tau and tangle hypothesis suggest that changes in 
an unknown biological pathway or pathways cause both the increased production of Aβ and 
phosphorylation of tau (Small & Duff, 2008).  The next steps for scientists are to identify 
biological pathways that when altered lead to an increased production of both Aβ and 
phosphorylated tau, and then determine if these biological pathways are potential therapeutic 
targets.  Current research is also focused on the pre-clinical stages of AD and investigating if 
administering disease modifying therapies to older adults who may be in the pre-clinical stages of 
AD have efficacy in delaying or preventing progression of AD. 
An Increase in Public Awareness of Alzheimer’s Disease 
 
Biomedical research attention along with growing federal funding targeting AD came at a 
time when population aging was becoming increasingly recognized as a social issue.  Retirement 
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migration was having profound impacts on the age structure of such places as Florida and 
Arizona (Bohland & Rowles, 1988; Litwak & Longino, 1987; A. Rogers & Watkins, 1987), and 
even the local population aging as a result of labor outmigration (Wiseman & Roseman, 1979) 
attracted public attention.  An increase in fertility following World War II, along with public 
health advances that dramatically affected mortality and life expectancy, brought elders into the 
public spotlight.  This lead to elders becoming a larger part of what the population saw each day 
and their unique needs also became more visible, and more contentious, to the American public.  
By the 1990’s, demographic changes in the United States had brought significant 
attention to the social implications of AD and the anticipated increase in AD prevalence during 
the coming decades was alarming to scientists and the general public.  A significant event in the 
public awareness of AD occurred on November 4, 1994 when President Ronald Reagan wrote a 
letter to the American public that announced he had been diagnosed with AD.  Even before his 
announcement, President Reagan had worked hard to increase awareness of AD.  In 1982 he, 
along with the Alzheimer’s Association, established the week of Thanksgiving as National 
Alzheimer’s Disease Awareness Week.  While President Reagan’s announcement immediately 
increased the awareness of AD among the general public, the disease was already widely 
recognized as a significant public health concern within the scientific community due to the 
anticipated increase in the prevalence4 of AD as the baby boomer generation advanced towards 
old age. 
In 1980, an estimated 2.88 million adults 65 years of age or older were living with AD 
(D. A. Evans, 1990).  This was approximately 11.3% of adults who were 65 years of age and 
over, but only 3.9% of adults between 65 and 74 years of age were estimated to have AD, 
whereas 16.4% of adults between the ages of 75 and 84, and 47.6% of adults 85+ were estimated 
                                                        
4 Prevalence is a measure that indicates the total number of people in a population with a specific 
disease.  
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to have AD.  Several studies that examined secular trends in the prevalence and incidence rate5 of 
dementia during the 1980’s, 1990’s and early 2000’s have provided evidence for a decline in 
dementia during this time period.  In one of the first studies to examine trends in AD incidence 
rate over time, Kokmen et al., (1993) observed a U shaped trend in the age and sex adjusted five 
year cumulative incidence6 of AD over a twenty-five year period beginning in 1960.  In this 
study, Kokmen and colleges observed that the cumulative incidence rate of AD from 1960-64 
was 74.8 cases per 100,000 people, which declined from 1965-69 to 59.6 cases/100,000 people.  
The decline in the cumulative incidence was followed by a steady increase from 1970-74 (75.2 
cases/100,000 people), 1975-79 (87.4 cases/100,000 people), which continued from 1980-84 
(94.8 cases/100,000 people).  A follow-up analysis conducted by Rocca et al., (2011), which 
included data collected from 1985-94 detected a small but statistically significant 3% decline per 
year in the cumulative incidence of AD during this period.  These findings (Rocca et al., 2011) 
are consistent with an earlier study conducted by Manton, Gu, and Ukraintseva (2005) in which 
the estimated prevalence of dementia in the U.S. decreased from 5.7% in 1982 to 2.9% in 1999.  
Finally, there is also evidence for a decreasing trend in the prevalence of mild cognitive 
impairment (MCI), which is often described as a transitional stage between normal cognitive 
aging and AD (Petersen, 2000, 2004), in the United States during the 1990’s and early 2000’s.  
Utilizing data from the Health and Retirement Study, Langa et al. (2008) observed that the 
prevalence of MCI from 1993 to 2002 among two different cohorts of adults 70 years of age and 
older declined from 5.2% (1993 cohort) to 3.5% (2002 cohort), and that the prevalence of older 
adults with cognitive impairment consistent with dementia declined from 7.0% (1993 cohort) to 
5.2% (2002 cohort).  Collectively, the decreasing trends for dementia, AD and cognitive 
                                                        
5 An incidence rate reflects the number of new cases of a disease per person in the at risk 
population over a specified period of time, typically ranging from days to a year.   
6 Cumulative incidence accounts for the number of new cases of a disease (i.e. incidence) 
reported in the at-risk population over a rather long period of time compared to the common 
incidence rate. Whereas the incidence rate allows examination of immediate disease trends, the 
cumulative incidence addresses overall impact of a disease and its spread. 
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impairment from 1980 to 2000 have been attributed to a greater proportion of older adults with 
high educational attainment, improved vascular health, increased physical activity and greater 
access to medical resources (Langa et al., 2008; Manton et al., 2005; Rocca et al., 2011).  The 
number of adults 65 years of age and older living with AD in the U.S. has increased during the 
past decade from approximately 4.5 million in 2000 (Hebert et al., 2003) to 4.7 million in 2010 
(Hebert, Weuve, Scherr, & Evans, 2013).  The increase in the number of older adults with AD is 
due largely in part to the growing segment of the population that is living well into old age.  
According to the U.S. Census, the number of adults 65 years of age and older increased from 35 
million in 2000 (Meyer, 2001) to 40 million in 2010 (Werner, 2011).  When the 2000 and 2010 
estimates for the number of AD cases reported by Hebert et al. are divided by the number of older 
adults living in the U.S. in 2000 and 2010, the percentage of adults 65 years of age and older with 
AD actually decreased slightly from 12.9% in 2000 to 11.8% in 2010.           
Since AD risk increases with advancing age, the aging of the baby boomers all but 
guarantees that the number of older adults diagnosed with AD will increase in the coming 
decades.  Many studies that have projected the future prevalence of AD estimate the number of 
older adults living with AD by 2050 will approach or exceed 10 million people (Brookmeyer, 
Gray, & Kawas, 1998; D. A. Evans et al., 1989; Hebert et al., 2003; Hebert et al., 2013).  
However, it is important to take into account changes in the secular trends of AD risk factors and 
how these changes may influence the future prevalence and incidence of AD.  Compared to 
previous generations, there is higher prevalence for obesity, diabetes and hypertension among 
baby boomers (D. E. King, Matheson, Chirina, Shankar, & Broman-Fulks, 2013), but the higher 
educational attainment (Day & Bauman, 2000), decreased prevalence of smoking (D. E. King et 
al., 2013) and better access to medical care (Freid & Bernstein, 2010) may make baby boomers 
less susceptible to AD.  There is concern, however, that the continued increase in obesity (Wang 
& Beydoun, 2007), diabetes (Mokdad et al., 2001) and hypertension (Ford, Giles, & Mokdad, 
 
 14 
2004) among young and middle aged adults may lead to an increase in the future prevalence and 
incidence of AD (Larson, Yaffe, & Langa, 2013).    
The Future of Alzheimer’s Disease Research 
   
Memantine and other FDA approved medications are designed to lessen the severity of 
AD symptoms but do not change the progression of the disease because these medications do not 
target the biological mechanisms believed to cause AD (Golde, Schneider, & Koo, 2011; Huang 
& Mucke, 2012).  Several disease-modifying therapies for AD that target Aβ or phosphorylated 
tau are currently in development (Table 1.2).  The majority of these therapies target Aβ by either: 
(1) altering the function of the enzymes that cut APP (Best et al., 2005; Eriksen et al., 2003); (2) 
preventing Aβ from aggregating into neuritic plaques (Gervais et al., 2007; McLaurin et al., 
2006); or (3) removing Aβ from the brain (Bard et al., 2000; DeMattos et al., 2001; Escribano et 
al., 2010).  There are other disease-modifying therapies that focus on other biological 
mechanisms that are believed to cause AD.  Two of these therapies are designed to target the tau 
protein.  The first prevents tau from becoming phosphorylated (Hong, Chen, Klein, & Lee, 1997) 
and the second prevents phosphorylated tau from aggregating into neurofibrillary tangles 
(Wischik, Edwards, Lai, Roth, & Harrington, 1996).  A third therapy is designed to maintain 
mitochondrial function in neurons (S. Zhang, Hedskog, Petersen, Winblad, & Ankarcrona, 2010).  
Mitochondria are structures found inside of cells that produce the main energy source used by 
cells (Freeman, 2008).  It has been hypothesized that a decrease in mitochondrial functioning with 
age contributes to the onset of AD and that maintaining mitochondrial functioning may prevent 
the cascade of biological events that culminate in AD (Swerdlow, Burns, & Khan, 2010; 
Swerdlow & Khan, 2004).   
A limited number of studies have reported that disease-modifying therapies improve 
cognitive functioning among patients diagnosed with mild to moderate AD.  Encouraging results 
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from animal models7 of AD for treatments that inhibit the aggregation of phosphorylated tau have 
been reported (Deiana, Harrington, Wischik, & Riedel, 2009) and a Phase II clinical trial 
demonstrated that patients with moderate AD who received the treatment had slower disease 
progression compared to patients who were given a placebo (Gura, 2008).  The findings from a 
randomized clinical trial of the drug nilvadipine, which is designed to modify the processing of 
APP and remove Aβ (Paris et al., 2011), indicated that mild AD patients in the treatment group 
exhibited less declines in overall cognitive functioning and executive functioning8 compared to 
AD patients who received a placebo (Kennelly et al., 2012).  A point must be made that this was 
an open-label study, which means that both the study investigators and participants were aware of 
which participants were in the control group and which were in the treatment group (Kennelly et 
al., 2012).  Finally, a Phase II9 clinical trial of the drug dimebon, which is designed to maintain 
mitochondrial function, indicated that treatment was associated with improved cognitive 
performance over a 26-week period among participants diagnosed mild to moderate AD relative 
to those who received a placebo (Doody et al., 2008).  While initial reports for the benefits of 
dimebon were promising, later clinical trials did not support these findings and dimebon did not 
move past phase III clinical trials.   
  Despite the encouraging results from some clinical trials and animal models of AD, the 
majority of Phase III clinical trials10 have produced discouraging results, with little to no 
observable benefits for cognitive functioning or overall quality of life (Extance, 2010; Gold et al., 
2010; Hampel et al., 2009; Salloway et al., 2009; Salloway et al., 2011; Siemers et al., 2010).  
                                                        
7 Scientists often use animals, such as mice or rats, when conducting research on biological 
mechanisms of disease or when developing new therapies.  These animals mimic the symptoms 
or pathologies of a particular disease and are used to eliminate the risk of harming human 
subjects.   
8 Executive functioning is the ability to manage several different cognitive tasks, such as memory, 
judgment, and decision-making.   
9 Phase II clinical trials include a large sample of patients to determine the effectiveness of the 
treatment and identify harmful side effects.   
10 Phase III clinical trials include a large sample of patients to confirm the effectiveness of the 
treatment and further identify harmful side effects. 
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The limited benefit of disease modifying therapies may be due to therapies being administered 
too late in the disease process when irreversible damage to the brain has already occurred (Roh & 
Holtzman, 2012).  Such results from drug trials suggest an urgency to develop methods to 
accurately identify older adults who may be in the preclinical stages of AD.  Identifying older 
adults in the pre-clinical stages of AD may increase the effectiveness of pharmaceutical 
interventions, and allow a longer time period for people to engage in behavioral changes and to 
begin planning for potential care needs.  But there are significant ethical implications that need to 
be considered.  An argument can be made that disclosing information to a person that they may 
be in the pre-clinical stages of AD could cause more harm than good because of the anxiety and 
fear brought on by the knowledge they will develop a disease that has no known cure.  Therefore, 
employing biomarkers to identify older adults with pre-clinical AD has valuable implications in 
research settings, but is unlikely to have significant clinical value until a cure for AD, or therapy 
that significantly slows or delays AD progression, is developed.  
There are five established biomarkers for AD that reflect AD pathology in the brain (Jack 
et al., 2010).  The accumulation of Aβ in the brain is indicated by a decrease of Aβ in 
cerebrospinal fluid (CSF; Andreasen et al., 1999) and detection of Aβ in the brain using imaging 
techniques (Klunk et al., 2004).  The loss of neurons in the brain is indicated by an increase in 
total and phosphorylated tau in the CSF (Andreasen, Vanmechelen, Vanderstichele, Davidsson, & 
Blennow, 2003), a decrease in glucose metabolism in the brain (Lowe et al., 2009), and cerebral 
atrophy (Dickerson et al., 2011).  These biomarkers accurately discriminate between older adults 
who may be in the preclinical stages of AD and older adults who maintain normal cognitive 
function (Shaw et al., 2009), but cost and physical discomfort are potential barriers to collecting 
these biomarkers.  These limitations have motivated research into detecting other biomarkers that 
may identify older adults who are in the preclinical stages of AD.  In a recent study (Mapstone et 
al., 2014), older adults who transitioned from normal cognition to impaired memory during a 
five-year period had lower concentrations for ten different phospholipids compared to older 
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adults who maintained normal cognition.  When an independent sample of older adults was 
examined, this biomarker profile was highly accurate in identifying older adults who went on to 
convert from normal cognition to impaired memory over a five-year period.  These results 
suggest that a biomarker profile obtained through a simple blood draw may be able to identify 
older adults who develop memory impairment before any cognitive impairment is observed.  The 
full implications of these findings will not become clear until additional research is conducted, 
but these findings are an important step forward in developing a blood test that accurately 
identifies older adults who may be in the preclinical stages of AD.  
Purpose and Objectives of Dissertation Research 
 
There is a clinical need for a marker that can be collected quickly and is relatively non-
invasive, such as a blood draw, that can be used to assess a person’s risk for AD long before 
cognitive symptoms are observed.  Mounting evidence for a relationship between cholesterol and 
AD strongly suggest that continued research in this area is warranted because cholesterol is 
routinely measured in clinical settings.  This dissertation research utilized data from the 
Framingham Heart Study (FHS) Original and Offspring Cohorts and engaged a life span 
approach to study how cholesterol trajectories relate to both AD diagnosis and cognitive 
functioning.  The purpose of this research was to determine if longitudinal trajectories of 
cholesterol from midlife through late life differ between older adults diagnosed with AD and 
those without dementia and, further, if these cholesterol trajectories are associated with cognitive 
functioning among older adults without dementia.  Participants in the FHS have received a 
comprehensive neuropsychological battery comprised of twelve cognitive assessments.  The 
ability of three different summary scores of the FHS neuropsychological battery to differentiate 
between subjects classified as having normal cognition, impaired cognition, and dementia was 
therefore investigated. 
The life span research approach emphasizes human development as an ongoing process 
from birth until death (Baltes, 1987).  The dissertation research focused on examining continuous 
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changes in cholesterol with age as opposed to treating midlife and late life as discrete life stages 
as has been frequently done in previous studies.  This allowed for potentially important changes 
in the trajectories of total cholesterol, HDL cholesterol and total/HDL ratio to be detected.  The 
FHS is a multigenerational study and this research utilized data from the Original and Offspring 
Cohorts.  The Offspring Cohort is comprised of subjects, and their spouses, who had at least one 
parent who participated in the Original Cohort.  Subjects recruited to participate in the FHS 
Original Cohort were between 28 and 74 years of age during the first clinical examination.  The 
FHS Offspring Cohort does include subjects who were as young as five years of age during the 
first clinical exam, but this Cohort has not been followed for a long enough period of time to 
allow for these subjects to reach what would be considered an old age.  Therefore, this research is 
limited in that only a segment of the life span can be studied at the individual level and potentially 
significant factors prior to middle age are unable to be examined.  This limitation needs to be 
acknowledged because childhood, adolescence and young adulthood are potentially important life 
stages that may influence AD risk and cognitive functioning later in life.  An analysis of 
biographies written by Catholic Nuns during their early 20’s conducted by Snowdon et al. (1996), 
for example, revealed that low idea density and low grammatical complexity were both associated 
with poor cognitive functioning nearly 60 years later.  Idea density and grammatical complexity 
were both positively correlated with educational attainment (Snowdon et al., 1996), which makes 
it plausible that educational experiences during childhood and adolescence may influence 
cognitive functioning during old age.  This explanation is supported by the findings from other 
studies that have identified low socioeconomic status during childhood to be associated with poor 
cognitive functioning during old age (Moceri et al., 2001; R. S. Wilson et al., 2005).  Childhood 
and adolescence play a significant role in health outcomes among middle-aged adults, and these 
early life stages may have lasting consequences for cognitive functioning during old age.  
Subsequent research is necessary to examine how genetic, physiological, behavioral and social 
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factors during childhood and young adulthood influence cholesterol during adulthood and if these 
early life factors modify the relationship between cholesterol and AD. 
Cholesterol is a vital molecule for healthy brain function (Mauch et al., 2001; Pfrieger, 
2003), but excess cholesterol has been hypothesized to be harmful to the brain by altering APP 
processing and increasing production of insoluble Aβ (Frears, Stephens, Walters, Davies, & 
Austen, 1999).  Furthermore, variations in genes that regulate cholesterol balance in the brain, 
such as CYP46A1 (Combarros, Infante, Llorca, & Berciano, 2004), ABCA1 (Katzov et al., 2004) 
and APOE (Corder et al., 1994; Corder et al., 1993) have all been observed to modify the risk for 
AD.  The blood brain barrier effectively prevents the exchange of cholesterol between the brain 
and the periphery (Bjorkhem & Meaney, 2004), which makes it unlikely that peripheral 
cholesterol (i.e. cholesterol outside of the brain) directly contributes to AD neuropathology.  
While clear biological mechanisms that explain the apparent relationship between peripheral 
cholesterol and AD remain unknown, there are several reasons why it is important to conduct 
research on longitudinal trajectories of cholesterol, AD and cognitive functioning.  First, the 
anticipated findings from the dissertation research may generate evidence that patterns of change 
in cholesterol from midlife to late life differ according to AD status and cognitive functioning 
later in life.  Second, the anticipated findings of the dissertation research may provide insight into 
the approximate age in which physiological changes associated with AD begin to occur.  Finally, 
the anticipated findings may open new avenues of research to determine if longitudinal 
trajectories of cholesterol can be used to identify individuals who are at an increased risk for AD 
before symptoms are observed. 
This dissertation is comprised of six chapters.  Chapter Two offers a comprehensive 
literature review from areas of research that influenced the dissertation research.  This literature 
review is meant to establish the background knowledge on the relationship between cholesterol 
and AD to establish necessary context for this study’s specific aims.  Chapter Three describes the 
life span as a conceptual research framework and how this framework was engaged in the 
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dissertation research.  Chapter Four describes in detail the methods utilized for each of the three 
specific aims, and Chapter Five presents the results of each specific aim.  Finally, Chapter Six 
summarizes the results generated by the dissertation research and discusses these findings within 
the context of previous research.  This chapter also describes the life course perspective and how 
applying this perspective to the study of AD and cognitive functioning later in life can contribute 
to future research.
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Therapy Mechanism Strengths Limitations 
Donepezil 
(Aricept™).   
Cholinesterase 
inhibitor 
Evidence that treatment 
slows the progression of 
cognitive impairment and 
physical decline for up to 
a year or more.  
Increased occurrences of adverse events, 
such as falls, urinary tract infection, 
pneumonia, and aggression, among 
patients who received 23 mg/d dose 
versus standard 10 mg/d dose. 
Galantamine 
(Reminyl™) 
Cholinesterase 
inhibitor 
Evidence that treatment 
maintains/improves 
behavioral changes 
associated with AD, 
which contributes to a 
decrease in self-reported 
caregiver burden.   
Treatment does not appear to be more 
effective for mild to moderate AD 
compared to previously FDA approved 
cholinesterase inhibitors (Mintzer & 
Kershaw, 2003). 
Rivastigmine 
(Exelon™) 
Cholinesterase 
inhibitor 
Treatment has been 
shown to be effective in 
moderately severe cases 
of AD.   
Side effects such as nausea and vomiting 
can be severe in some patients (Mimica 
& Presecki, 2009). 
Tacrine 
(Cognex™) 
Cholinesterase 
inhibitor 
Treatment has been 
shown to be beneficial for 
cognitive functioning, 
ability to perform ADL 
and overall quality of life.  
Treatment can be harmful to the liver 
(Watkins et al. 1994) due to multiple 
daily doses being required (Bentue-
Ferrer, Tribut, Polard, & Allain, 2003). 
Memantine 
(Ebixa™, 
Namenda™) 
Prevents NMDA 
receptors from 
functioning 
Treatment is able to 
delay/slow progression of 
cognitive decline, 
behavioral changes, and 
loss of ability to perform 
ADL. 
Side effects include incontinence, 
diarrhea, difficulty sleeping, and 
agitation. 
Table 1.1: FDA Approved Symptomatic Treatments for Alzheimer’s Disease 
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 Table 1.2: Disease Modifying Therapies for Alzheimer’s Disease 
 
 
Drug Mechanism Results 
Rosiglitazone Increases removal 
of Aβ from the 
brain. 
Evidence for a decline of Aβ in specific regions of the 
brain of mouse models of AD.  Effectiveness of 
treatment in humans may depend upon APOE 
genotype.  Improvement in cognitive functioning 
among APOE e4- AD patients, but no observable 
benefits for APOE e4+ AD patients. 
Semagacestat  Decreases γ-
secretase activity.   
Evidence that treatment significantly decreases Aβ 
production among patients with AD.  However, Elli 
Lilly halted the development of semagacestat because 
of significantly worse cognitive performance among 
AD patients compared to AD patients who received 
placebo.    
Tarenflurbil 
(Flurizan™) 
Decreases γ-
secretase activity. 
Limited to no evidence that treatment is able to delay 
or slow cognitive decline among patients with mild to 
moderate AD. 
Tramiprosate 
(Alzhemed™) 
Prevents Aβ from 
forming neuritic 
plaques.  
Evidence that treatment has short-term benefits for 
cognition, but treatment was not successful in a Phase 
III clinical trial.  Evidence that treatment may increase 
the deposition of phosphorylated tau in the brain. 
Scyllo-inositol  Prevents Aβ from 
forming neuritic 
plaques. 
Findings from a Phase II clinical did not support that 
Scyllo-inositol had a significant benefit for cognition 
compared to placebo in patients diagnosed with mild 
to moderate AD.  The two highest doses of Scyllo-
inositol were terminated due to an increased risk of 
death in the treatment group. 
Bapineuzumab Increases removal 
of Aβ from the 
brain. 
Evidence for a slower rate of cognitive decline among 
patients with mild to moderate AD who were APOE 
e4-, but not for patients who were APOE e4+.  Two 
Phase II clinical trials did not find bapineuzumab to be 
effective for patients with mild to moderate 
Alzheimer’s disease.  
Solanezumab Increases removal 
of Aβ from the 
brain. 
No observed benefit for cognitive functioning among 
patients with mild to moderate Alzheimer’s disease. 
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Figure 1.1: Flow of Calcium and Sodium Through an Ion Channel 
 
Charged particles pass through the lipid bilayer via protein structures called ion channels.  
Calcium and sodium cannot pass through the lipid bilayer when an ion channel is closed (1).  An 
ion channel opens when glutamate and glycine bind to specialized receptors (2).  Once the 
magnesium “cork” leaves the ion channel, calcium and sodium are able to enter the neuron (3).  
Eventually, glutamate and glycine are removed from their binding sites on the ion channel and the 
flow of calcium and sodium into the neuron is stopped (4).   
 
Figure 1.2:  Effects of Memantine on Flow of Calcium and Sodium Through Ion Channels 
 
 
During Alzheimer’s disease, it is hypothesized that excess glutamate causes the ion channel to 
remain open for too long.  This leads to an increase in the amount of sodium and calcium that 
enters into the neuron, which causes the neuron to become damaged or destroyed due to over 
stimulation.  Memantine prevents neurons from becoming damaged from over stimulation by 
blocking sodium and calcium from passing through an ion channel and into the neuron.  Sodium 
and calcium are able to pass through the ion channel once glycine and glutamate bind to their 
receptors on the ion channel (1).  However, memantine blocks sodium and calcium from entering 
into the neuron by creating a physical barrier in the ion channel (2). 
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Chapter Two: Review of the Literature 
 
This chapter comprehensively reviews literature from the areas of scholarship that 
contributed to this dissertation research.  Chapter Two is divided into three major sections.  
Section one is a broad overview of the exogenous and endogenous sources of cholesterol, how the 
body uses cholesterol, how the body maintains cholesterol homeostasis, age related changes to 
cholesterol, and the detrimental effects of abnormal levels of cholesterol on health.  It is not 
feasible to review all of these areas of research in detail, and section one is designed to provide 
only the necessary background knowledge for subsequent sections of this chapter and the 
dissertation research.  Section two is a literature review of epidemiological studies that have 
examined the relationship between cholesterol and AD.  This includes reviews of midlife and late 
life measures of total, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein 
(HDL) cholesterol and the change in these cholesterol measures with increasing age.  Section 
three is an overall summary of the literature presented in section two and describes how this 
research will contribute to the current scientific understanding of the relationship between 
cholesterol and AD, as well as cholesterol and cognitive functioning. 
Background 
 
There is a negative connotation associated with cholesterol among the general public due 
to the established relationship between high cholesterol and adverse health events, such as heart 
attack and stroke (Pancioli et al., 1998).  This perception is somewhat misguided because 
cholesterol is an essential molecule for healthy functioning of the human body.  The liver is the 
primary source of cholesterol for the body (van der Wulp, Verkade, & Groen, 2013), but animal 
based food products such as meat, eggs, and cheese are also significant sources of cholesterol 
(Ford & Capewell, 2013).  Cholesterol is necessary for maintaining the structural integrity of cell 
membranes (de Meyer & Smit, 2009) and is a precursor for several molecules that have important 
biological functions (Rezen, Rozman, Pascussi, & Monostory, 2011), including testosterone and 
estrogen, vitamin D, and bile salts, which aid in digestion. 
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Types of Cholesterol 
  
 Cholesterol is transported in the bloodstream by combining with specialized proteins to 
form lipoproteins.  The efficiency in which a lipoprotein travels through the bloodstream depends 
on the proportion of protein to cholesterol that comprises the lipoprotein.  There are three 
different lipoproteins that are commonly found in the body.  Lipoproteins that contain less protein 
in relation to cholesterol have a low density and do not travel through the bloodstream very 
efficiently.  These lipoproteins are commonly referred to as “bad” cholesterol because it can 
accumulate on the walls of blood vessels.  The primary function of LDL is to transport 
cholesterol from the liver through the bloodstream to be used by cells throughout the body 
(Goldstein & Brown, 2009).  Conversely, lipoproteins that contain more protein than cholesterol 
have a high density and travel more efficiently through the bloodstream than LDL.  These 
lipoproteins are commonly referred to as “good” cholesterol because they carry excess cholesterol 
in the bloodstream back to the liver where it is secreted into bile and eventually delivered to the 
intestine (C. J. Fielding & Fielding, 1995).  HDL and LDL are the two main lipoproteins that 
transport cholesterol to and from the liver, but a third lipoprotein called very-low density 
lipoprotein (VLDL) transports triglycerides along with cholesterol to cells where they are used 
for energy (Hussain, 2000).  Once VLDL has transported the triglycerides to a cell, it is converted 
to LDL (Havel, 1984).  Total cholesterol is the sum of HDL, LDL, and VLDL cholesterol that is 
found in the bloodstream. 
Maintaining Cholesterol Homeostasis 
 
Homeostasis is the constant internal state that is maintained by adjusting chemical, 
biological, and physiological processes in response to changes in the environment.  The body 
maintains cholesterol homeostasis by tightly regulating how much cholesterol the liver produces 
based on how much dietary cholesterol is consumed, how much cholesterol is removed from the 
bloodstream, and how much cholesterol is excreted from the body.  Cholesterol levels fall out of 
homeostasis if the biological mechanisms that regulate cholesterol synthesis, removal, or 
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excretion become disrupted or do not function properly.  Normative physiological changes in 
liver function and cholesterol absorption that occur with age contribute to disruption in 
cholesterol homeostasis (Schatz et al., 2001; Silbernagel et al., 2010; Strandberg, Gylling, Tilvis, 
& Miettinen, 2010; Tilvis, Valvanne, Strandberg, & Miettinen, 2011) 
Effects of Diet on Cholesterol Homeostasis:  There is not strong evidence that consuming 
a high cholesterol diet substantially increases the concentration of cholesterol in the bloodstream 
(Harman, Leeds, & Griffin, 2008; Katz et al., 2005; Mutungi et al., 2008).  This is because 
complex biological mechanisms regulate cholesterol synthesis and the liver increases or decreases 
the amount of cholesterol that is produced based on how much cholesterol is consumed in the diet 
(Brown & Goldstein, 1997).  For example, a person whose typical diet contains a lot of animal 
products will synthesize less cholesterol because the body is able to utilize dietary cholesterol, 
whereas a person whose typical diet contains a lot of plant based products, which do not contain 
cholesterol, will synthesize more cholesterol to meet the body’s needs (P. J. Jones et al., 1996; 
Sundram, French, & Clandinin, 2003).  Foods that are high in fat, specifically trans fat and 
saturated fat, such as red meat, fried and processed foods, and baked goods have a much greater 
impact on cholesterol levels in the bloodstream (Mensink & Katan, 1990; Mensink, Zock, Kester, 
& Katan, 2003).  Consuming foods that are high in fat increase LDL cholesterol and decrease 
HDL cholesterol (Mozaffarian, Katan, Ascherio, Stampfer, & Willett, 2006).  This means that 
there is more cholesterol being transported from the liver to cells throughout the body in the form 
of LDL cholesterol and less cholesterol being transported back to the liver in the form of HDL 
cholesterol resulting in a net increase in cholesterol.  
Absorption and Excretion of Cholesterol:  The small intestines play an important role in 
maintaining cholesterol homeostasis because they regulate cholesterol absorption and excretion 
from the body.  Cholesterol that is consumed in the diet is first absorbed by the intestines and is 
then transported to the liver where it is either used to make bile salts (J. Y. Chiang, 2004) or is 
distributed throughout the body as VLDL, which is subsequently converted into LDL cholesterol 
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(Havel, 1984).  There is considerable variability among humans in the percentage of dietary 
cholesterol that is absorbed by the intestines, which can range between 20 and 80 percent 
(Bosner, Lange, Stenson, & Ostlund, 1999; Sehayek et al., 1998; Sudhop et al., 2002).  Research 
suggests that genetics accounts for largest source of variability in cholesterol absorption (Berge et 
al., 2002; Gylling & Miettinen, 2002; Kesaniemi, Ehnholm, & Miettinen, 1987), but age related 
changes in cholesterol synthesis and absorption and the use of cholesterol-lowering medications 
also influence how much dietary cholesterol the intestines absorb.  These factors are summarized 
in subsequent sections of this chapter.  Cholesterol is removed from the body in feces either in its 
original form as cholesterol or in its modified form as bile salts (van der Wulp et al., 2013).   
Genetic Contributions to Cholesterol Homeostasis:  Several genes play an important role 
in the absorption, transport, and excretion of cholesterol (Bjorkhem & Eggertsen, 2001; Chawla, 
Repa, Evans, & Mangelsdorf, 2001; Keller et al., 2013).  The most pertinent of these genes to the 
dissertation research is apolipoprotein E (APOE).  APOE is located on chromosome 19 (Olaisen, 
Teisberg, & Gedde-Dahl, 1982) and encodes the apoE protein.  APOE includes three different 
variations or alleles, e2, e3, and e4.  All people inherit one allele from each parent resulting in one 
of six possible genotypes (e2/e2, e2/e3, e2/e4, e3/e3, e3/e4, and e4/e4).  Among Caucasians an 
estimated 78% of the APOE alleles are the e3 allele, whereas 15% are the e4 allele and the 
remaining 7% are the e2 allele (Plassman & Breitner, 1996).  The apoE protein is one of several 
proteins that transport dietary cholesterol and triglycerides through the bloodstream as VLDL and 
is also involved in the conversion of VLDL to LDL cholesterol and the absorption of dietary 
cholesterol by the small intestines (Hauser, Narayanaswami, & Ryan, 2011).  The apoE protein 
plays an important role in cholesterol homeostasis as indicated by the differences in cholesterol 
concentrations according to APOE genotypes.  Adults with the e3/e3 genotype tend to have lower 
cholesterol than adults with either the e3/e4 or e4/e4 genotypes, but higher cholesterol compared 
to adults with either the e2/e4, e2/e3 or e2/e2 genotypes (Boerwinkle & Utermann, 1988; 
Ehnholm, Lukka, Kuusi, Nikkila, & Utermann, 1986; C. E. Tan et al., 2003).   When 
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environmental factors such as high body mass index, high calorie diet and high blood sugar are 
also present, adults with the APOE e2/e2 genotype often develop type III hyperlipidemia (de Beer 
et al., 2002; Mahley, Huang, & Rall, 1999); a rare condition that is characterized by abnormally 
high concentrations of chylomicrons in the bloodstream, which are another lipoprotein that 
transports triglycerides to cells (Hussain, 2000). 
The relationship between the gene APOE and cholesterol is important to the dissertation 
research because the APOE e4 allele is the most widely recognized genetic risk factor for late 
onset AD.  The APOE e4 allele was first reported to be linked to AD by Pericak-Vance et al. 
(1988).  Subsequent research conducted by Saunders et al., (1993) and Strittmatter et al. (1993) 
indicated that the APOE e4 allele frequency was significantly higher in AD cases compared to 
controls.  Finally, Corder et al. (1993) reported that compared to subjects with no APOE e4 
alleles, those who carried one APOE e4 allele were nearly three times as likely to develop AD 
and subjects with two APOE e4 alleles were eight times as likely to develop AD.  Also, the 
average age of AD diagnosis decreased with the presence of each APOE e4 allele.  The average 
age of diagnosis for subjects with no APOE e4 alleles was 85 years, those with one APOE e4 
allele was 75 years, and subjects with two APOE e4 alleles was 68 years (Corder et al., 1993).      
    Cholesterol-Lowering Medications: There are several different cholesterol-lowering 
medications that are commonly prescribed for the treatment of high cholesterol (Table 2.1).  The 
most well known class of these medications is HMG-CoA reductase inhibitors, more commonly 
known as statins.  Statins lower the concentration of cholesterol in the bloodstream by decreasing 
the amount of cholesterol produced by the liver.  Cholesterol is synthesized by the liver through a 
series of complex steps regulated by the enzyme HMG-CoA reductase (Goldstein & Brown, 
1984).  Statins lower the concentration of cholesterol in the bloodstream by limiting the function 
of HMG-CoA reductase to decrease cholesterol synthesis by the liver (Istvan & Deisenhofer, 
2001).  Statins are an effective therapy for lowering high LDL cholesterol and high triglycerides 
(P. Jones, Kafonek, Laurora, & Hunninghake, 1998).  However, statins are not able to lower 
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cholesterol to a healthy level in all adults with high cholesterol.  In these instances a physician 
may prescribe another cholesterol lowering medication in addition to a statin and dietary changes, 
the combination of which is an effective method to lower cholesterol.   
   Other classes of cholesterol-lowering medications include niacin, resins, fibrates, and 
selective cholesterol absorption inhibitors.  The benefits of niacin for cholesterol levels were first 
reported in 1955 (Altschul, Hoffer, & Stephen, 1955).  Niacin, also known as nicotinic acid, is a 
type of B vitamin that effectively increases the amount of HDL cholesterol in the bloodstream by 
decreasing the uptake of HDL cholesterol by the liver (L. H. Zhang, Kamanna, Zhang, & 
Kashyap, 2008).  Resins are a second class of cholesterol lowering medication that increases the 
synthesis of HDL cholesterol, but also decreases LDL cholesterol (Davidson et al., 1999; Insull et 
al., 2001).  Resins improve LDL cholesterol levels by decreasing the amount of bile that is 
reabsorbed by the small intestines during the digestive process.  This requires the liver to increase 
the amount of cholesterol that is converted into bile salts (Sheng, Otani, Brown, & Goldstein, 
1995).  The fourth class of cholesterol lowering medications is fibrates.  These therapies lower 
triglycerides and increase HDL cholesterol (Rubins et al., 1999) by decreasing the liver’s 
synthesis of triglycerides while increasing HDL synthesis (Staels et al., 1998).  The final class of 
cholesterol lowering medications is selective cholesterol absorption inhibitors.  These therapies 
lower LDL cholesterol by decreasing the amount of dietary cholesterol that is absorbed by the 
small intestines (Altmann et al., 2004; Ballantyne et al., 2003; Kastelein et al., 2008).  All five 
classes of cholesterol lowering medications are generally well tolerated by patients and common 
side effects include flushing of the skin, headache, constipation, and dizziness (Beltowski, 
Wojcicka, & Jamroz-Wisniewska, 2009; Bissonnette et al., 2006; Davidson et al., 1999; Goldberg 
et al., 2000; Jeng et al., 1997).  However, rhabdomyolysis, which is severe muscle inflammation, 
is a rare but serious side effect of statins (P. H. Jones & Davidson, 2005).  
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Age Related Changes to Cholesterol  
 
Longitudinal studies indicate that total, HDL, and LDL cholesterol all tend to increase 
with age among young and middle age adults and decline with age later in life (Carroll et al., 
2005; Ferrara, Barrett-Connor, & Shan, 1997; P. W. Wilson, Anderson, Harris, Kannel, & 
Castelli, 1994).  There are several factors that contribute to the age related changes in cholesterol.  
The most consistent predictors for an increase in total and LDL cholesterol among young and 
middle aged adults are consuming a high fat diet (Johansson et al., 2012) and weight gain (Ferrara 
et al., 1997).  The decline in cholesterol among older adults coincides with weight loss, a decrease 
in body fat, and the use of statins and other cholesterol lowering medications (Carroll et al., 
2005).  Previous studies have reported that the effect of age on cholesterol among older adults 
remains significant even after adjusting for changes in diet, physical activity and the use of statins 
and other lipid lowering medications (P. W. Wilson et al., 1994).  This indicates that additional 
factors influence the decline in cholesterol among older adults.  One such factor is hormone 
differences between men and women.  Young and middle-aged women tend to have higher HDL 
cholesterol and lower total and LDL cholesterol compared to men but these differences become 
less apparent with increasing age (Jousilahti, Vartiainen, Tuomilehto, & Puska, 1999).  Women 
have a more desirable lipid profile earlier in life because the hormone estrogen regulates 
cholesterol levels (Lundeen, Carver, McKean, & Winneker, 1997).  As women age, total and 
LDL cholesterol tend to increase and HDL cholesterol decreases due to a decline in estrogen 
production preceding menopause (Matthews et al., 2009; Stevenson, Crook, & Godsland, 1993).  
Postmenopausal women with other risk factors for cardiovascular disease may begin estrogen 
replacement therapy (ERT) to improve their cholesterol levels and decrease their risk for 
cardiovascular disease (Stampfer et al., 1991).  Estrogen replacement therapy may be prescribed 
for men diagnosed with prostate cancer (Ho, Lee, Lam, & Leung, 2011) but ERT is not used to 
control high cholesterol among men.  There is evidence from comparable studies examining the 
relationship between testosterone and cholesterol levels among men that a decline in testosterone 
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with advancing age coincides with an increase in triglycerides and decrease in HDL cholesterol 
(Barrett-Connor, 1995; Zmuda et al., 1997).  Supplementation of endogenous testosterone, 
however, has not been consistently observed to improve the lipid profile among men (Meriggiola, 
Marcovina, Paulsen, & Bremner, 1995; Zgliczynski et al., 1996). 
The decline in cholesterol with increasing age among older adults observed in 
longitudinal studies may be the result of a survivor effect in which subjects at an increased risk 
for mortality due to diseases caused by elevated cholesterol die and subjects with healthy 
cholesterol levels remain in a study into old age (Bilheimer, 1991).  While this certainly needs to 
be taken into consideration, the decline in cholesterol synthesis by the liver and decline in the 
amount of dietary cholesterol absorbed by the intestines plays a significant part in the decline of 
cholesterol later in life.  This was demonstrated in a study conducted by Tilvis et al. (2011) in 
which older adults exhibited a decline in the concentrations of lathosterol, which reflects 
cholesterol synthesis (Kempen, Glatz, Gevers Leuven, van der Voort, & Katan, 1988) and 
sitosterol, which reflects cholesterol absorption (Miettinen, Tilvis, & Kesaniemi, 1990) along 
with a decline in total cholesterol with increasing age.  These findings replicate those from earlier 
studies (Schatz et al., 2001; Silbernagel et al., 2010; Strandberg et al., 2010) and may reflect an 
overall decline in biological functioning with age that decreases the body’s ability to maintain 
cholesterol homeostasis. 
Cholesterol and Cardiovascular Health 
  
 A lipid profile test is often included as part of a routine medical exam and involves taking 
a blood sample to estimate how much total cholesterol, HDL cholesterol, LDL cholesterol, and 
triglycerides are in the blood.  Current guidelines recommend that a lipid profile test be 
performed after an eight to twelve hour fast (Grundy et al., 2004) because the concentration of 
triglycerides in the blood increases after consuming a high fat meal (B. A. Fielding et al., 1996).  
A physician is able to use the results from a lipid profile test along with additional health 
information, such as age and family health history, to estimate a person’s risk for different 
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cardiovascular diseases.  According to the National Cholesterol Education Program's Adult 
Treatment Panel III guidelines, total cholesterol should not exceed 200 mg/dl, LDL cholesterol 
should not exceed 100 mg/dl, and HDL cholesterol should not be below 40 mg/dl for men and 50 
mg/dl for women (Grundy et al., 2004).  Triglyceride levels should not exceed 150 mg/dl 
(Grundy et al., 2004).  Based on data from the National Health and Nutrition Examination Survey 
(NHANES), the percentage of adults between the ages of 40 and 74 with high LDL cholesterol 
has declined from 59% between 1976-1980 to 27% between 2007-2010 (Kuklina, Carroll, Shaw, 
& Hirsch, 2013).  This decline is due largely to the increasing trend in the number of Americans 
who have been prescribed cholesterol-lowering medications during the same time period 
(Kuklina et al., 2013).  Maintaining healthy levels of cholesterol is still a significant public health 
concern because adults with high LDL cholesterol or low HDL cholesterol are at a substantial 
risk for atherosclerosis (Assmann, Cullen, & Schulte, 2002), condition described by a hardening 
and narrowing of arteries due to accumulation of fatty deposits inside the arterial wall (Berliner et 
al., 1995).  If left untreated the fatty deposits will increase in size and substantially restrict blood 
flow, which may lead to a heart attack or stroke (Lloyd-Jones et al., 2009).  Maintaining healthy 
levels of HDL cholesterol decreases the risk for atherosclerosis because HDL is able to remove 
cholesterol from fatty deposits and bring it back to the liver (von Eckardstein, Nofer, & Assmann, 
2001).   
Cholesterol and the Brain 
 
The brain is a cholesterol rich organ and contains up to 30 percent of all the cholesterol 
found in the human body (Reitz, 2013).  Dietary cholesterol and cholesterol that is synthesized by 
the liver does not contribute to the cholesterol that is found in the brain because the blood-brain 
barrier prevents the exchange of cholesterol between the bloodstream and the brain (Dietschy & 
Turley, 2001).  Instead, specialized cells in the brain called oligodendrocytes and astrocytes are 
responsible for synthesizing nearly all of the cholesterol found in the brain (Bjorkhem & Meaney, 
2004).  Neurons are also capable of synthesizing cholesterol, but in much smaller amounts 
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(Funfschilling, Saher, Xiao, Mobius, & Nave, 2007).  Oligodendrocytes need to synthesize large 
amounts of cholesterol because they use cholesterol to produce myelin (Jurevics & Morell, 1995), 
which is essential for the normal functioning of the brain and other parts of the nervous system.  
Myelin insulates the axons of certain nerve cells similar to the insulating cover that surrounds a 
wire and allows for electrical impulses to travel quickly along a nerve cell (Sherman & Brophy, 
2005).  The cholesterol that is synthesized by astrocytes is transported to neurons where it is then 
incorporated into the cell membrane (Bjorkhem, 2006).               
    Oligodendrocytes and astrocytes synthesize cholesterol using the same biological 
pathway as the liver (Maioli et al., 2013).  Oligodendrocytes synthesize a limited amount of 
cholesterol in utero because very little myelination occurs in the brain during the fetal stage of 
development (Dietschy & Turley, 2004)11.  The rate of cholesterol synthesis in the brain increases 
following birth and remains high up until young adulthood at which point the rate of synthesis 
begins to decline as the brain becomes fully developed (Dietschy & Turley, 2004).  While the 
brain needs to synthesize cholesterol to maintain normal physiological functioning, it is important 
that excess cholesterol is removed from the brain.  The brain maintains cholesterol homeostasis 
by modifying the structure of cholesterol into a form that is able to pass through the blood brain 
barrier (Lutjohann et al., 1996).  The inability to adequately modify the structure of cholesterol 
and remove it from the brain is linked to several neurodegenerative diseases, including AD 
(Casserly & Topol, 2004), Parkinson’s disease (Vance, 2012), and Huntington’s disease 
(Karasinska & Hayden, 2011). 
                                                        
11 Children who do not synthesize an adequate amount of cholesterol by the liver and the brain in 
utero and during the first few years of life exhibit developmental, physical, and neurological 
abnormalities.  Smith–Lemli–Opitz syndrome (SLOS) is a genetically inherited cholesterol 
deficiency syndrome that is caused by a defect in the enzyme that converts 7-dehydrocholesterol 
into cholesterol during the final step of the cholesterol synthesis pathway (Fitzky et al., 1998).  
The number of live births that are diagnosed with SLOS is estimated to be between 1 in 2,100 and 
1 in 19,000 (Battaile, Battaile, Merkens, Maslen, & Steiner, 2001).  Children diagnosed with 
SLOS may be born with physical abnormalities, such as a cleft-pallet and small head 
circumference and exhibit delayed growth and intellectual delays (Tint et al., 1994). 
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There are many different biological mechanisms proposed to explain the relationship 
between high total cholesterol during midlife and AD.  One potential mechanism is the link 
between high cholesterol and atherosclerosis.  The Circle of Willis is a collection of arteries that 
supplies blood to the brain and atherosclerosis in these arteries is more prevalent among older 
adults diagnosed with AD (Roher et al., 2011).  The blood-brain barrier significantly limits the 
exchange of cholesterol between the circulatory system and the brain (Dietschy & Turley, 2001) 
making it unlikely that cholesterol directly contributes to Aβ production in the brain.  While 
cholesterol may not directly cause AD neuropathology, targeting high cholesterol may disrupt the 
biological chain of events that triggers the deposition of Aβ and tau pathologies that ultimately 
lead to neurodegeneration, cognitive decline, and AD.  High cholesterol causes inflammation of 
the brain (Thirumangalakudi et al., 2008) and to the small blood vessels that surround the brain 
(Granger, Rodrigues, Yildirim, & Senchenkova, 2010).  This inflammation has been linked to an 
increase in Aβ generation (Lee et al., 2008).  The accumulation of Aβ in the brain contributes to 
the deposition of hyperphosphorylated tau (Busciglio, Lorenzo, Yeh, & Yankner, 1995; 
Takahashi, Capetillo-Zarate, Lin, Milner, & Gouras, 2010), but the biological mechanisms 
driving this relationship are not fully understood (Armstrong, 2011).      
Epidemiology of Cholesterol and Alzheimer’s Disease 
 
Epidemiologists primarily study how a disease or other health outcome is distributed 
within a population and the factors that protect or predispose a population to that disease or 
outcome.  There is increasing evidence from epidemiological studies that indicate concentrations 
of total, LDL, and HDL cholesterol in the bloodstream modify the risk for AD.  This section 
addresses literature that examines how the relationship between cholesterol and AD varies 
according to the type of cholesterol that is measured (total, LDL, or HDL cholesterol), the age 
that cholesterol is measured (midlife versus late life) and the change in cholesterol with age. 
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Midlife Total, LDL, and HDL Cholesterol 
 
Studies that examine the relationship between midlife measures of cholesterol and AD 
are summarized in Table 2.2.  In general, the findings from these studies indicate that high total 
cholesterol during midlife is associated with an increased risk for AD during old age.  There were 
no studies identified by the literature review that assessed HDL or LDL cholesterol during 
midlife.  The findings of the three studies that reported a significant relationship between midlife 
total cholesterol and AD suggest that the concentration of total cholesterol must surpass a specific 
threshold before the risk for AD is increased.  All three of these studies reported that an increased 
risk for AD was only observed for subjects with total cholesterol that was >240 mg/dl whereas 
subjects with borderline high cholesterol (200 mg/dl - <240 mg/dl) were not at an increased risk 
compared to subjects with normal total cholesterol (<200 mg/dl).  Mielke et al., (2010) did not 
observe that high midlife total cholesterol increased AD risk but this may have been due to only 
being able to examine women.  None of the other four studies tested for an interaction between 
total cholesterol and sex, so the potential interactive effects of sex on the relationship between 
cholesterol and AD could not be determined based on the evidence from the literature review.  
The age cut-off used to define midlife may also modify the relationship between total cholesterol 
and AD. Of the three studies that detected a significant relationship, two restricted their sample 
population to include subjects between 40 and 60 years of age (Kivipelto, Helkala, & Hallikainen, 
2000; Notkola et al., 1998) and the third limited their sample to include subjects between 40 and 
45 years of age (Solomon, Kivipelto, et al., 2009).  C. J. Chiang et al. (2007) excluded subjects 
who were younger than 30 years of age upon enrollment into the study, but this was the only 
study identified in the literature to not specify if an upper limit was placed on age.  Age was 
treated as a continuous variable in all four of these studies.    
Late Life Total, LDL, and HDL Cholesterol 
 
Studies that examined the relationship between late life measures of cholesterol and AD 
are summarized in Table 2.3.  All of these studies assessed total cholesterol, whereas a limited 
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number of studies included measures of LDL cholesterol or HDL cholesterol.  The relationship 
between cholesterol measures during late life and AD appears to vary according to total, LDL, or 
HDL cholesterol.  Based on evidence from the available literature, low total cholesterol during 
late life appears to be a risk factor for AD.  Nine studies detected a significant relationship 
between total cholesterol and AD.  Three of these studies reported that total cholesterol was 
significantly lower in AD cases compared to controls (Lepara, Valjevac, Alajbegovic, Zaciragic, 
& Nakas-Icindic, 2009; Merched, Xia, Visvikis, Serot, & Siest, 2000; Siest et al., 2000) and four 
studies observed that higher total cholesterol decreased the risk for AD (R. M. Evans et al., 2000; 
Kuusisto et al., 1997; Mielke et al., 2005; Reitz et al., 2004).  Furthermore, Hayden et al., (2006) 
reported that older adults with a history of high total cholesterol after the age of 65 had a 
decreased risk of developing AD three years later.  However, Lesser et al. reported that AD cases 
had significantly higher total cholesterol compared to controls.  Two of the seven studies that 
examined LDL cholesterol found a significant association with AD.  Lepara et al., (2009) 
reported that AD cases had significantly lower LDL cholesterol during late life compared to 
controls, whereas Lesser et al., (2001) observed that AD cases had higher LDL cholesterol 
compared to controls.  Finally, of the eleven studies that examined late life HDL cholesterol, only 
three detected a significant association between HDL cholesterol and AD.  Merched et al., (2000) 
reported that AD cases had lower HDL cholesterol during late life compared to non-demented 
controls.  This is consistent with the findings reported by Reitz et al., (2004) in which high HDL 
cholesterol during late life was protective against AD, but this finding was not replicated when 
the data were examined using a prospective study design.  However, Kalman et al., (1999) 
observed that older adults diagnosed with AD had higher HDL cholesterol compared to controls. 
Close examination of these studies suggests that the age cut-offs to define late life 
influences the relationship between total cholesterol during late life and AD.  Eleven of the 
seventeen studies that assessed cholesterol during late life reported if the final sample was 
restricted according to age and the majority of these studies removed subjects who were younger 
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than 65 years of age.  The results of studies that excluded subjects who were not 65 years of age 
or older were much more consistent and seven of the ten studies reported that low total 
cholesterol was associated with AD.  The only study to contradict the above findings was 
conducted by Lesser et al. (2001).  In this study, Lesser et al. reported that AD cases had 
significantly higher total cholesterol compared to controls (210.0 mg/dl vs. 194.0 mg/dl P<0.05).  
There are several explanations as to why the results from this study contradict those reported by 
the majority of studies.  First, the sample population studied by Lesser et al. (2001) was 
considerably older than the sample populations of the other studies.  The median age of the final 
sample of the Lesser et al. study was 89 years and only twelve of the 106 participants were 
younger than 80 years of age.  This is due to Lesser et al. only including participants in the final 
sample who had received a postmortem autopsy of the brain to definitively diagnose AD.  
Second, the control group consisted of subjects who had received a diagnosis of dementia while 
living but did not meet the neuropathological criteria for possible, probable or definitive AD 
based on a brain autopsy.  The advantage of selecting a control group that consists of subjects 
who exhibit the outward symptoms of a disease but do not actually have the disease is it can 
decrease sampling bias.  However, this is only the case if the exposure is not related to the 
observed symptoms (Wacholder, Silverman, McLaughlin, & Mandel, 1992).  Lesser et al. may 
have violated this assumption because there is evidence that low cholesterol during late life is 
associated with impaired cognitive functioning among non-demented older adults (Solomon, 
Kareholt, et al., 2009; J. Zhang, McKeown, & Hajjar, 2005).  These characteristics of the study 
by Lesser et al. need to be considered when comparing their findings with those of other studies. 
There is little evidence to suggest that there is a significant relationship between late life 
LDL and HDL cholesterol and AD.  Furthermore, the findings from the few studies that detected 
a significant relationship between LDL, HDL, and AD are inconsistent.  Two of the seven studies 
that examined LDL cholesterol found a significant association with AD.  Lepara et al., (2009) 
reported that AD cases had significantly lower LDL cholesterol during late life compared to 
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controls (3.51 mmol/L vs. 4.08 mmol/L P<0.05), whereas Lesser et al., (2001) observed that AD 
cases had higher LDL cholesterol compared to controls (132.5 mg/dl vs. 119.5 mg/dl P<0.05).  
Eleven studies examined late life HDL cholesterol, but only three studies detected a significant 
association between HDL cholesterol and AD.  Merched et al., (2000) reported that AD cases had 
lower HDL cholesterol during late life compared to non-demented controls.  This is consistent 
with the findings reported by Reitz et al., (2004) in which high HDL cholesterol during late life 
was protective against AD, but this finding was not replicated when the data was examined using 
a prospective study design.  However, Kalman et al., (1999) observed that older adults diagnosed 
with AD had higher HDL cholesterol compared to controls.  This conflicting finding may be due 
to Reitz et al., (2004) and Merched et al., (2000) using fasting measures of HDL cholesterol 
whereas Kalman et al. did not specify if fasting or non-fasting measures of HDL cholesterol were 
used in the analysis.  
Change in Total, LDL, and HDL Cholesterol 
 
A summary of the four studies that examined the change in cholesterol and AD risk is 
provided in Table 2.4.  All four of these studies assessed total cholesterol, but none examined 
changes in LDL or HDL cholesterol. Notkola et al. (1998) collected a total of six measures of 
cholesterol over a thirty-year period beginning in 1959 from 444 Finish men.  According to the 
results from repeated measures ANOVA, men diagnosed with AD had higher total cholesterol on 
average from 1959-1974 and a greater decrease in total cholesterol from 1974 to 1989 compared 
to men without AD.  In a more recent study, Mielke et al. (2010) used Cox proportional hazards 
regression models to examine the time-dependent change in cholesterol and the onset of dementia 
and AD among 1,462 Swedish women.  Cholesterol change was defined by Mielke et al. (2010) 
as the difference in cholesterol between consecutive examinations and was analyzed as quartiles.  
Women in the quartile of greatest decrease in cholesterol (difference > -0.5 mmol/L between 
examinations) were at an increased risk for all-cause dementia compared to women in the middle 
two quartiles (cholesterol change of -0.5 mmol/L to 0.75 mmol/L between examinations).  When 
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only cases of AD were examined, women in the quartile of greatest decrease in cholesterol were 
at a greater risk for AD compared to women in the middle two quartiles, but these results were 
not statistically significant (Mielke et al., 2010).  Tan et al., (2003) calculated the change in total 
cholesterol using data that had been collected during two observation periods, but did not observe 
that a greater decrease in cholesterol increased the risk for AD   Finally, there is limited evidence 
to suggest that subjects who develop AD exhibit a different trajectory of cholesterol over time 
compared to subjects without dementia.  In a study conducted by Stewart et al. (2007), random-
effects models were used to estimate the trajectories of cholesterol among Japanese American 
men over a twenty-six year period.  Stewart et al. (2007) did not observe any differences in total 
cholesterol according to dementia status during the baseline examination, but men who developed 
AD exhibited a greater non-linear decline in cholesterol with age compared to men who did not 
develop dementia.     
Summary  
 
 Many studies in this literature review did not detect a significant relationship between 
late life cholesterol, midlife cholesterol, or changes in cholesterol and AD.  There are several 
explanations for the inconsistent findings between studies.  First, results differed according to 
study design.  For example, Reitz et al., (2004) examined data from two cohorts (1992 – 1994, 
1999 – 2002) of the Washington Heights-Inwood Columbia Aging Project to perform cross-
sectional and prospective analyses on the relationship between cholesterol and AD.  When data 
from both cohorts were combined and examined cross-sectionally, high HDL cholesterol was 
associated with lower odds for AD but no significant association between total cholesterol and 
AD was observed.  When a prospective analysis using data from the 1992 cohort was performed, 
high total cholesterol during late life was associated with a reduced risk for AD and the finding 
for HDL cholesterol was not replicated.  Reitz et al. (2004) did not specify if the 1992 and 1999 
cohorts differed according to age, gender, education, statin use or other factors, and the 
inconsistent findings may be an artifact of differences between the 1992 and 1999 cohorts.  
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Differences in findings according to study design may also be due to the cross-sectional analysis 
including prevalent cases of AD, whereas the prospective design examines incident cases of AD.  
The disadvantage of utilizing a cross-sectional design is that some subjects with low cognitive 
performance not due to disease (e.g. low educational attainment) may have been incorrectly 
classified as having AD, which would potentially weaken the relationship between AD and 
cholesterol.  The potential for misclassification is reduced in a prospective study design that 
includes incident cases of AD because all subjects entered into the study non-demented and a 
diagnosis of AD is made based on cognitive performance over a number of years.   
 Another potential explanation for the inconsistent findings is the wide range in the 
sample sizes examined by different studies.  The sample sizes of the studies included in the 
review ranged from N=39 (Kalman et al., 1999) to N=848505 (Kimm et al., 2011), and it is likely 
that several studies were either under or over powered.  Power is the likelihood that a statistical 
test will reject the null hypothesis given a specified level of significance (often α<0.05), the 
strength of the relationship between independent and dependent variables (i.e. effect size), and 
sample size (J. Cohen, 1992).  Studies that include a large number of participants are likely to 
detect a significant relationship between cholesterol and AD even when the effect size is small, 
whereas studies with small sample sizes will be less likely to detect a significant relationship 
unless the effect size is very large. 
 A third explanation for inconsistent findings is that some studies did not control for the 
effects of potentially important covariates in either the design stage or analysis stage of the study.  
Covariates are independent variables that may influence the outcome of interest and whose effect 
needs to be controlled for in the study.  Common covariates included in studies that examine the 
relationship between cholesterol and AD include age, sex, and APOE e4 allele status.  A 
summary of the covariates included in the review is provided in Table 2.5.  Surprisingly, several 
studies did not include what would seem to be potentially important covariates when performing 
multivariable analyses, and two studies (C. J. Chiang et al., 2007; Wieringa, Burlinson, Rafferty, 
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Gowland, & Burns, 1997) did not control for the effects of any covariates.  Sixteen studies 
controlled for age and sex, and eight studies included age, sex and education as covariates when 
performing multivariable analyses.  Six studies included history of statin use and seven studies 
included APOE e4 allele status as covariates in multivariable analyses, and only ten studies 
specified that they used fasting measures of cholesterol.  Including additional variables such as 
age or sex is important to avoid confounding, which occurs when a third variable is related to 
both the independent variable and dependent variable, but is not in the causal pathway of the 
disease.  Potentially confounding variables can most often be detected by conducting a thorough 
literature review and by comparing results of unadjusted and adjusted analyses.  Not accounting 
for the effect of a confounding variable will falsely increase or decrease the strength of the 
association between independent and dependent variables (McNamee, 2003).  For example, 
statins are effective treatments for lowering high cholesterol, but there is evidence that patients 
who have a history of taking a statin are less likely to develop AD later in life (Jick, Zornberg, 
Jick, Seshadri, & Drachman, 2000; Wolozin, Kellman, Ruosseau, Celesia, & Siegel, 2000).  
Therefore, if the effect of statin use is not accounted for in the study, then a relationship between 
low cholesterol and decreased risk for AD may actually be due to the confounding effect of statin 
use.   
The effects of a confounding variable can be controlled for in the design phase or 
analysis phase of a study.  Confounding can be controlled for in the design phase several ways.  
The first is randomization in which subjects are randomly assigned into a study group or control 
group.  Randomization controls for confounding by making the treatment and control groups 
similar for known characteristics, such as age, gender, education, and unknown characteristics 
that may also be confounders.  An investigator can ensure that the randomization was effective by 
comparing the characteristics of the treatment and control groups to make sure that there are no 
significant differences between the groups.  Randomization is well suited for clinical trials where 
participants are randomly assigned to receive a placebo or the treatment, but is not possible in 
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observational studies.  For example, it is not ethical to randomly assign a large group of people to 
consume a high fat diet so that they develop high cholesterol and then examine if they are at an 
increased risk for AD later in life.  A second way to control for confounding is to restrict study 
recruitment according to a specific characteristic.  For example, if an investigator is concerned 
that sex is a potential confounder then the sample population may only include men or women.  
While this approach is very straightforward, there are several limitations.  Restriction makes it 
difficult to generalize the findings of the study to an entire population, may reduce the size of the 
final sample, and makes it impossible to examine the effect the factor that subjects were restricted 
against has on the outcome (e.g. cannot examine potential differences in the relationship between 
cholesterol and AD according to sex).  The third way to control for confounding in the design 
phase of a study is called matching.  Matching can be done at the population level or at the 
individual level.  Individual level matching means that participants are chosen according to 
specific characteristics.  For example, if a study matched subjects according to age then every 35 
to 45 year old with high cholesterol that was enrolled in a study would be paired with a 35 to 45 
year old with normal cholesterol.  When matching is done at the population level, the goal is to 
make sure that the distribution of important characteristics, such as age and gender, are similar 
between cases and controls or exposed and unexposed individuals.  This approach is effective 
when wanting to control for a complex characteristic such as socioeconomic status, but matching 
can be time consuming, greatly reduce sample size, and the effects of the characteristics that were 
matched for can no longer be evaluated.  Also, the fact that subjects were matched in the design 
stage needs to be accounted for in the analysis stage of the study. 
Confounding can be adjusted for in the analysis stage of a study by conducting either a 
stratified analysis or multivariable analysis.  A stratified analysis means that the sample is divided 
according to a specific characteristic.  For example, if sex is a potential confounding variable then 
subjects can be stratified so that only men are included in one analysis and only women are 
included in the other analysis.  The results from these separate analyses can be compared to help 
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clarify if gender is confounding the relationship between the independent and dependent 
variables.  Stratification is a straightforward method of controlling for confounding, but it is 
difficult to control for multiple confounding variables because the number of substrata increases 
rapidly.  A multivariable analysis is appropriate when several variables need to be controlled for 
in a study, and allows for the effect of an independent variable on the dependent variable to be 
determined while controlling for the effects of potential confounders. A multivariable approach 
was utilized in the dissertation research to take into account the effects of gender, education, 
smoking, blood pressure and blood sugar, the use of cholesterol lowering medications, the use of 
estrogen replacement, and APOE e4 allele status when examining the relationship between 
cholesterol and AD. 
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Table 2.1: Cholesterol Lowering Medications 
 
Medication  Examples Mechanism Effects of treatment Common side effects  
Statins Atorvastatin 
(Lipitor®) 
Rosuvastatin 
(Crestor®) 
Simvastatin 
(Zocor®) 
Inhibits HMG-CoA 
reductase to 
decrease synthesis 
of cholesterol by the 
liver. 
Lowers LDL 
cholesterol and 
triglycerides. 
Headache, dizziness, 
and flushing of the 
skin.  Potentially 
more serious side 
effects include 
muscle inflammation 
(myositis) or muscle 
weakness. 
Niacin Nicolar 
Niaspan   
Decreases the 
amount of HDL 
cholesterol that is 
reabsorbed by the 
liver. 
Lowers LDL 
cholesterol and 
increases HDL 
cholesterol. 
Flushing of the skin, 
headache, nausea, 
and diarrhea. 
Resins Colestipol 
(Colestid®) 
Colesevelam 
(WelChol®) 
Decreases the 
reabsorption of bile, 
which increases the 
conversion of 
cholesterol into bile 
salts. 
Decreases LDL 
cholesterol and 
increases HDL 
cholesterol. 
Constipation, 
diarrhea, and nausea. 
Fibrates Gemfibrozil 
(Lopid®) 
Fenofibrate 
(Tricor®) 
Decreases the 
synthesis of 
triglycerides and 
increased synthesis 
of HDL by the liver. 
Decrease triglycerides 
and increase HDL 
cholesterol. 
Indigestion, 
abdominal pain, and 
headache. 
Selective 
cholesterol 
absorption 
inhibitors 
Ezetimibe 
(Zetia®) 
Decreases 
cholesterol 
absorption by the 
small intestines. 
Decreases LDL 
cholesterol. 
Constipation, 
dizziness, diarrhea.   
 
 
 
 
 
 
 
 
Total Cholesterol 
Study Population Sample size Baseline Age/Year Follow up 
Age/Year 
Result (95% CI) 
Kivipelto 
et al., 
2000 
Finland 48 AD, 1352 
cntrl 
1972, 1977, 1982 
or 1987.  Age 
during baseline 
defined as midlife 
Participants 
between 
65-70 
yrs./1997 
<6.5 mmol/L vs. >6.5 mmol/L 
OR 2.1  (1.2, 4.7) P<0.05 
Mielke et 
al., 2010 
Sweden 
(women only) 
80 AD, 1382 
cntrl 
Midlife 38 – 60 yrs.  
 
2000–2001 >6.5 mmol/L HR 1.48 (0.73, 
2.96) P>0.05 
Q1 vs. Q2 HR 2.05 (0.70, 
6.04) P>0.05 
Q1 vs. Q3 HR 2.51 (0.87, 
7.26) P>0.05 
Q1 vs. Q4 HR 2.82 (0.94, 
8.43) P>0.05 
Solomon et 
al., 2009 
United States 469 AD, 9248 
cntrl  
Midlife 40 – 45 yrs.  
 
2005 – 
2007 
<200 mg/dl vs. 200-239 mg/dl 
HR 1.2 (.97, 1.6) P>0.05 
<200 mg/dl vs. >240 mg/dl 
HR 1.57 (1.23, 2.01) P<0.05 
Q1 vs. Q2 HR 1.25 (0.96, 
1.63) P>0.05 
Q1 vs. Q3 HR 1.31 (1.01, 
1.71) P>0.05 
Q1 vs. Q4 HR 1.58 (1.22, 
2.06) P>0.05 
Chiang et 
al., 2007 
Taiwan  73 AD, 292 cntrl Midlife >30 yrs./  
1982 – 1986  
2000 – 
2001  
Chi-square (2df) 0.96, P>0.05 
Notkola et 
al., 1998 
Finland  (men 
only) 
27 AD, 397 cntrl, 
20 other 
dementia 
Midlife age 40 – 59  1989 <6.5 mmol/L vs. >6.5 mmol/L 
OR 3.1 (1.2, 8.5) P<0.05 
 
Abbreviations: AD (Alzheimer’s disease), VD (vascular dementia), NA (data not provided), cntrl (control), OR (odds 
ratio), RR (relative risk) HR (hazard ratio).   
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Total Cholesterol 
Study Population Sample size  Baseline Age/Year Follow up Age/Year Result (95% CI) 
Evans et al., 
2000 
African 
American, >65 
yrs 
N=77  
AD 46, cntrl 31  
1990 NA OR 1.018 (NA) 
P=0.027 
Kalman et 
al., 1999 
Hungary N=39 
AD 24, cntrl 15 
AD 70.2, cntrl 64.8 NA AD 160 mg/dl vs. 
cntrl 160 mg/dl 
P>0.05 
Lepara et 
al., 2009 
Sarajevo, Bosnia 
and Herzegovina, 
>65 yrs 
N=60 
AD 30, cntrl 30 
AD 79.9, cntrl 77.5  NA AD 5.4 mmol/L vs. 
cntrl 5.9 mmol/L 
P<0.05 
Lesser et al., 
2001 
United States N=106 
AD 22, cntrl 84 
1986 – 1994  Median 3.26 yrs 
(median age 89) 
AD 210.0 mg/dl vs. 
cntrl 194.0 mg/dl 
P<0.05 
Li et al., 
2005 
United States, 
>65 yrs 
N=2141 
AD 152, cntrl 
1989 
74.9 years  
 
 Mean follow up 5.6 
yrs. 
HR 1.001 (1.0, 1.1) 
P>0.05 
Merched et 
al., 2000 
France N=157 
AD 98, cntrl 59 
77.6 case; 75.4 cntrl NA AD 5.44 mmol/L vs. 
cntrl 5.9 mmol/L 
P<0.05 
Reitz et al., 
2004 
United States, 
Medicare 
recipients >65 yrs 
N=2820 
AD 244, VD 119, 
stroke 231, cntrl 
2226 
AD 82.6, cntrl 76.4 
 
NA Q1 vs. Q2 OR 0.96 
(0.61, 1.53) P>0.05 
Q1 vs. Q3 OR 0.72 
(0.44, 1.16) P>0.05 
Q1 vs. Q4 OR 0.94 
(0.58, 1.52) P>0.05 
Reitz et al., 
2004 
United States, 
Medicare 
recipients >65 yrs 
N=1168 
AD 119, VD 48, 
cntrl 856 
1992 – 1994 AD 81.5, cntrl 77.8 
 
Q1 vs. Q2 HR 0.58 
(0.34, 0.79)  
Q1 vs. Q3 HR 0.82 
(0.48, 1.41) 
Q1 vs. Q4 HR 0.48 
(0.26, 0.86)  
Abbreviations: AD (Alzheimer’s disease), VD (vascular dementia), NA (data not provided), cntrl (control), OR (odds 
ratio), RR (relative risk) HR (hazard ratio).   
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Total Cholesterol 
Study Population Sample size  Baseline Age/Year Follow up Age/Year Result (95% CI) 
Wieringa et al., 
1997 
United 
Kingdom 
N=70 
AD 37, cntrl 33 
77.4 case; 77.9 cntrl / 
1994 
NA AD 6.01mmol/L vs. cntrl 
6.1 mmol/L P>.05 
Yoshitake et 
al., 1995 
Japan, >65 yrs N=828 
AD 42, 725 cntrl, 61 
other dementia 
1985 – 1992 1985 – 1992 RR 1.10 (0.80, 1.51) 
P>0.05 
Hayden et al., 
2006 
United States, 
>65 years 
N=3264 
AD 104, cntrl 3123, 
37 VD 
1995-1998 81.5 case; 73.7 cntrl / 
1998 – 1999 
History of high cholesterol 
(No; ref) 
HR 0.47 (0.19, 0.98) 
P<0.05 
Dufouil et al., 
2005 
France, >65 yrs N=8506 
AD 112, cntrl 8394 
AD 79.1, cntrl 74.1 / 
1999 – 2001 
NA <6.2 mmol/L vs. >6.2 
mmol/L  
OR 1.18 (.62, 2.23) 
P>0.05 
Kimm et al., 
2010 
Korea, > 40 yrs N=848505 
AD 1851, cntrl 
846654 
1992 – 1995 1993 – 2006  Normal vs. borderline 
high: Men 1.2 (1.0, 1.4) 
P=0.05 
Normal vs. high: Men 1.2 
(1.0, 1.5) P=0.05 
Normal vs. borderline: 
Women 1.0 (0.9, 1.2) 
P>0.05 
Normal vs. high: Women 
1.1 (0.9, 1.3) P>0.05 
Kuusisto et al., 
1997 
Finland, 65-74 
yrs 
N=961 
AD 46, cntrl 915 
1986-1988 1990 – 1991  OR 0.69 (0.52, 0.92) 
P=0.011 
Ghebranious et 
al., 2011 
United States, 
>60 yrs. for 
cases, >80 yrs 
for cntrls 
N=455 
AD 153, cntrl 302 
AD 78.2, cntrl 87.2 NA AD 259.3 mg/dl vs. cntrl 
259.0 mg/dl P>0.05 
 
 
Abbreviations: AD (Alzheimer’s disease), VD (vascular dementia), NA (data not provided), cntrl (control), OR (odds ratio), 
RR (relative risk) HR (hazard ratio) 
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Total Cholesterol 
Study Population Sample size  Baseline Age/Year Follow up Age/Year Result (95% CI) 
Mielke et al., 
2005 
Sweden, 70 yrs N=382 
AD 19, 337 cntrl, 23 
VD, 3 other dementia 
70 yrs / 1971 - 1972 88 yrs / 1989 – 1990 Q1 vs. Q2 HR 1.05 
(0.48, 2.29) P>0.05 
Q1 vs. Q3 HR 0.97 
(0.43, 2.17) P>0.05 
Q1 vs. Q4 HR 0.31 
(0.11, 0.85) P<0.05 
Siest et al., 
2000 
ApoEurope  N=918 
AD 489, 429 cntrl 
AD 74.5, 71.0 cntrl/ 
1996 – 1998 
NA AD 5.62 mmol/L vs. 
cntrl 5.94 mmol/L 
P<0.0001 
Tan et al., 
2003 
United States N=1026 
AD 77, cntrl 949 
1988 - 1989 NA HR 0.97 (0.90, 1.05) 
P>0.05 
LDL Cholesterol 
Kalman et 
al., 1999 
Hungary N=39 
AD 24, cntrl 15 
AD 70.2, cntrl 64.8 NA AD 82.2 mg/dl, cntrl 
86.5 mg/dl P>0.05 
Lepara et al., 
2009 
Sarajevo, Bosnia and 
Herzegovina, >65 yrs 
N=60 
AD 30, cntrl 30 
AD 79.9, cntrl 77.5  NA AD 3.51 mmol/L, 
cntrl 4.08 mmol/L 
P<0.05 
Lesser et al., 
2001 
United States N=106 
AD 22, cntrl 84 
1986 – 1994 (median 
age 86) 
Median 3.26 yrs 
(median age 89) 
AD 132.5 mg/dl, cntrl 
119.5 mg/dl P<0.05 
Wieringa et 
al., 1997 
United Kingdom N=70 
AD 37, cntrl 33 
77.4 case; 77.9 cntrl NA AD 3.78 mmol/L vs. 
cntrl 3.89 mmol/L 
P>0.05 
Yoshitake et 
al., 1995 
Japan, >65 yrs N=828 
AD 42, 725 cntrl, 61 
other dementia 
1985 – 1992 1985 – 1992 RR 0.89 (0.63, 1.26) 
P>0.05 
Ghebranious 
et al., 2011 
 
 
 
United States, >60 
yrs. for cases, >80 
yrs for cntrls 
N=455 
AD 153, cntrl 302 
AD 78.2, cntrl 87.2 NA AD 167.6 mg/dl vs. 
cntrl 169.3 mg/dl 
P>0.05 
Abbreviations: AD (Alzheimer’s disease), VD (vascular dementia), NA (data not provided), cntrl (control), OR (odds ratio), RR 
(relative risk) HR (hazard ratio) 
 
T
ab
le
 2
.3
 (C
on
tin
ue
d)
 
 
49 
 
 
 
LDL Cholesterol 
Study Population Sample size  Baseline Age/Year Follow up Age/Year Result (95% CI) 
Reitz et al., 
2004 
United States, 
Medicare 
recipients >65 yrs 
N=2820 
AD 244, VD 119, 
stroke 231, cntrl 2226 
AD 82.6, cntrl 76.4 
1992 – 1994 
NA Q1 vs. Q2 OR 0.87 
(0.54, 1.40) P>0.05 
Q1 vs. Q3 OR 0.84 
(0.52, 1.36) P>0.05 
Q1 vs. Q4 OR 1.02 
(0.63, 1.65) P>0.05 
Reitz et al., 
2004 
United States, 
Medicare 
recipients >65 yrs 
N=1168 
AD 119, VD 48, cntrl 
856 
1992 – 1994 AD 81.5, cntrl 77.8 
1999 – 2002  
Q1 vs. Q2 HR 0.99 
(0.59, 1.65) P>0.05 
Q1 vs. Q3 HR 0.78 
(0.46, 1.34) P>0.05 
Q1 vs. Q4 HR 0.80 
(0.46, 1.40) P>0.05 
HDL Cholesterol 
Kalman et al., 
1999 
Hungary N=39 
AD 24, cntrl 15 
AD 70.2, cntrl 64.8 NA AD 49.3 mg/dl vs. 
cntrl 39.4 mg/dl 
P<0.05 
Lepara et al., 
2009 
Sarajevo, Bosnia 
and Herzegovina, 
>65 yrs 
N=60 
AD 30, cntrl 30 
AD 79.9, cntrl 77.5  NA AD 1.26 mmol/L vs. 
cntrl 1.17 mmol/L 
P>0.05 
Lesser et al., 
2001 
United States N=102 
AD 21, cntrl 81 
1986 – 1994 (median 
age 86) 
Median 3.26 yrs 
(median age 89) 
AD 41.5 mg/dl, cntrl 
38.5 mg/dl P>0.05 
Li et al., 2005 United States, >65 
yrs 
N=2141 
AD 152, cntrl 1989 
74.9 years /  
1994 – 1996 
 Mean follow up 5.6 
yrs. 
HR 1.00 (0.99, 1.01) 
P>0.05 
Merched et al., 
2000 
France N=157 
AD 98, cntrl 59 
77.6 case; 75.4 cntrl NA AD 1.03 mmol/L vs. 
cntrl 1.45 mmol/L 
P<0.0001 
Tan et al., 2003 United States N=1026 
AD 77, cntrl 949 
76.4 male; 76.1 
female 
NA HR 1.1 (0.93, 1.31) 
P>0.05 
Abbreviations: AD (Alzheimer’s disease), VD (vascular dementia), NA (data not provided), cntrl (control), OR (odds ratio), RR (relative 
risk) HR (hazard ratio) 
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HDL Cholesterol 
Study Population Sample size  Baseline 
Age/Year 
Follow up Age/Year Result (95% CI) 
Wieringa et al., 
1997 
United Kingdom N=70 
AD 37, cntrl 33 
77.4 case; 77.9 
cntrl 
NA AD 1.42 mmol/L vs. 
cntrl 1.39 mmol/L 
Yoshitake et 
al., 1995 
Japan N=828 
AD 42, cntrl 725, 61 
other dementia 
1985 – 1992 1985 – 1992 RR 1.06 (0.77, 1.47) 
P>0.05 
Reitz et al., 
2004 
United States, 
Medicare 
recipients >65 
years 
N=2820 
AD 244, VD 119, 
stroke 231, cntrl 2226 
AD 82.6, cntrl 
76.4 
1992 – 1994 
NA Q1 vs. Q2 OR 0.47 
(0.28, 0.78) P<0.05 
Q1 vs. Q3 OR 0.58 
(0.35, 0.97) P<0.05 
Q1 vs. Q4 OR 0.66 
(0.41, 1.08) P>0.05 
Reitz et al., 
2004 
United States, 
Medicare 
recipients >65 
years 
N=1168 
AD 119, vascular 
dementia 48, cntrl 
856 
1992 – 1994 AD 81.5, cntrl 77.8 
1999 – 2002  
Q1 vs. Q2 HR 0.79 
(0.44, 1.42) P>0.05 
Q1 vs. Q3 HR 0.97 
(0.54, 1.75) P>0.05 
Q1 vs. Q4 HR 0.70 
(0.37, 1.32) P>0.05 
Ghebranious et 
al., 2011 
United States, >60 
yrs. for cases, >80 
yrs for cntrls 
N=455 
AD 153, cntrl 302 
AD 78.2, cntrl 
87.2 
NA AD 59.5 mg/dl vs. 
cntrl 62.9 mg/dl 
P>0.05 
Kuusisto et al., 
1997 
Finland, 65-74 yrs N=961 
AD 46, cntrl 915 
1986-1988 1990 – 1991  OR (0.25, 1.45) 
P>0.05 
Abbreviations: AD (Alzheimer’s disease), VD (vascular dementia), NA (data not provided), cntrl (control), OR (odds ratio), RR 
(relative risk) HR (hazard ratio)  
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Total Cholesterol 
Study Population Sample size Baseline 
Age/Year 
Follow up Age/Year Result (95% CI) 
Mielke et 
al., 2010 
Sweden 
(women 38 – 
60 yrs 
baseline) 
AD 80, cntrl 
1382 
1968 - 1969 1974–1975, 1980–1981, 
1992–1993, and 2000– 2001 
Stable vs. decline HR 1.66 (0.71, 
3.89) P>0.05 
Stable vs. increase HR 1.03 
(0.35, 3.04) P>0.05 
Stewart et 
al., 2007 
Japanese-
Americans 
(males only) 
AD 56, cntrl 
971 
1965-1968 1970-1972, 1971-1974, 
1980- 1982, and 1991-1993 
AD x time Coefficient 2.2 
AD x time2 Coefficient -0.33 
AD x time3 Coefficient 0.0097 
Tan et al., 
2003 
United States AD 77, cntrl 
949 
1948 – 1953 Biannual exams from 1948 – 
1990  
Change in cholesterol over 10 yr. 
period  
H.R. 1.01 (0.92, 1.11) 
Notkola et 
al., 1998 
Finland  (men 
only) 
27 AD, 397 
cntrl, 20 
other 
dementia 
Midlife age 
40 – 59  
1989 Greater decline in total 
cholesterol for AD cases 
compared to controls (P<0.008) 
Abbreviations: AD (Alzheimer’s disease), VD (vascular dementia), NA (data not provided), cntrl (control), OR (odds ratio), 
RR (relative risk) HR (hazard ratio) 
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Abbreviations : BMI (body mass index), Edu (education), hyper (hypertension)  
 
Study Age Sex Edu Smoking Statin  APOE BMI Diabetes Hyper Heart 
disease 
Fasting 
cholest. 
Evans et 
al., 2000 
X     X      
Kalman et 
al., 1999 
 X  X        
Lepara et 
al., 2009 
X X          
Lesser et 
al., 2001 
X X    X      
Li et al., 
2005 
X X X  X  X X X X  
Merched 
et al., 
2000 
X X         X 
Reitz et 
al., 2004 
X X X  X X X X X X X 
Siest et al., 
2000 
X X    X     X 
Tan et al., 
2003 
X X  X X  X X  X  
Wieringa 
et al., 
1997 
           
Yoshitake 
et al., 
1995 
X X      X X   
Hayden et 
al., 2006 
X X X   X X X    
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Abbreviations : BMI (body mass index), Edu (education), hyper (hypertension) 
 
 
 
Study Age Sex Edu Smoking Statin  APOE BMI Diabetes Hyper Heart 
disease 
Fasting 
cholest 
Kuusisto et 
al., 1997 
X X X   X  X X  X 
Ghebranious 
et al., 2011 
X X  X X  X     
Mielke et 
al., 2005 
X X X X       X 
Kivipelto et 
al., 2000 
X  X X   X     
Mielke et 
al., 2010 
X X X X   X  X  X 
Solomon et 
al., 2009 
X X X    X X X  X 
Chiang et 
al., 2007 
           
Notkola et 
al., 1998 
X     X      
Stewart et 
al., 2007 
X  X X X  X X X X  
Dufouil et 
al., 2005 
X X X X X  X  X X X 
Kimm et al., 
2010 
X X         X 
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Chapter Three: A Life Span Approach to the Epidemiology of Alzheimer’s Disease 
 
Previous epidemiological research provides evidence for a significant relationship 
between cholesterol and AD, but the direction of this relationship appears to be dependent upon if 
cholesterol is measured during midlife or late life.  The age dependent relationship between 
cholesterol and AD makes it important for investigators to provide strong justification for how 
and why specific age boundaries to define midlife or late life were used.  Unfortunately, the age 
boundaries used to define midlife and late life in previous studies appear to be defined arbitrarily 
and justification for why specific age boundaries were chosen has been limited to citing previous 
studies that used similar boundaries.  Based on the literature review presented in Chapter Two, 
the sample populations of previous studies that have examined the relationship between 
cholesterol and AD come from a variety of ethnic and cultural backgrounds and the historical 
time periods in which these populations were examined also vary between studies.  These factors 
should be considered when conducting research on the relationship between distinct stages of the 
life span because the normative behaviors and characteristics associated with distinct life stages 
are shaped by social, cultural and historical influences that are dynamic.  As a result, the 
normative behaviors and characteristics associated with distinct life stages may change, which 
leads to the socially imposed age boundaries used to define life stages to also change.  Therefore, 
sufficient justification as to how and why specific age boundaries were chosen to define life 
stages when conducting research needs to be provided.  The dissertation research used concepts 
of the life span research framework to construct age boundaries for midlife and late life that were 
based on changes in the relationship between cholesterol and chronological age.  This approach 
was influenced by the large body of research in developmental psychology that has focused on 
defining life stages according to changes in mental, cognitive and personality characteristics with 
age.  More importantly, this approach provides sufficient justification for how and why specific 
age boundaries for midlife and late life were chosen. 
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The purpose of this chapter is to describe how the concepts of a life span framework were 
engaged in this dissertation research.  This chapter begins by providing necessary background 
information for the reader to appreciate why age boundaries for midlife and late life were 
constructed according to distinct changes in the relationship between cholesterol and 
chronological age.  This includes an introduction to the life span research framework, a summary 
of the major concepts of life span research, and brief review of pertinent research from 
developmental psychology that influenced the dissertation research.  Section one concludes by 
briefly describing how normative behaviors associated with distinct life stages are influenced by 
social, cultural and historical contexts that change over time.  This is relevant to the dissertation 
research because behavioral changes initiated by social, cultural and historical events may 
contribute to changes in the socially constructed age boundaries associated with distinct life 
stages.  Section two is a detailed description of the approach used to define age boundaries for 
midlife and late life according to trends in the relationship between total cholesterol and 
chronological age.  This chapter concludes by summarizing the findings presented in section two 
and describing the contributions of a life span approach to research on the etiology, progression 
and prevention of AD. This section also introduces the life course perspective and briefly 
summarizes the differences between the life course and life span.  The life course perspective is 
introduced in this chapter because the terms life course and life span are often used 
interchangeably, but there are important differences between these terms that are relevant to the 
dissertation research.      
Review of the Life Span Research Framework 
 
At the most basic level, the life span is the duration of time from birth to death.  The life 
span of an individual organism is influence by biological and environmental characteristics and 
the life span of any given organism can range from only a few minutes or hours to many decades 
or even centuries.  When studying the human life span, biologists and scientists in related fields 
focus their efforts on understanding the endogenous changes that occur over time and identifying 
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factors that influence the duration of the life span, whereas social scientists are concerned with 
understanding the behavioral, emotional and psychological changes that occur over time and the 
influence of exogenous factors on the life span.  All areas of science have made significant 
contributions to our understanding of the human life span and there is growing appreciation for 
the importance of studying how the life span is influenced by interactions between endogenous 
and exogenous factors.  As a research framework, the life span seeks to understand the 
physiological, behavioral, cognitive and psychosocial changes that occur over time and to identify 
factors that contribute to and influence the within person changes that occur as people age.  
Studies that utilize the life span framework may examine a prolonged period of the life span and 
often times study the relationship between two or more distinct life stages (childhood, young 
adulthood, middle age or old age).   
The concept of life span has a long history that is believed to have originated over two 
hundred years ago when German psychologist J. N. Tetens wrote the first manuscript on human 
development utilizing a life span perspective (Muller-Brettel & Dixon, 1990), which 
subsequently ushered in the field of developmental psychology12 (Baltes, Reese, & Lipsitt, 1980).  
The theories of several prominent developmental psychologists that describe the stages of 
psychosocial (Erikson, 1980), cognitive (Piaget, 1977) and personality (Jung, 2001) development 
have contributed to the evolution of life span framework.  A review of specific developmental 
theories is beyond the scope of this chapter, but it is necessary to understand how these theories 
have contributed to understanding the life span.  Sigmund Freud is arguably the most influential 
developmental theorist and many theories were proposed in response to his theory of 
psychosexual development.  Freud’s theory emphasized that an adult’s personality is heavily 
influenced by childhood experiences and that personality traits are for the most part established 
within the first five to six years of life.  Many developmental theorists who studied under Freud 
                                                        
12 G. Stanley Hall has also been credited with founding developmental psychology in the United 
States (White, 1992). 
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also focused their attention on childhood and adolescence.  However, Carl Jung, who was a 
former student of Freud’s, recognized that humans continue to develop after childhood.  Jung’s 
theory of personality included four periods (childhood, youth, middle life and old age), but he 
emphasized the importance of development during adulthood.  One of the first theorists to 
acknowledge that human development is a life long process and that no one stage is more 
important than the others was Erik Erikson.  Erikson’s stage theory of psychosocial development 
was a direct response to the psychosexual development work conducted by Sigmund Freud.  
Erikson agreed with Freud that early life experiences are important to human development, but 
disagreed with the notions that childhood experiences are more important to development than 
later life experiences, and that the majority of human development occurs within the first few 
years of life.  Erikson’s original theory of psychosocial development includes eight stages from 
childhood through old age.  His wife Joann Erikson added a ninth stage after he passed away to 
account for the growing proportion of older adults who were living into their 80’s and 90’s and 
displayed unique characteristics that differentiated them from younger age groups.     
Concepts of Developmental Psychology and the Life Span Framework 
 
Seven major concepts of developmental psychology are commonly incorporated into the 
life span framework (Baltes, 1987).  The first concept emphasizes that human development is a 
life long process and that there is no distinct age period that takes precedence in regulating human 
development.  The second concept states that development does not always move in a positive 
direction (i.e. growth) and that periods of growth may be followed by prolonged periods in which 
a developmental domain remains constant or declines.  Similarly, the third concept recognizes 
that development is multidirectional.  This means that during the same age period some domains 
may exhibit trajectories of growth whereas other domains may exhibit trajectories of decline or 
remain constant.  The fourth concept states that early life events influence later life outcomes and 
that an individual’s developmental trajectory is shaped by environmental conditions and 
individual experiences.  The fifth concept acknowledges that human development is influenced 
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by the social and cultural factors that may be unique to a specific generation.  The sixth concept 
builds upon this notion by stating that historical context along with normative age related 
developmental changes and unique non-normative events all interact to influence an individual’s 
development over time.  Therefore, to gain a complete understanding of human development 
requires taking into account the environment in which a person has lived and the unique events 
and experiences that shape a person’s development from birth until death. The final concept of 
the life span framework acknowledges that gaining a complete understanding of human 
development requires a multidisciplinary approach.  The life span framework emerged from the 
field of developmental psychology and research on the psychological, cognitive and intellectual 
changes that occur with age, but a complete understanding of human development also requires 
knowledge of the biological, physical and behavioral changes that occur with age. 
Socially Constructed Stages of the Life Span 
 
 Chronological age by itself has little meaning and age should not be accepted as a valid 
explanation for a behavior or health event.  The perceived significance of chronological age is 
due to the correlation between chronological age and important biological, physical, cognitive, 
behavioral and social characteristics or events. This correlation allows for people to generate a 
preconceived notion of a person’s physical or cognitive abilities, social standing or likelihood to 
experience a particular health event based on their chronological age.  However, changes to the 
social structure and environment in which people age may alter the timing (i.e. age) in which a 
person passes through socially constructed developmental landmarks (e.g. graduating college, 
marriage, starting a family).  This may lead to a change in the behavior associated with a 
particular age period and change the social perceptions for specific life stages such as childhood, 
young adulthood, middle age and old age.  As an example, most Americans in the 1990’s 
believed that men should be finished having children in their mid-forties and women in their late 
thirties (Settersten & Hagestad, 1996).  These social expectations are beginning to change, 
especially among women, as more people are choosing to start a family later in life.  This is 
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indicated by a steady decline in the birth rates for women between 20 and 29 years of age from 
1990 to 2010, but the birth rates among women between 30 and 44 have steadily increased over 
the same period (Martin et al., 2012).  The observed increase in fertility may be due to women 
choosing to have children at an older age in order to pursue advanced educational opportunities 
because of the emphasis that has been placed on education in Western societies due to an 
increasingly competitive job market.  Over time this may lead to a change in the socially imposed 
age boundaries associated with young adulthood and middle age. 
Defining Age Boundaries for Midlife and Late Life According to  
Trends in Total Cholesterol 
 Previous studies that have examined the relationship between cholesterol and AD define 
midlife and late life using predetermined age boundaries, and the justification for why specific 
boundaries were chosen is limited to citing previous studies that used similar boundaries.  While 
this limited justification is generally accepted, such an approach to defining life stages does not 
take into account that the age periods associated with distinct life stages are influenced by the 
social and cultural characteristics of the environment in which people age.  Therefore, instead of 
using predetermined age boundaries for midlife and late life, the dissertation research employed a 
more rigorous approach that define midlife and late life that was motived by the research of 
Erikson, Jung, and other theorists who constructed developmental stages based on observed 
changes to cognitive, psychosocial and emotional characteristics that occur with age. This 
approach allowed for age boundaries to define midlife and late life to emerge out of the observed 
trends between chronological age and total cholesterol.   
The results from cross-sectional and longitudinal studies indicate that cholesterol tends to 
increase during young adulthood and middle age and decline during old age (Carroll et al., 2005; 
Ferrara et al., 1997; P. W. Wilson et al., 1994).  While dietary changes (Johansson et al., 2012), 
weight loss and weight gain (Ferrara et al., 1997) and the use of cholesterol lowering medications 
(Carroll et al., 2005) all contribute to the apparent relationship between cholesterol and 
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chronological age, there is evidence that the rate of cholesterol synthesis by the liver also 
increases through middle age and then declines later in life (Miettinen, Gylling, Raitakari, 
Hallikainen, & Viikari, 2008; Tilvis et al., 2011).  Visually examining the cross-sectional and 
longitudinal changes in total cholesterol with age will provide insight into the developmental 
trajectory of total cholesterol across the life span and suggests a novel approach to obtain age 
cutoffs to define midlife and late life.  The following section provides a detailed description of 
how the life span framework was utilized to determine age cutoffs for midlife and late life based 
on the trajectories of total cholesterol among participants of the Framingham Heart Study (FHS) 
Original and Offspring Cohorts. 
Methods 
 
 Age boundaries for midlife and late life were obtained by visually examining cross-
sectional trends in the relationship between total cholesterol and chronological age during the first 
clinical examinations for the Original and Offspring Cohort.  The Original and Offspring Cohorts 
were examined separately to account for potential cohort effects that may influence cholesterol.   
A total of 3,092 participants of the Original Cohort (60.9% of initial cohort) had a recorded 
measure for total cholesterol for the first clinical examination (exam dates 1948 – 1953) and 
4,928 participants of the Offspring Cohort (98.2% of initial cohort) had a recorded measure of 
total cholesterol for the first clinical examination (exam dates 1971 – 1975).  The age range 
during the first clinical examination for participants of the Original Cohort with a recorded 
measure of total cholesterol was 29 – 74 (mean 44.1 years).  The mean age of the 1,987 
participants of the Original Cohort who did not have a recorded measure of total cholesterol was 
44.2 years (range 28 – 62), which was not significantly different compared to the participants 
who did have measure of total cholesterol.  The age range during the first clinical examination for 
participants of the Offspring Cohort with a recorded measure of total cholesterol was 6 – 70 
(mean 36.2 years).     
 
 62 
 Scatterplots describing the relationship between total cholesterol and age during the first 
clinical examination for the Original and Offspring Cohorts were created to determine if there 
were any outlying values in the data (Figures 3.1 and 3.2)13.  The average measure of total 
cholesterol for the Original Cohort was 221.5 mg/dl (range 96 mg/dl – 503 mg/dl) and the 
majority of measures were between 191 mg/dl and 249 mg/dl.  The Offspring Cohort had lower 
average total cholesterol (196.0 mg/dl, range 96 mg/dl – 450 mg/dl) and the majority of measures 
were between 169 mg/dl and 220 mg/dl.  Subjects with recorded measures of total cholesterol that 
were 1.96 standard deviations above or below what would be expected based on their age and sex 
or had a history of using cholesterol lowering medications were removed from the sample 
populations.  This was done so that the relationship between cholesterol and chronological age 
would not be influenced by unexpectedly high or low measures of cholesterol potentially due to 
genetic factors or diseases that disrupt cholesterol homeostasis.  Once these subjects were 
removed, the trends in the cross-sectional relationship between total cholesterol and chronological 
age were visually examined to identify age boundaries for midlife and late life.        
Results 
 
 Age Ranges for Midlife in the Original and Offspring Cohorts:  Apparent differences in 
the trends for total cholesterol between the Original (Figure 3.3) and Offspring Cohorts were 
observed (Figure 3.4) and there were differences in the trends of total cholesterol according to 
sex in both cohorts (Figures 3.5 and 3.6).  Based on Figure 3.3, total cholesterol increased 
steadily among subjects of the Original Cohort who were in their early thirties to mid fifties.  
However, total cholesterol increased steadily among women who were 30 to 55 years of age and 
then plateaued among women in their late fifties and early sixties (Figure 3.5).  In general, there 
was little change in total cholesterol among men with increasing age.  Total cholesterol increased 
slightly for men in their thirties and fifties before plateauing between fifty and sixty years of age 
                                                        
13 Figure 3.1 indicates that there was one subject in the Original Cohort who was considerably 
older than the other subjects during the first clinical exam and was therefore removed from the 
analysis.  There were no outlying values for age in the Offspring Cohort (Figure 3.2).   
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(Figure 3.5).  Based on Figure 3.5, midlife was defined in the Original Cohort as between 30 and 
55 years of age.   
The relationship between age and total cholesterol appeared to be almost perfectly linear 
in the Offspring Cohort (Figure 3.4).  When the Offspring Cohort was stratified according to sex, 
total cholesterol appeared to plateau in men by 50 years of age, whereas the trend for total 
cholesterol remained linear for women (Figure 3.6).  The linear trend in total cholesterol for the 
Offspring Cohort may be due to the age distribution of subjects during the first clinical exam.  
While the age range during the first clinical exam for the Offspring Cohort was similar to the 
Original Cohort, only 2.5 percent of subjects in the Offspring Cohort were older than 55 years of 
age compared to 12.6 percent in the Original Cohort during their respective first clinical exams.  
Therefore, the above analysis was repeated for the Offspring Cohort utilizing data from the 
second clinical exam because 15.4 percent of the subjects were older than 55 years.  A total of 43 
subjects reported using cholesterol-lowering medications during the second clinical exam.  There 
were 143 subjects in the 95th percentile and 45 subjects in the 5th percentile for total cholesterol 
(see Figure 3.7).  Based on Figure 3.8, total cholesterol increased steadily until approximately 55 
years of age when the trend plateaued and then began to decline.  However, there were clear 
differences in the trends for total cholesterol when subjects were stratified according to sex 
(Figure 3.9).  Women exhibited four distinct trends in total cholesterol.  There was a decreasing 
trend for total cholesterol among women in their late teens to late twenties, which was followed 
by a steady increase among women in their early thirties to mid-forties.  The trend in total 
cholesterol increased slightly among women in their late forties to early fifties, which may 
indicate the approaching onset of menopause.  A total of 404 women reported that they had not 
menstruated during the previous year due to natural causes.  The average age of these women was 
54.5 years and their average total cholesterol was 226.5 mg/dl.  The trend in total cholesterol 
plateaued among women in their late fifties and early sixties.  There was an increase in total 
cholesterol among women in their mid to late sixties, but it is unlikely that this increase is of any 
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real meaning because there were relatively few subjects between the ages of sixty and seventy 
during the second clinical exam.  There were no observable fluctuations in the trend for total 
cholesterol for men as was observed in women.  In general there was a slight increasing trend in 
total cholesterol until the mid forties at which point the trend plateaued.  Based on Figure 3.9, 
midlife was defined for the Offspring Cohort as between 30 and 45 years of age.   
Age Cutoffs for Late Life in the Original and Offspring Cohorts:  While distinct trends in 
total cholesterol that may be used to define midlife in both FHS cohorts were identified, the 
above analysis did not detect specific ages where the trend in total cholesterol began to decline 
that may indicate the transition to late life.  A potential explanation is that the age in which 
cholesterol begins to decline may not actually occur within the age range of the subjects included 
in the cross sectional analyses and that subjects with older chronological age would need to be 
included in the sample before a decreasing trend in total cholesterol may be observed.  A second 
explanation for the observed trends in cholesterol is a sampling bias due to the cross sectional 
design of the analysis.  A decline in body mass, muscle mass and other health characteristics are 
representative of an overall decline in functioning that occurs as a person approaches death (Bales 
& Ritchie, 2002).  Subjects with low cholesterol, especially among older age groups, may not 
have been recruited to participate in the FHS due to illness or death and may explain why a 
decreasing trend in total cholesterol consistent with the transition into late life was not detected in 
the cross-sectional analysis.  Another limitation of utilizing a cross-sectional design is that 
apparent age related differences in the outcome of interest are often times confounded by the 
unique characteristics of a particular age group, also known as a cohort effect.  The relationship 
between cholesterol and chronological age for the Original and Offspring Cohorts were plotted 
separately, but the wide age distribution among participants recruited into both Cohorts means 
that there is still the potential for cohort effects to be present.   
The limitations of examining cross-sectional trends in cholesterol can be addressed by 
utilizing the repeated measures of cholesterol that have been collected from participants of the 
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FHS Original and Offspring Cohorts over the course of the study.  The trajectories of total 
cholesterol for subjects in the Original and Offspring Cohorts who were within their respective 
age ranges for midlife during the first clinical exam were examined longitudinally to determine 
late life according to the age of onset for a prolonged decline in total cholesterol for men and 
women.  Subjects who had a history of ever using cholesterol-lowering medications [Original 
Cohort n= 493 (9.7%); Offspring Cohort n= 926 (18.5%)] were excluded from the analysis and 
all measures of total cholesterol were within the 5th and 95th percentiles according to age and 
gender adjusted norms.    
The trajectories of total cholesterol for the Original and Offspring Cohorts both had a 
parabolic shape in which there was a prolonged increasing trend in total cholesterol, followed by 
a plateau and then a decreasing trend.  Despite the similarities in the overall trajectories of total 
cholesterol, there were apparent differences between the Original and Offspring cohorts and when 
the trajectories were stratified according to sex.  The longitudinal trajectory of total cholesterol 
for men and women in the Original Cohort indicates that total cholesterol began to decline at 
approximately 65 years of age (Figure 3.10).  The accelerated decline in total cholesterol for men 
was preceded by a slight decline in total cholesterol beginning at roughly 50 years of age, 
whereas the trajectory of total cholesterol for women continued to increase until 55 and remained 
constant until 65 years of age (Figure 3.11).  Therefore, based on the ages in which changes in 
the trajectory of total cholesterol were observed in Figures 3.10 and 3.11 late life will be defined 
as 65 years of age or older in the Original Cohort. 
The overall trajectory of total cholesterol for the Offspring Cohort followed a smooth 
trend and there were no abrupt changes in the trajectories of total cholesterol (Figure 3.12), but 
differences in the longitudinal trends of total cholesterol between men and women were visually 
apparent once the trajectories of total cholesterol were stratified according to sex (Figure 3.13).  
Total cholesterol began to decline at approximately 60 years of age for women, but similar to 
what was observed in the Original Cohort, the initial decline in total cholesterol for men occurred 
 
 66 
earlier at approximately 50 years of age.  Based on Figure 3.13, late life will be defined in the 
Offspring Cohort as 60 years of age and older. 
Summary 
 
Based on the cross-sectional and longitudinal trends between cholesterol and 
chronological age, midlife was defined as between 30 and 55 years of age for the Original Cohort 
and between 30 and 45 years of age for the Offspring Cohort.  Late life was defined as 65 years 
of age in the Original Cohort and 60 years of age in the Offspring Cohort14.  These definitions for 
midlife and late life are similar to those used in previous studies, but the approach employed in 
the dissertation research provides stronger justification for the proposed age cutoffs than citing 
previous research.  A narrower age range was chosen for the Offspring Cohort because of the 
observed increase in total cholesterol among women that occurred at approximately 50 years of 
age.  The slight increase in total cholesterol may be partly due to the onset of menopause.  This 
trend was not observed among women in the Original Cohort and data regarding the onset of 
menopause was not collected during the first clinical exam for the Original Cohort, which 
prevented the potential influence of menopause on cholesterol from being examined.  Subtle 
differences in the average age at which cholesterol began to decline between the Original and 
Offspring Cohort were also observed.  Based on the longitudinal changes in cholesterol with 
advancing age, late life was defined as 65 years of age and older for the Original Cohort and 60 
years of age and older for the Offspring Cohort.  The younger age cutoff for late life used for the 
Offspring Cohort does not suggest these participants are approaching late life at a younger age 
compared to participants of the Original Cohort.  Rather, the younger average age in which total 
cholesterol begins to decline may be due to an increased understanding of the importance of 
controlling high cholesterol.  The most apparent differences between the Original and Offspring 
                                                        
14These definitions for late life are not meant to imply that adults who are 60 or 65 years of age 
and older are a homogeneous group.  It is generally accepted that there are specific stages within 
late life (old, old-old and oldest old) that have distinct physical, cognitive and psychosocial 
characteristics.   
 
 67 
Cohorts in the longitudinal trajectories of total cholesterol is that participants of the Original 
Cohort had much higher total cholesterol by the time they were 60 years of age due to a rapid 
increase in total cholesterol from approximately 30 to 55 years of age, whereas participants of the 
Offspring Cohort exhibited a much more subtle increase in total cholesterol during the same 
period and therefore had much lower cholesterol by the time they were 60 years of age.  These 
differences in total cholesterol may be due to differences in diet, exercise, smoking history and 
other factors that directly modify total cholesterol.  By the time the Offspring Cohort was initiated 
in 1971, the discoveries from several studies that utilized data from the Original Cohort had made 
significant progress towards identifying risk factors for heart disease (Dawber, 1960; Kannel, 
1967; Kannel, Dawber, Kagan, Revotskie, & Stokes, 1961).  These discoveries contributed to the 
growing social awareness of the importance of controlling high cholesterol, high blood pressure, 
engaging in regular exercise and the dangers of smoking.  The influence of the greater social 
awareness is reflected by the lower total cholesterol, on average, of the Offspring Cohort 
compared to the Original Cohort.  The Offspring Cohort had lower average total cholesterol 
(196.0 mg/dl, range 96 mg/dl – 450 mg/dl) and the majority of measures were between 169 mg/dl 
and 220 mg/dl.  The difference in average total cholesterol between the Offspring and Original 
Cohorts during their respective examinations may also be due to differences in the use of 
cholesterol lowering medications between the two cohorts.  Data regarding the use of cholesterol 
lowering medications was not collected until the sixth clinical examination for the Original 
Cohort (years 1958 – 1963) because the benefits of niacin, also known as vitamin B3, for 
controlling high cholesterol were not reported until 1955 by Altschul et al. (1955).  By the time 
the Offspring Cohort was initiated in 1971, several anti-cholesterol agents were available and the 
use of cholesterol lowering medications has been assessed during each clinical examination for 
the Offspring Cohort.   
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Contributions of the Life Span Framework to Alzheimer’s Disease Research 
 
 Alzheimer’s disease is characterized by the accumulation of neuritic plaques that are 
comprised of the amyloid beta (Aβ) protein and neurofibrillary tangles that form from the 
hyperphosphorylation of the protein tau in the brain (McKhann et al., 2011).  The progressive 
decline in cognitive functioning associated with AD does not begin to occur until the 
accumulation of these neuritic plaques and neurofibrillary tangles surpasses a critical threshold.  
This threshold model of AD was proposed by Blessed, Tomlinson, and Roth (1968) based on 
their findings that older adults with dementia had significantly higher plaque count compared to 
subjects without dementia, but the correlation between plaque count and dementia symptoms was 
not significant among subjects with advanced dementia.  This led to the hypothesis that sufficient 
damage to the brain has occurred once the number of plaques in the brain surpasses a critical 
threshold, and continued accumulation does not necessarily result in more severe dementia 
symptoms (Blessed et al., 1968).  The poor correlation between brain pathology and degree of 
cognitive impairment (Bennett et al., 2006; Giannakopoulos et al., 2003; Haroutunian et al., 2008; 
Knopman et al., 2003) suggests that the relationship is influenced by a person’s ability to engage 
other cognitive processes to compensate for increasing neuropathology (Stern, 2002).  This 
supports the hypothesis that a critical threshold of brain pathology varies from person to person, 
which adds an additional challenge to determining where in the disease process a critical 
threshold is located.  An active model of reserve provides an explanation for why people with 
anatomically similar brains and similar pathology may express differing degrees of cognitive 
impairment.  An active model of reserve is supported by evidence that older adults with higher 
educational attainment engage additional regions of the brain when performing cognitive tasks 
(Scarmeas et al., 2003; Springer, McIntosh, Winocur, & Grady, 2005), have higher cognitive 
function despite similar AD pathology (Bennett et al., 2003), and have greater brain pathology at 
time of AD diagnosis (Stern, Alexander, Prohovnik, & Mayeux, 1992) compared to older adults 
with less educational attainment.  These findings have important implications when interpreted 
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using a life span framework because plausible pathways for the observed associations between 
psychosocial characteristics during childhood and the risk for dementia during old age become 
apparent.  As an example, a child born into a family of high socioeconomic status will likely be 
provided with educational opportunities and a mentally stimulating environment from a young 
age.  These early life advantages may contribute to additional advantages later in life, such as 
earning a college degree and working in a stimulating environment.  Advantages accumulate over 
the life span and contribute to greater brain and cognitive reserves during old age.  This decreases 
a person’s risk for AD by increasing the critical threshold that pathological changes to the brain 
must surpass before cognitive declines are observed.  
 The threshold model for AD has had significant implications for treatment and prevention 
because it has increased the urgency to determine when in the disease process a person who 
develops AD crosses the critical threshold.  Available treatments for AD temporarily improve 
clinical symptoms and slow the progression of the disease (S. L. Rogers, Farlow, Doody, Mohs, 
& Friedhoff, 1998; Rosler et al., 1999), but there are currently no treatments that reverse or stop 
the declines in cognitive and physical functioning associated with AD.  This is possibly due to 
treatments being administered too late in the disease process when irreversible damage to the 
brain has already occurred (Roh & Holtzman, 2012).  This has led to a significant shift in the 
therapeutic approach to AD from administering disease-modifying treatments to patients who are 
in the mild to moderate stages of the disease to the preclinical stages of the disease before 
cognitive symptoms are observed.  The challenge is determining how early in the disease process 
the critical threshold is crossed and sufficient and irreversible damage to the brain has occurred.  
Advances in brain imaging techniques and the discovery of biomarkers that reflect pathological 
changes to the brain have allowed for the presence of AD neuropathology to be detected many 
years before clinical symptoms associated with AD are observed (Jack et al., 2013; Jack et al., 
2010).  The period between the onset of AD neuropathology and clinically observable symptoms 
represents the preclinical stages of AD (Jack, Albert, et al., 2011).  Adults with biomarker 
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evidence for accumulation of beta-amyloid (Aβ) protein in the brain, neurodegeneration, or both, 
but no detectable cognitive impairment are believed to be in the early stages of preclinical AD; 
adults with biomarker evidence for Aβ accumulation or neurodegeneration who exhibit subtle 
impairment on cognitive assessments are believed to be on the verge of progressing from 
preclinical AD into mild cognitive impairment (Sperling et al., 2011).  Clinical trials to determine 
efficacy of disease-modifying treatments administered during preclinical AD will need to be large 
and will require prolonged follow up periods (Blennow, Hampel, & Zetterberg, 2014).  
Fortunately, these challenges have not discouraged investigation into this area of research and 
several programs are in place for clinical trials on disease-modifying agents and preclinical AD 
(Bateman et al., 2012; Garber, 2012; Reiman, Langbaum, & Tariot, 2010).  
 A life span approach also has implications for research focused on determining if there is 
a period within the life span that interventions may have the greatest lasting effects.  In 
epidemiology, a critical period is a limited time frame in which an exposure has a greater 
protective or adverse effect for a disease compared to if the exposure is present outside of the 
critical period (Kuh, Ben-Shlomo, Lynch, Hallqvist, & Power, 2003).  Midlife is a potential 
critical period for dementia due to the identification of factors related to vascular health 
associated with an increased risk for dementia, including hypertension (Kivipelto et al., 2000) 
high cholesterol (Kivipelto et al., 2002) and obesity (Whitmer, Gunderson, Quesenberry, Zhou, & 
Yaffe, 2007).  The relationship between middle age and cognitive functioning later in life is 
supported by evidence that pathological changes to the brain associated with AD begin many 
years or even decades prior to the onset of cognitive decline (Jack et al., 2013).  There is evidence 
that hypertension and related conditions negatively impact the brain by decreasing blood flow to 
the brain (Beason-Held, Moghekar, Zonderman, Kraut, & Resnick, 2007).  The decrease in blood 
flow deprives the brain of oxygen and may lead to brain infarcts or “mini” strokes.  Over time the 
damage from these brain infarcts accumulates, making the brain more sensitive to AD 
neuropathology (Kalaria, 2010) and increasing the likelihood of developing AD (Vermeer et al., 
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2003).  Furthermore, the inflammatory affects of poor vascular health on the brain may contribute 
to Aβ deposition (Lee et al., 2008).  These plausible biological mechanisms suggest that 
interventions targeting vascular risk factors during midlife may substantially reduce the future 
prevalence of dementia (Barnes & Yaffe, 2011).  The challenge, however, is several decades must 
pass before the effectiveness of interventions administered during middle age for cognitive 
functioning during old age can be determined.  Furthermore, there may be a threshold effect in 
which a person must engage in regular exercise, consume a healthy diet or other positive health 
behaviors for a prolonged period of time for benefits to have a lasting effect into old age.  This 
increases the importance of encouraging people to adopt positive health behaviors during 
adolescence and young adulthood so these behaviors become a part of their everyday routines and 
carry through middle age and into old age. 
 The vast majority of epidemiological studies have focused on midlife as a potential 
critical period for AD, but it is necessary to consider the importance of childhood and 
adolescence when examining AD.  These life stages are potential critical periods because it is 
during childhood and adolescence that foundational experiences occur that often times shape 
health behaviors.  These behaviors, when reinforced and carried through life as habits, may 
influence cognitive development through the life span.  Childhood and adolescence have 
potentially significant implications to AD research when interpreted in the contexts of cumulative 
advantage and threshold models of AD, which points to the need for careful selection of controls 
during the design stage of a study that takes into account early life biopsychosocial 
characteristics.        
Differences between the Life Span and Life Course 
 
 The life span framework acknowledges that the social and cultural environment in which 
people age changes over time and that these changes influence human development.  An 
argument can be made that the fifth and sixth concepts of the life span framework add an 
additional layer of complexity that requires a life course perspective.  The life course is the 
 
 72 
temporal sequence of events, transitions, and trajectories that occur within socially constructed 
life domains (e.g. education, work, family) from birth until death, such as graduating from high 
school, entering the workforce, marriage or retirement (Elder, 2000; Elder, Johnson, & Crosnoe, 
2003).  Glen Elder and his colleagues have proposed five principals of the life course framework 
(Elder et al., 2003): (1) principal of life span development, (2) principle of agency, (3) principle 
of time and place, (4) principle of timing, and (5) the principle of linked lives.  The principle of 
life span development is similar to the first concept of the life span framework and emphasizes 
that human development and aging is an ongoing process from birth until death.  The remaining 
principles distinguish the life course framework from the life span framework.  The second 
principle recognizes that an individual’s behavior and choices are influenced by the social 
constraints that are presented to them.  The third principal of time and place acknowledges that an 
individual’s life course is influenced by historical events and geographic processes that shape the 
society and culture in which they live.  The fourth principle of timing acknowledges that the 
influential effects of specific events depend on the timing (i.e. age and historic period) in which 
the event occurs.  The fifth principle emphasizes that successive generations are connected 
through shared relationships that emerge, both predictably and vicariously, from membership in a 
vast array of social groups throughout life.   
    There are similarities between the life span and life course perspectives that need to be 
acknowledged.  First, the life course and the life span recognize that human development and 
aging is a life long process that is ongoing from birth until death.  Second, both constructs 
acknowledge the relationship between early life events and later life outcomes.  Finally, both life 
course and life span emphasize the influence of characteristic social and cultural environments on 
human development and aging.  These similarities often lead to confusion as when to use the term 
life span or life course, but there are important differences between these two terms.  First, the life 
course perspective emphasizes that people live their lives interdependently (Alwin, 2012; Elder, 
1994), meaning people are influenced by the choices, behaviors and actions of people around 
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them (Elder et al., 2003).  The life span perspective does not acknowledge this interdependence in 
which people live their lives.  Second, there is an important difference between the life span and 
life course in regards to the treatment of past time.  Life span constrains the past to early life 
experiences, situations, and influences that occur once a person is born, whereas the life course 
recognizes that the pre-birth past influence of both current and anticipated future perceptions and 
behaviors.  This needs to be acknowledged because lessons learned from the experiences of 
previous generations (e.g. parents, grandparents, societal/cultural events) can be passed down 
from generation to generation, which is not considered in the life span framework.  Finally, the 
life course recognizes that the choices and decisions made in the present may be shaped by 
anticipation of what may happen in the future (Hosier, Downer, Watkins, & Zanjani, 2012b), 
which is also not considered in the life span framework.  An example of how the anticipation of 
future events may influence present-day behavior is the use of cancer screening among women 
with a family history of breast cancer (Andersen, Smith, Meischke, Bowen, & Urban, 2003; 
Isaacs et al., 2002).  Additional examples of this notion are readily available in scientific 
literature, but critical theoretical development of the future aspect of the life course is lacking. 
 The life course perspective emphasizes the trajectories of socially constructed domains, 
but health is an additional domain that plays a significant role in the life course.  Incorporating 
health into the life course perspective makes this a useful approach for conducting AD research 
because genetic, physiological, behavioral and social factors all contribute to the etiology and 
progression of AD.  A thorough discussion of the life course and the implications of a life course 
perspective for AD research are discussed in chapter six of this dissertation.    
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Figure 3.1:  Scatter Plot of Total Cholesterol According to Chronological Age,  
Original Cohort 
 
Figure 3.2:  Scatter plot of total cholesterol according to chronological age,  
Offspring Cohort 
 
Figure 3.3: Cross-Sectional Trend in Total Cholesterol, Original Cohort 
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Figure 3.4: Cross-Sectional Trend in Total Cholesterol, Offspring Cohort 
 
Figure 3.5: Cross-Sectional Trends in Total Cholesterol Stratified by Sex, Original Cohort 
 
Figure 3.6: Cross-Sectional Trends in Total Cholesterol Stratified by Sex, Offspring Cohort 
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Figure 3.7: Scatter Plot of Total Cholesterol According to Chronological Age, Offspring 
Cohort (Exam 2) 
 
Figure 3.8: Cross-Sectional Trends in Total Cholesterol, Offspring Cohort (Exam 2) 
 
Figure 3.9: Cross-Sectional Trends in Total Cholesterol Stratified by Sex, Offspring Cohort 
(Exam 2) 
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Figure 3.10: Longitudinal trends in total cholesterol, Original Cohort
 
Figure 3.11: Longitudinal Trends in Total Cholesterol Stratified by Sex, Original Cohort 
 
 
Figure 3.12: Longitudinal Trend in Total Cholesterol, Offspring Cohort 
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Figure 3.13: Longitudinal Trends in Total Cholesterol Stratified by Sex, Offspring Cohort 
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Chapter Four: Research Design and Methodology 
 
This dissertation presents a secondary analysis of cognitive, phenotypic and genetic data 
collected from subjects of the FHS Original Cohort and Offspring Cohort.  A brief overview of 
the study design and methodology for each of the specific aims of the dissertation research is first 
provided followed by an overview of the FHS and detailed descriptions of the sample populations 
and statistical methods for each specific aim, which are provided in subsequent sections of this 
chapter.   
Overview of Specific Aims 
 
 The research addressed three specific aims.  Aim One utilized a cross-sectional study 
design and involved examining cognitive data collected from participants of the FHS Offspring 
Cohort between 1999 and 2005 using a neuropsychological battery to calculate a series of three 
composite scores of cognitive functioning: (1) a composite score that provided equal weight to 
each subtest included in the neuropsychological battery; (2) a composite score that provided equal 
weight to each cognitive domain assessed by the neuropsychological battery; and (3) an 
abbreviated summary score comprised of the subtests that assessed learning and memory.  
Receiver operating characteristic (ROC) analysis was conducted to determine which of the three 
summary scores was best able to differentiate between participants who were classified as having 
normal cognition, test-based impaired learning and memory (ILMTB), test-based multi-domain 
impaired (MDITB), or dementia based on the area under the curve (AUC), sensitivity, specificity, 
positive predictive value, negative predictive value and overall accuracy for each of the summary 
scores.  The summary score that was best able to differentiate between the cognitive groups was 
used as the measure of cognitive functioning in Aim Three.  Aim Two utilized a longitudinal 
study design.  Repeated measures of total cholesterol and HDL cholesterol collected from 
subjects of the FHS Original Cohort between 1948 and 2005 were used to model the longitudinal 
trajectories of total cholesterol, HDL cholesterol and total/HDL ratio from midlife to late life.   
Generalized additive mixed modeling allowed for the longitudinal trajectories of total cholesterol, 
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HDL cholesterol and total/HDL ratio according to AD status to be visually examined.  Aim Three 
also utilized a longitudinal study design.  For this aim, repeated measures of total cholesterol 
collected from participants of the FHS Offspring Cohort between 1971 and 2008 were used to 
predict subject-specific trajectories of total cholesterol using a growth-curve approach via mixed 
effects regression models.  The subject-specific trajectories of cholesterol were plotted according 
to degree of cognitive functioning.  This allowed for visual interpretations of the relationship 
between cognitive functioning and subject-specific trajectories of cholesterol to be made.  
The Framingham Heart Study 
 
The FHS is an ongoing prospective cohort study of residents from Framingham, 
Massachusetts created with the goal of generating knowledge on the onset and progression of 
cardiovascular disease and lung disease, as well as genetic and environmental risk factors for 
these diseases.  The FHS includes a total of five cohorts: (1) Original, (2) Offspring, (3) Third 
Generation, (4) Omni 1, and (5) Omni 2.   
The FHS Original Cohort was initiated in 1948 and included adults residing in 
Framingham, Massachusetts who did not have cardiovascular disease.  A total of 5079 
participants between the ages of 28 and 74 (mean age 44.2 years) completed a baseline clinical 
exam between 1948 and 1953.  Thirty clinical examinations have been completed since 1948, and 
141 participants (mean age 92, range 88-102) attended the thirtieth clinical exam, which 
concluded in 2010.   
The Offspring Cohort was initiated in 1971 and includes children, and their spouses, who 
had one or both parents who were subjects of the Original Cohort (Feinleib, Kannel, Garrison, 
McNamara, & Castelli, 1975).  A total of 5124 subjects between the ages of 5 and 70 (mean age 
36) attended the first clinical exam between 1971 and 1975.  Eight clinical exams have been 
completed since 1971 and 3021 (mean age 67, range 40 – 93) subjects attended the most recent 
examination, which concluded in 2008.  Data collection for the ninth clinical examination began 
in 2011.   
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Beginning in 2002, 4095 individuals who had one or more parents who were subjects in 
the FHS Offspring Cohort attended the first clinical examination for the Third Generation Cohort 
(Splansky et al., 2007).  Only two clinical exams have been completed since 2003.   
The FHS also includes two Omni Cohorts, which were initiated to reflect the increasing 
ethnic diversity of Framingham Massachusetts.  The Omni 1 cohort was initiated in 1994 and is 
comprised of 506 residents of Framingham, Massachusetts and surrounding areas who responded 
to being a member of a minority group (Quan et al., 1997).  The third clinical exam was 
completed in 2008 and was attended by 298 subjects.  Data collection for the fourth examination 
is ongoing.  A second Omni cohort began in 2003 and included 410 subjects from Framingham 
Massachusetts.  The Omni 2 cohort includes subjects who are unrelated to subjects of the Omni 1 
cohort, but many of the subjects in this cohort are related to subjects in the Omni 1 cohort. The 
Omni Cohorts include subjects of African-American, Hispanic, Asian, Indian, and Native 
American descent.     
During each wave of data collection for the five cohorts, subjects received an extensive 
physical examination, which included non-invasive tests (e.g. body composition, x-ray, and 
pulmonary function), lab tests (e.g. lipid and hormone levels), and a health history questionnaire 
to assess health behavior and the onset of any health conditions since the previous wave of data 
collection.  DNA collection from living members of the Original and Offspring Cohorts began in 
the 1980’s and genotyping has been performed using Affymetrix 100K and 550K SNP chips 
(Cupples et al., 2007).  Current information regarding the status, recruitment and data collection 
for the five FHS cohorts can be found at http://www.framinghamheartstudy.org. 
Aim One: Summary Score for the FHS Neuropsychological Battery 
 
Sample Population 
 
 A total of 2557 members of the FHS Offspring Cohort received a neuropsychological 
battery between 1999 and 2005.  There were 1713 (67.0%) subjects from the Offspring Cohort 
who attended a follow-up evaluation prior to 2007 in which they received the same 
 
 82 
neuropsychological battery.  There were 325 members of the FHS Original Cohort who also 
received a neuropsychological battery between 1999 and 2005.  Members of the Original Cohort 
were excluded from all analyses in Aim One because of significant differences in cognitive 
functioning between the Original and Offspring Cohorts that remain after adjusting for education, 
age, and sex (Au et al., 2004). Subjects of the Offspring Cohort with missing data for one or more 
subtests of the neuropsychological battery during the baseline examination (n=54, 2.1%) were 
excluded from the final sample.  This was done so the summary scores for each subject would 
reflect the same combination of overall measures of cognitive functioning.  The final sample 
included 2503 subjects from the FHS Offspring Cohort. 
The FHS Neuropsychological Battery 
 
 The cognitive assessments included in neuropsychological battery were the Boston 
Naming Test (Goodglass & Kaplan, 1983), Trail Making Tests A and B (TMT A, B) (Armitage, 
1946), Finger Tapping Test (Shimoyama, Ninchoji, & Uemura, 1990), Hooper Visual 
Organization Test (Hooper, 1966), Wide Range Achievement Test-3 Reading (WRAT) 
(Wilkinson, 1993), and subtests from the Wechsler Memory Scale (Wechsler, 1945;  logical 
memory immediate and delayed recall, paired-associate memory, visual reproduction immediate 
and delayed recall), and Wechsler Adult Intelligence Scale (Wechsler, 1955; similarities).  A brief 
description of the cognitive abilities examined by each assessment is provided in the Table 4.1.  
A higher score on each subtest of the neuropsychological battery, with the exception of the TMT 
A and B, indicates better cognitive function.  The TMT A and B are timed assessments that 
require a subject to connect a random alphabetic sequence (TMT A) and alphanumeric sequence 
(TMT B).  The times to complete the TMT A and TMT B subtests were used to create an 
additional measure that represented cognitive flexibility by calculating TMT B minus TMT A 
(Arbuthnott & Frank, 2000; Corrigan & Hinkeldey, 1987).    
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Case Definitions for Dementia and Cognitive Impairment  
 
Incident cases of dementia in the Offspring Cohort have been recorded as part of the 
Epidemiology of Dementia study since 1986 (Bachman et al., 1992; Bachman et al., 1993)15.  
Thirty-six subjects diagnosed with dementia received the FHS neuropsychological battery 
between 1999 and 2005, but seven cases (n=5 AD; n=2 other dementia) had missing data for one 
or more assessments. 
Subjects included in the final sample were randomized to either a training set or 
validation set.  The training set was used to estimate the effects of age, sex (coded as 0=male, 
1=female), and education (<high school, some college, college degree) on cognitive performance 
among subjects with normal cognition (absent of dementia or a decline >1.5 standard deviations 
on one or more subtests).  The effects of these characteristics on cognitive performance were 
determined using a univariate model (UV; Table 4.2) in which each variable was examined 
separately and a multivariable (MV) model that included age, sex, and education in the same 
model.  The regression coefficients from the MV model were used to calculate predicted scores 
for each of the cognitive assessments based on a subject’s age, sex and educational attainment 
(Table 4.3).  The cognitive assessments included in the FHS neuropsychological battery were 
used to classify subjects into the following cognitive groups: (1) normal cognition (NC); (2) test-
based impaired learning and memory (ILMTB); and (3) test-based multidomain impaired (MDITB).  
A classification of ILMTB was given to subjects with no dementia and who had impaired 
performance on one or more assessments of learning and memory, but non-impaired performance 
on all other assessments (Abner et al., 2012).  A classification of MDITB was given to participants 
with no dementia and who had impaired performance on one or more assessments in the 
neuropsychological battery, which could include learning and memory subtests.  A classification 
of NC was given to participants who did not have an impaired performance on any assessments.  
                                                        
15 A more detailed description of the protocol used to diagnose dementia in the FHS is provided 
in the methods for Aim Two. 
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Impaired performance for each assessment was defined as >1.5 SD below age, sex, and education 
expected norms based on the estimates for age, sex, and education obtained from the test sample.  
This definition of impairment is consistent with the criteria provided by the National Institute on 
Aging- Alzheimer’s Association workgroup (Albert et al., 2011).  
Generating Summary Scores for the FHS Neuropsychological Battery  
 
 Composite Subtests Summary Score:  All of the assessments included in the FHS 
neuropsychological battery, with the exception of the Finger Tapping Test and WRAT, and the 
calculated measure of cognitive flexibility (TMT B minus TMT A) were included in this 
summary score.  The Finger Tapping Test was excluded because this assessment is frequently 
used to measure motor functioning (Volkow et al., 1998).  The WRAT was excluded because this 
assessment is a word identification test that measures literacy (Davis, Michielutte, Askov, 
Williams, & Weiss, 1998) and is often used as a proxy for educational quality (Manly, Jacobs, 
Touradji, Small, & Stern, 2002).  The composite subtests summary score was calculated by first 
transforming the score of each assessment into a z score by subtracting an individual subject’s 
assessment score minus the sample mean and dividing by the standard deviation.  The z scores for 
TMT A and B and cognitive flexibility were multiplied by -1 to account for these being timed 
assessments.  Once a z score was calculated for each assessment, the average of the z scores was 
calculated to obtain the summary score.   
 Learning and Memory Summary Score:  The learning/memory summary score was 
obtained by calculating the average of the six z-scores for the subtests that assessed learning and 
memory.  The average of the z-scores was used for the summary score as opposed to the sum of 
the scores so that each assessment provided equal weight to the summary score.   
         Composite Domains Summary Score: The specific cognitive domains assessed by the FHS 
neuropsychological battery were determined by conducting a factor analysis, followed by an 
orthogonal (varimax) rotation.  A total of three factors were extracted (eigenvalue >1) and a 
fourth factor with an eigenvalue of 0.9 was also included (remaining eigenvalues <0.71).  The 
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following subtests loaded onto the four factors based on a rotated factor pattern score above 0.5: 
visual/spatial memory [Visual Memory Immediate Recall (0.90), Visual Memory Delayed Recall 
(0.9), Hooper Visual Organization Test (0.5)]; verbal memory [Logical Memory Immediate 
Recall (0.93), Logical Memory Delayed Recall (0.90)]; new learning [Paired Associates 
Immediate Recall (0.88), Paired Associates Delayed Recall (0.9)]; and attention/concentration 
[TMT A (0.87), TMT B (0.77)].  Cognitive flexibility was added to the attention/concentration 
domain.  Once these cognitive domains were identified, the next step was to sum the scores for 
the subtests to create a total score for each specific cognitive domain.  These total scores were 
then transformed into z scores and the average of these z scores was calculated to obtain the 
composite domain summary score. 
Statistical Analysis 
 
 Receiver operator characteristic (ROC) analysis was conducted to obtain ROC curves for 
each of the summary scores. The area under the curve (AUC) is interpreted as the probability that 
a randomly selected subject who is a case (dementia, ILMTB, or MDITB) has a lower summary 
score than a randomly selected subject who was classified as having normal cognition.  To 
control for the effects of age, sex and educational attainment, the residuals of the summary scores 
were obtained by calculating the difference between the observed summary score and predicted 
summary score given a subject’s age, sex and educational attainment.  The ROC analysis was 
also used to determine the sensitivity (proportion of cases who were correctly identified), 
specificity (the proportion of controls who are correctly identified), positive predictive value 
(ppv; the probability that subjects who test positive for the disease are true cases), negative 
predictive value (npv; the probability that subjects who test negative are true controls), and 
diagnostic accuracy (proportion of cases and controls who are correctly identified) for the cut-
point of the residuals for each summary score.  The ROC curve analysis was conducted using 
data from the validation sample.   
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Aim Two: Differences in the Longitudinal Trajectories of Cholesterol from Midlife to Late 
Life According to Alzheimer’s Disease Status 
Sample Population 
 
 A total of 5079 subjects of the FHS Original Cohort between the ages of 28 and 74 (mean 
age 44.2 years) completed a baseline clinical exam between 1948 and 1953.  Thirty clinical 
examinations have been completed since 1948 and 141 participants (mean age 92, range 88-102) 
attended the thirtieth clinical exam, which concluded in 2010.  A sub-cohort of subjects from the 
FHS Original Cohort who were said to be absent of dementia was established from 1976 to 1978 
with the purpose of recording incident cases of dementia (Bachman et al., 1993).  A total of 3210 
subjects were said to be absent of dementia and these subjects have been evaluated during each 
biennial examination to assess dementia status (yes / no), date last known to be cognitively intact, 
and date of incident dementia, death or censoring.  Because the purpose of this aim was to 
examine trajectories of cholesterol from midlife to late life, subjects who were younger than 30 
years (n=21, <1%) or older than 55 years (n=174, 5.4%) during the first clinical exam were 
excluded from the final sample.  An additional 124 subjects (3.9%) who were younger than 65 
years of age when they were last known to be cognitively intact were also excluded.  The age 
cutoffs for midlife (age 30 – 55) and late life (age > 65) were based on distinct trends in the 
relationship between total cholesterol and chronological age among subjects of the Original 
Cohort (see Chapter Three for a detailed description of how the definitions for midlife and late 
life were obtained).     
Diagnosis of Dementia in the FHS Original Cohort 
 
 The methods used in the FHS to diagnose dementia have been previously described 
(Bachman et al., 1992; Bachman et al., 1993).  From 1976 to 1978 surviving members of the FHS 
Original Cohort were screened for dementia using the Mini Mental State Exam (MMSE; Folstein, 
Folstein, & McHugh, 1975) to establish a dementia-free cohort of 3210 subjects.  These 3210 
subjects received the MMSE during each subsequent clinical examination.  Subjects who scored 
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below the education-adjusted cut-off score on the MMSE (score < 22 for < 7 yrs. Education; 
score < 24 for 8 to 11 yrs. Education; score < 25 for high school graduate; and score < 26 for any 
education beyond high school), declined three or more points since the previous examination, or 
were referred by themselves, a family member, family physician, or FHS physician were given a 
comprehensive neuropsychological battery.  The neuropsychological battery included subtests 
that assessed the following cognitive domains: (1) verbal and visual learning, (2) attention,  (3) 
language, (4) visuospatial construction, and (5) abstract thinking (Farmer et al., 1987).  A subject 
was said to be cognitively impaired if they performed at a level one or more standard deviations 
below age-adjusted norms on three or more of the five cognitive domains assessed by the 
neuropsychological battery.  An expert panel reviewed all available records for subjects who met 
the criteria for cognitive impairment to determine if the cognitive impairment was likely due to 
dementia.  Subjects were considered as having dementia if they met the criteria for cognitive 
impairment for at least one year and exhibited progressive cognitive decline over a prolonged 
period.  For cases of dementia, the panel also reviewed dementia severity (mild or moderate) and 
dementia subtype (Alzheimer’s disease [AD], AD with stroke, vascular dementia [VaD], AD with 
VaD [mixed dementia], or other).  For the purposes of this study, only subjects diagnosed with 
AD were included in the final sample.    
Measures of Cholesterol 
 
 Measures for total cholesterol and HDL cholesterol were collected from participants of 
the FHS Original Cohort using standard laboratory procedures (Abel, Levy, Brodie, & Kendall, 
1952).  Fasting measures for total cholesterol were collected during twenty clinical examinations 
(clinical exams 1-11, 13-15, 20, 22, 24-27) and measures of HDL cholesterol were collected 
during ten clinical examinations (clinical exams 9-11, 15, 20, 22, and 24-27).  Total/HDL ratio 
was calculated by dividing the measure of total cholesterol by the measure of HDL cholesterol.  
The distributions for total/HDL ratios were highly right skewed so log transformations were used.   
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Statistical Analysis 
 
 The demographic characteristics of the final sample were described according to AD 
status (non-demented or AD).  T-tests were used to compare group means for continuous 
variables and chi-square tests were used to compare group differences for categorical variables. 
The trajectories of total cholesterol, HDL cholesterol, and log-total/HDL ratio according to AD 
status were modeled using generalized additive mixed models (GAMM; Lin & Zhang, 1999)  
implemented using the gamm4 package (S. Wood & Scheipl, 2013) in R (http://www.r-
project.org).  GAMM are semi-parametric models that utilize a data driven approach to model a 
non-linear relationship between the dependent and independent variables as opposed to including 
quadratic, cubic or higher level polynomial terms.  The general form of the GAMM used for this 
study is: 
𝑔�𝑢𝑖𝑗� = 𝑿𝒊𝑻𝜷 +  𝑠𝐴𝐷�𝑥𝑖𝑗�𝐴𝐷𝑖 +  𝑠1−𝐴𝐷�𝑥𝑖𝑗�(1 − 𝐴𝐷𝑖)  +  𝑏𝑖 +  𝜖𝑖𝑗                       (4.1) 
 where 𝑢𝑖𝑗= E(Yij) is the expected value of cholesterol for the ith subject during the jth 
observation given the covariates included in the model (see Covariates), and bi is a subject-
specific random effect that allows for the baseline value of cholesterol to vary for each subject; 
g( )is the link function that specifies the relationship between the expected value of cholesterol 
and the covariates included in the model.  The link function for the model was the identity 
function because total, HDL, and log-total/HDL cholesterol ratio were continuous variables.  Xi is 
a k-length vector comprising the k time-invariant covariates of subject i and 𝜷 is a k-length vector 
of the fixed effects for the corresponding k covariates; xij is the age of the ith subject during the 
jth observation; sAD and s1-AD are the smoothing terms that were generated for subjects with AD 
and subjects without dementia, respectively.  ADi is an indicator variable denoting AD status in 
the ith subject.  Since every subject is either AD or non-demented, the term 1-ADi specifies 
subjects who do not have AD and prevents over parameterization of the model.  The inclusion of 
two different smooth terms allowed for the trajectories of cholesterol to vary according to AD 
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status.  The smoothing function models the potentially non-linear trajectory of cholesterol with 
advancing age.  A thin plate regression spline function was applied to age for both AD and non-
demented subjects.  An advantage of the thin plate regression spline function over other 
smoothing functions is that the number and placement of knots that control the flexibility of the 
model do not need to be specified (S. Wood, 2003).  The more knots included in the model, the 
more precisely the model will fit the data, but this is at the risk of over fitting the data and 
producing a curve that is not sufficiently smooth.  Concerns of over fitting are addressed by 
adding a second derivative function on the penalty to the least squares fitting approach (S. Wood, 
2003) providing a tradeoff between model fit and model smoothness (S. Wood, 2006).  The term 
𝜖𝑖𝑗 is the within-subject error term, which is the difference between the observed measure of 
cholesterol and the expected measure of cholesterol based on the model.  Both bi and 𝜖𝑖𝑗 are 
assumed to be randomly distributed with mean zero and variances of 𝜎𝑏2 and 𝜎𝜖2, respectively.  An 
additional assumption is that bi and 𝜖𝑖𝑗 are independent of one another.   
 The estimated trajectories of total cholesterol, HDL cholesterol, and log-total/HDL ratio 
based on the models were plotted along with point-wise 95% confidence intervals that were 
constructed by calculating the upper and lower bounds for each predicted measure of cholesterol.  
This allowed for the trajectories of total cholesterol, HDL cholesterol and log-total/HDL ratio 
according to AD status to be visually examined.  The degree to which the trajectories of 
cholesterol departed from linearity is reflected by the effective degrees of freedom (EDF) of the 
smooth term (James, Witten, Hastie, & Tibshirani, 2013).  A smooth term with x EDF can be 
interpreted as an x degree polynomial term.  An EDF of 1 indicates that the trajectory is linear 
and increasing values of EDF indicate greater degrees of non-linearity 
Covariates 
 
  Data for several potential confounding variables were collected during each clinical 
examination using standard laboratory procedures and a medical history interview.  Educational 
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attainment was initially recorded according to the following categories: (1) none, (2) fourth grade 
or less, (3) fifth, sixth or seventh grade, (4) completed grade school, (5) some high school, (6) 
graduated high school, (7) some college, (8) college graduate or (9) post graduate.  For the 
purposes of this study, educational attainment was dichotomized according to receiving a high 
school degree (< high school degree or > high school degree).  Smoking status was assessed 
during each clinical examination and subjects were dichotomized as having ever reported 
smoking (yes/no).  The use of cholesterol lowering medications (statins, fibrates, resins, or 
niacin) was assessed during clinical examinations 7-27.  Subjects were dichotomized as having 
reported ever using a cholesterol lowering medication during a clinical examination (yes/no).  
Data for systolic and diastolic blood pressure was collected during each clinical examination and 
blood glucose was measured during clinical exams 1-11, 13-15, 20, 22, 24-27.  Blood pressure 
and blood glucose were included in the models as the average of these measures across all of the 
clinical examinations attended by the subject.  APOE e4 allele status was dichotomized according 
to the presence of one or more APOE e4 alleles (e4+ or e4-). 
A subsequent analysis was conducted that included the use of supplemental estrogen as a 
covariate.  Estrogen replacement therapy is an effective approach for maintaining a healthy lipid 
profile for women who are approaching or experiencing menopause (Vehkavaara et al., 2001).  
There is evidence that women who take supplemental estrogen are at a decreased risk for AD 
(Kawas et al., 1997; Paganini-Hill & Henderson, 1994), but some studies have reported no 
benefits of estrogen use (Brenner et al., 1994) or even an increased risk for cognitive impairment 
among estrogen users (Shumaker et al., 2004; Shumaker et al., 2003).  Based on the results from 
previous studies, additional models were used to visually inspect for differences in the trajectories 
of total cholesterol, HDL cholesterol and log-total/HDL cholesterol ratio according to AD status 
after controlling for the effects of a history of using supplemental estrogen.  The use of 
supplemental estrogen (oral, patch, or cream) was assessed during clinical exams 17-27 and was 
included in the models as having reported using supplemental estrogen (yes/no).   
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Aim Three: Subject-Specific Trajectories of Total Cholesterol According to  
Cognitive Functioning 
Sample population 
 
The FHS Offspring Cohort began in 1971 and includes the children of the Original 
Cohort and their spouses.  Details regarding the design and methods of data collection of the FHS 
Offspring Cohort have been described previously (Feinleib et al., 1975).  Eight clinical 
examinations were completed between 1971 and 2008.  A total of 5124 subjects between the ages 
of 5 and 70 (mean age 36) attended the first clinical exam and 3021 (mean age 67, range 40 – 93) 
subjects attended the eighth clinical examination.   
Beginning in 1999, subjects who were actively participating in the FHS Offspring Cohort 
were recruited to participate in a secondary study in which they received a comprehensive 
neuropsychological battery (Massaro et al., 2004).  A total of 2557 subjects of the Offspring 
Cohort received a neuropsychological battery between 1999 and 2005.  Because the purpose of 
this study was to examine trajectories of cholesterol from midlife to late life, subjects who were 
not between 30 and 45 years of age during the first clinical examination and were not 60 years of 
age or older upon receiving the neuropsychological battery were not included in the final sample.  
The age cutoffs for midlife (age 30 – 45) and late life (age > 60) were based on distinct trends in 
the relationship between total cholesterol and chronological age among subjects of the Offspring 
Cohort (see Chapter Three for a detailed description of how the definitions for midlife and late 
life were obtained).  These definitions are different than those used in Aim Two because the ages 
in which visually apparent changes in total cholesterol varied between the Offspring and Original 
Cohorts.  A total of 967 subjects (37.8%) were between 30 and 45 years of age during the first 
clinical exam and 60 years of age or older upon receiving a baseline neuropsychological battery.  
Subjects who had received a diagnosis of dementia (n=13) and did not complete all of the 
assessments included in the neuropsychological battery (n=16) were removed from the sample.  
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Finally, subjects who did not have data for apolipoprotein E (APOE) genotype (n=206) were 
removed from the sample.  The final sample included 761 subjects. 
Measure of Cognitive Functioning 
 
 A description of the FHS neuropsychological battery was provided in the methods for 
specific aim one.  A summary score of the FHS neuropsychological battery was obtained by 
standardizing a subject’s raw score for each cognitive assessment according to the sample mean 
and standard deviation, followed by calculating the average of these standardized scores.  The 
findings from aim one of the dissertation research provided evidence that this method produces a 
summary score that is able to accurately differentiate between subjects classified as having 
normal cognition, cognitive impairment, and dementia (see Chapter Five Aim One for complete 
results).  Subjects were grouped into quartiles based on their summary score for the FHS 
neuropsychological battery.  This was necessary to visually examine potential differences in 
subject-specific trajectories of total cholesterol according to cognitive functioning.  Subjects in 
the first quartile represent those who had a summary score in the bottom 25 percent of the sample 
population and subjects in the fourth quartile were those who had a summary score in the top 25 
percent of the sample population.  Subjects in the second and third quartiles were treated as the 
reference category for the purposes of identifying potential differences in the trajectories of total 
cholesterol among subjects with low or high cognitive functioning. 
Measures of Cholesterol 
 
 Fasting measures for total cholesterol have been collected from subjects during all eight 
clinical examinations.  It should be noted that fasting cholesterol measures, especially when used 
for epidemiological studies, are subject to biases emerging from different effects that control 
individual adherence to prescriptive fasting prior to blood draws. 
Statistical Analysis 
 The demographic characteristics of the final sample were described according to the 
quartiles of cognitive functioning.  Analysis of variance was used to compare group means for 
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continuous variables and chi-square tests were used to compare group differences for categorical 
variables. 
 Mixed effects modeling (Laird & Ware, 1982) was used to visually examine the subject-
specific trajectories of total cholesterol split according to the cognitive quartiles.  This approach 
was used because it provides valid estimates when data are highly unbalanced due to differences 
in the number and timing at which subjects are observed (Cnaan, Laird, & Slasor, 1997).  The 
general form of the mixed effects model is given by:            
𝑌𝑖𝑗 = 𝑿𝒊𝑻𝜷 + 𝑏1𝑖 + 𝑏2𝑖𝑎𝑔𝑒𝑖𝑗 +  𝑏3𝑖𝑎𝑔𝑒𝑖𝑗2 +  𝜖𝑖𝑗                                        (4.2) 
where Yij is the measure of cholesterol for subject i during the jth observation.  Xi is a k-length 
vector of values for the time-invariant covariates for subject i and β is the k-length vector of fixed 
effects for the corresponding covariates; ageij is the age of subject i during the jth observation; b1i 
is the random intercept for subject i and b2i is the random slope term for subject i.  A quadratic 
term for age was also included as a fixed effect and random effect to account for a non-linear 
relationship between cholesterol and age.  The generalized additive mixed models that were used 
in Aim Two could not be utilized in this specific aim because a smoothing function cannot be 
included as a random effect, which is necessary for a smooth function to be applied to each 
subject’s trajectory of total cholesterol.  The random effects b1i, b2i and b3i are all assumed to be 
randomly distributed with mean zero and variances of 𝜎𝑏12 , 𝜎𝑏22  and 𝜎𝑏32 , respectively.  The 
random intercept represents how much an individual’s baseline measure of cholesterol deviates 
from the population average, whereas the random trajectory represents how an individual’s 
change in cholesterol with age deviates from the population average.  Finally, 𝜖𝑖𝑗 is the within-
subject measurement error, which allows for a measure of cholesterol during any observation 
period to vary randomly above or below a subject’s mean trajectory of cholesterol.  The error 
terms are assumed to be independent and normally distributed with a mean 0 and variance 𝜎𝜖2.  
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An additional assumption is that the random effects (b1i, b2i and b3i) and 𝜖𝑖𝑗 are independent of 
one another.   
 Two-way interaction terms for age by cognition quartile and age-squared by cognition 
quartile were included in all models to determine if subjects in the first and fourth cognitive 
quartiles had different trajectories of cholesterol compared to subjects in the middle two quartiles.  
Two-way interactions between age and sex, and age-squared and sex were included to account for 
differences in the trajectories of cholesterol between men and women.  Random effects for age 
and age-squared were included in the model to allow for the trajectory of cholesterol to vary for 
each subject.  A random intercept term was also included to account for each subject having a 
different baseline measure of cholesterol.  Estimates for subject-specific trajectories of cholesterol 
were obtained by combining the values for the random and fixed effects.  As an example, if ?̂?1 is 
the fixed effect for the intercept and ?̂?2 and ?̂?3 are the fixed effects for the trajectory of 
cholesterol (i.e. the population average cholesterol trajectory), and 𝑏�1𝑖 is the random intercept and 
𝑏�2𝑖  and 𝑏�3𝑖 are the random trajectories then the subject-specific intercept is ?̂?1 + 𝑏�1𝑖 and the 
subject-specific trajectory is ?̂?2 + ?̂?3 + 𝑏�2𝑖 + 𝑏�3𝑖.   
 The random effects for each subject are predicted by the best linear unbiased predictor 
(BLUP) via maximum likelihood to estimate the covariance between the repeated measures of 
cholesterol (Fitzmaurice, Laird, & Ware, 2011).  The BLUP shrinks each subject’s predicted 
trajectory towards the population average trajectory based on the degree of within-subject 
variability (i.e. the random fluctuations of the repeated measures of cholesterol from a single 
subject) compared to the between-subject variability (i.e. the variation in the measures of 
cholesterol from different subjects).  The trajectory of cholesterol for a subject whose repeated 
measures of cholesterol have high within-subject variability relative to the between-subject 
variability will be shrunk closer to the population average trajectory compared to a subject whose 
repeated measures of cholesterol have relatively low within-subject variability.  The degree to 
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which a subject’s trajectory is pulled towards the population average trajectory is also influenced 
by the number of times a subject has been observed.  The fewer observations for a subject the 
closer their trajectory is shrunk to the population average.   
Covariates 
 Data for several potential confounding variables were collected during each clinical 
examination using standard laboratory procedures and a medical history interview.  Measures of 
total cholesterol were collected during all eight clinical examinations.  Educational attainment 
was assessed during the neuropsychological battery and was recorded as: (1) less than high 
school, (2) high school degree, (3) some college and (4) college degree or higher.  Smoking status 
was assessed during each clinical examination and subjects were dichotomized as having ever 
reported smoking (yes/no).  The use of cholesterol lowering medications (statins, fibrates, resins, 
or niacin) was assessed during all eight clinical examinations.  Subjects were dichotomized as 
having ever used a cholesterol lowering medication (yes/no).  Data for systolic and diastolic 
blood pressure was collected during each clinical examination and measures for blood glucose 
were recorded for the first through seventh clinical examinations.  Blood pressure and blood 
glucose were included in the analysis as the average of these measures across all of the clinical 
examinations attended by the subject.  Data for apolipoprotein E (APOE) genotype was recorded 
for 761 subjects.  There were 587 subjects who did not carry an APOE e4 allele, 158 who were 
heterozygous for the e4 allele and 16 who were homozygous for the e4 allele.  APOE e4 allele 
status was dichotomized according to the presence of one or more APOE e4 alleles (e4+ or e4) 
due to the low number of APOE e4 homozygotes in the final sample.  
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Table 4.1: Cognitive Assessments in the FHS Neuropsychological Battery 
 
Assessment Score  Cognitive ability  *Mean (SD) 
Boston Naming Test 0-36 Naming and language 27.4 (2.5) 
Trail Making Test A 0-300 (sec) Simple attention 0.55 (0.26) 
Trail Making Test B 0-300 (sec) Complex attention 1.4 (0.77) 
HVOT 0-30 Visuoperceptual skills, 
executive function 
25.0 (3.2) 
WRAT 0-57 Premorbid intelligence  48.7 (5.1) 
Logical memory 
immediate recall  
0-24 Verbal memory 11.5 (3.5) 
Logical memory delayed 
recall 
0-24 Verbal memory 10.5 (3.7) 
Paired-associates, 
immediate recall 
0-21 New learning 13.9 (3.4) 
Paired-associate delayed 
recall 
0-21 New learning 8.2 (1.5) 
Visual reproductions 
immediate recall 
0-14 Visual memory 9.0 (3.2) 
Visual reproduction 
delayed recall 
0-14 Visual memory 8.2 (3.4) 
Similarities 0-26 Abstract reasoning 16.8 (3.6) 
The Trail Making Test (TMT) A and B are timed assessments with a maximum of five minutes 
(300 seconds) being allowed to complete the assessment.  A longer time to complete each of the 
assessments indicates lower cognitive performance.   
HVOT - Hooper visual organization test 
WRAT - Wide range achievement test 
The mean score for TMT B – TMT A was 0.85 (SD=0.66) 
*Mean and SD for final sample (N=2503) 
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Table 4.2: Effects of Age, Sex and Education on Assessments in the FHS 
Neuropsychological Battery (Univariate Model). 
 
 Univariate Model 
Subtest Age Sex Some College College 
LMI -0.056 
(-0.080, -0.31) 
0.77 
(0.31, 1.23) 
1.03 
(0.44, 1.62) 
2.10  
(1.58, 2.62) 
LMD -0.066 
(-0.091, -0.40) 
0.95 
(0.47, 1.43) 
1.25  
(0.64, 1.87) 
2.16  
(1.62, 2.71) 
PASI -0.084 
(-0.11, -0.059) 
1.29 
(0.83, 1.75) 
0.68  
(0.077, 1.29) 
1.23 
(0.70, 1.77) 
PASD -0.035 
(-0.046, -0.024) 
0.50 
(0.31, 0.70) 
0.17 
(-0.89, 0.43) 
0.41  
(0.18, 0.64) 
VRI -0.11 
(-0.13, -0.088) 
-0.33 
(-0.76, 0.11) 
1.19 
(0.63, 1.74) 
1.89  
(1.40, 2.38) 
VRD -0.11 
(-0.13, -0.085) 
-0.27 
(-0.74, 0.19) 
1.28  
(0.69, 1.87) 
2.09 
(1.57, 2.61) 
TMT A 0.0059 
(0.0044, 0.0074) 
-0.029 
(-0.057, -8.0e-4) 
-0.050 
(-0.087, -0.013) 
-0.057  
(-0.090, -0.024) 
TMT B 0.024 
(0.020, 0.028) 
0.022 
(-0.62, 0.11) 
-0.16 
(-0.27, -0.051) 
0.31 
(-0.41, -0.22) 
TMT (B-A) 0.018 
(0.014, 0.021) 
0.051 
(-0.020, 0.12) 
-0.011 
(-0.20, -0.018) 
-0.26 
(-0.34, -0.18) 
HVOT -0.12 
(-0.14, -0.099) 
0.20 
(-0.22, 0.63) 
0.59 
(0.033, 1.14) 
1.02 
(0.53, 1.51) 
Similarities -0.089 
(-0.11, -0.064) 
-0.43 
(-0.90, 0.034) 
1.60 
(1.04, 2.17) 
3.09  
(2.59, 3.59) 
BNT -0.064 
(-0.081, -0.047) 
-0.49 
(-0.82, -0.17) 
1.13 
(0.74, 1.53) 
1.96 
(1.61, 2.31) 
 
*Based on subjects included in the test set that were absent of dementia or decline >1.5 SD on 
one or more subtests. 
Bold P<0.01 Underlined P<0.05 but not P<0.01 
Referent category for sex is male.  Referent category for education is high school degree or less.   
LMI = Logical Memory, Immediate Recall; LMD = Logical Memory, Delayed Recall; PASI = 
Paired Associates, Immediate Recall; PASD = Paired Associates, Delayed Recall; VRI = Visual 
Reproductions, Immediate Recall; VRD = Visual Reproduction, Delayed Recall; TMT A (B) = 
Trail Making Test A (B); HVOT = Hooper Visual Organization Test; BNT = Boston Naming 
Test 
TMT A, B and B-A are timed assessments; higher score indicates lower performance
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Table 4.3 Effects of Age, Sex and Education on Assessments in the FHS Neuropsychological 
Battery (Multivariable Model). 
 
Multivariable Model 
Subtest Age Sex Some College College 
LMI -0.041 
(-0.065, -0.017) 
1.18 
(0.73, 1.62) 
0.90 
(0.31, 1.48) 
2.21 
(1.69, 2.74) 
LMD -0.050 
(-0.75, -0.25) 
1.36 
(0.89, 1.82) 
1.09 
(0.49, 1.70) 
2.29  
(1.74, 2.83) 
PASI -0.076 
(-0.10, -0.052) 
1.55  
(1.10, 2.00) 
0.44 
(-0.15, 1.02) 
1.30 
(0.78, 1.83) 
PASD -0.033 
(-0.043, -0.023) 
0.60 
(0.40, 0.79) 
0.062 
(-0.19, 0.31) 
0.42 
(0.20, 0.65) 
VRI -0.099 
(-0.12, -0.077) 
-0.052 
(-0.46, 0.36) 
0.85 
(0.31, 1.38) 
1.53 
(1.05, 2.01) 
VRD -0.10 
(-0.12, -0.072) 
0.04 
(-0.40, 0.48) 
0.95  
(0.38, 1.53) 
1.75 
(1.23, 2.27) 
TMT A 0.0056 
(4.0e-3, 7.0e-3) 
-0.038 
(-0.065, -9.8e-3) 
-0.031 
(-0.067, 4.8e-3) 
-0.045 
(-0.078, -0.013) 
TMT B 0.022  
(0.018, 0.026) 
-0.028 
(-0.11, 0.051) 
-0.24 
(-0.19, 0.019) 
-0.24 
(-0.33, -0.15) 
TMT (B-A) 0.017 
(0.013, 0.020) 
0.0096 
(-0.058, 0.077) 
-0.053 
(-0.14, 0.035) 
-0.20 
(-0.27, -0.12) 
HVOT -0.12 
(-0.14, -0.095) 
0.36 
(-0.04, 0.76) 
0.19 
(-0.33, 0.71) 
0.68 
(0.21, 1.15) 
Similarities -0.068 
(-0.091, -0.045) 
0.074 
(-0.36, 0.50) 
1.37 
(0.81, 1.92) 
2.86  
(2.36, 3.37) 
BNT -0.050 
(-0.066, -0.034) 
-0.20 
(-0.50, 0.10) 
0.96 
(0.57, 1.34) 
1.73 
(1.38, 2.09) 
 
*Based on subjects included in the test set that were absent of dementia or decline >1.5 SD on 
one or more subtests. 
Bold P<0.01 Underlined P<0.05 but not P<0.01 
Referent category for sex is male.  Referent category for education is high school degree or less.   
LMI = Logical Memory, Immediate Recall; LMD = Logical Memory, Delayed Recall; PASI = 
Paired Associates, Immediate Recall; PASD = Paired Associates, Delayed Recall; VRI = Visual 
Reproductions, Immediate Recall; VRD = Visual Reproduction, Delayed Recall; TMT A (B) = 
Trail Making Test A (B); HVOT = Hooper Visual Organization Test; BNT = Boston Naming 
Test 
TMT A, B and B-A are timed assessments; higher score indicates lower performance 
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Chapter Five: Results 
Specific Aim One 
Sample Characteristics 
The demographic characteristics of the subjects included in the validation sample 
according to cognitive status are provided in Table 5.1.  Among subjects who completed a 
neuropsychological battery, 619 (49.5%) were classified as having normal cognition (NC), 214 
(17.1%) were classified as test-based impaired learning and memory (ILMTB), 399 (31.9%) were 
classified as multidomain impaired (MDITB).  There were 19 (1.5%) subjects who had received a 
diagnoses of dementia.  There were significant differences for age (P<0.01) and educational 
attainment (P=0.02) between all four of the cognitive groups.  There were no differences in the 
proportion of males and females in any of the cognitive groups.       
Effects of Age, Sex, and Education on Cognitive Function   
 Significant differences in the assessment scores of the FHS neuropsychological battery 
according to age, sex, and educational attainment were detected in the univariate (UV) and 
multivariable (MV) models.  Cognitive performance on all of the assessments significantly 
decreased with age in the UV model (P<0.01).  The effect of age remained after controlling for 
the effects of education and sex.  Subjects with a college degree had significantly higher 
performance (P<0.01) on all assessments compared to subjects with <high school degree even 
after accounting for the effects of age and sex.  Women performed better than men on Logical 
Memory (Immediate and Delayed Recall) and Paired Associates (Immediate and Delayed 
recall), whereas men performed better than women on TMT A and Boston Naming Test.  
However, the effect of sex on the Boston Naming Test was no longer significant once education 
was included in the model.  No significant differences according to sex in the UV or MV models 
were observed for Visual Recognition (Immediate and Delayed recall); TMT B; Hooper Visual 
Organization Test; Similarities, or cognitive flexibility (TMT B – TMT A). 
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Ability of Summary Scores to Differentiate between Cognitive Groups 
NC and Dementia:  Older adults diagnosed with dementia were considered to be cases in 
this analysis.  All three summary scores were very accurate when differentiating between 
subjects classified as NC and subjects diagnosed with dementia.  The areas under the curve 
(AUC16; the probability that a randomly selected dementia case has a lower score than a 
randomly selected NC control) among the three summary scores were all greater than 96 percent 
(Table 5.2; Figure 5.1).  The composite subtest summary score had significantly higher 
specificity and overall test accuracy compared to the composite domains summary score, but not 
compared to the learning/memory summary score.  These results provide evidence for the use of 
the composite subtests summary score for differentiating between NC and dementia subjects. 
NC and ILMTB: Subjects with ILMTB were considered to be cases in this analysis.  There 
were no significant differences in AUCs among the three summary scores (Table 5.3; Figure 
5.2).  The learning/memory summary score had the greatest sensitivity (84.6 [79.0-89.1]), 
specificity (78.8 [75.4-82.0]), npv (93.7 [91.2-95.6]), ppv (58.0 [52.3-63.6]), and overall test 
accuracy (80.3 [77.4-83.0]).  However, these differences were not statistically significant 
compared to the other summary scores.  Based on these results, there are no apparent differences 
between the three summary scores in their ability to differentiate between ILMTB and NC. 
NC and MDITB: Subjects with MDITB were considered to be cases in this analysis.  The 
composite subtests summary score had significantly greater AUC (90.5 [88.6-92.4]) and higher 
overall test accuracy (83.3 [80.9-85.5], compared to the composite domains and 
learning/memory summary scores (Table 5.4; Figure 5.3).  In addition, the composite domains 
summary score had a significantly greater AUC (85.8 [83.4-88.1]) compared to the 
                                                        
16 A receiver operator characteristic (ROC) curve is a plot of the sensitivity and specificity for 
different cut-points of each summary score and shows the tradeoff between sensitivity and 
specificity (i.e. as sensitivity increases, specificity decreases).  Sensitivity and specificity is for 
the optimal cut-off score for each summary score.   
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learning/memory summary score (80.0 [77.2-82.7]).  The composite subtest summary score had 
significantly higher specificity, ppv, and overall test accuracy compared to the composite 
domains and learning/memory summary scores, in addition to a higher npv compared to the 
learning/memory summary score.  Based on this evidence, a summary score that assesses only 
learning and memory should be avoided when differentiating between normal and MDITB 
subjects in the FHS. 
Dementia and ILMTB :  Older adults diagnosed with dementia were considered to be cases 
in this analysis.  The composite subtests summary score had the greatest AUC (89.3 [77.7-100]), 
but the wide confidence interval due to the small number of subjects diagnosed with dementia 
prevented any differences in AUC according to cognitive status from being observed.  The 
composite subtests summary score also had the highest specificity (93.0 [88.7-96.0]), ppv (51.6 
[33.1-69.8]) and overall test accuracy (92.2 [88.1-95.4]) among the three summary scores (Table 
5.5; Figure 5.4).  However, there were no significant differences between the three summary 
score for any of these measures.  Based on these results, there is insufficient evidence for a 
summary score that performs substantially better when differentiating between ILMTB and 
dementia. 
Dementia and MDITB:  Older adults diagnosed with dementia were considered to be cases 
in this analysis.  There were no significant differences between the AUCs for any of the three 
summary scores (Table 5.6; Figure 5.5).  The learning/memory summary score had higher 
specificity (92.2 [89.2-94.7]), ppv (29.5 [16.8-45.2]) and overall test accuracy (91.1 [88.0-93.7]), 
but these values were not significantly higher compared to the other summary scores.  As was 
observed when comparing ILMTB and dementia, there is insufficient evidence for a best summary 
score when differentiating between MDITB and dementia. 
ILMTB and MDITB:  Subjects with MDITB were considered to be cases in this analysis.  
The composite subtest summary score had significantly greater AUC (65.7 [61.4-69.9]) compared 
to composite domains summary score, but not the learning/memory summary score (Table 5.7; 
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Figure 5.6).  The composite subtests summary score had the highest sensitivity (58.6 [53.6-63.5]) 
among the three summary scores, which was significantly higher compared to the composite 
domains summary score (43.9 [38.9-48.9]).  The composite domains summary score had a 
significantly higher specificity, but significantly lower sensitivity compared to the 
learning/memory summary score.  There was no difference in specificity between the composite 
subtest and composite domains summary scores.  Based on this evidence, the composite subtest 
score is best able to differentiate between ILMTB and MDITB due to the significantly higher AUC 
and sensitivity compared to the composite domains summary score.  However, the composite 
domains score should be utilized if there is a greater priority on correctly identifying ILMTB.   
Specific Aim Two 
Sample Population 
The descriptive characteristics of subjects of the FHS Original Cohort included in the 
final sample according to AD status are provided in Table 5.8.  The final sample included a total 
of 2449 subjects, of which 2102 who did not have dementia and 347 who had received a 
diagnosis of AD.  The final sample was comprised predominately of females (n=1428, 58.3%) 
and the majority of subjects had a high school degree or less (n=1632, 68.5%).  There was no 
association between AD and educational attainment, but females were more likely than males to 
be diagnosed with AD (P<0.01).  There were 386 (15.8%) subjects who reported taking a 
cholesterol-lowering medication during one or more clinical examinations.  There was no 
difference in the proportion of subjects who reported using cholesterol-lowering medications 
according to AD status.  Subjects diagnosed with AD had slightly, albeit significantly, lower 
average blood glucose (P<0.01), systolic blood pressure (P=0.01) and diastolic blood pressure 
(P<0.01) compared to subjects without dementia.  Subjects without dementia were more likely to 
have a history of smoking compared to subjects diagnosed with AD (P<0.01).  The apparent 
protective effect of smoking against AD may be due to smokers dying before they would have 
been diagnosed with AD (Kryscio et al., 2013).   
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Data for APOE genotype was available for 568 subjects (23.2%) included in the final 
sample.  There were 125 subjects who carried one or more APOE e4 alleles (e4+) and 443 
subjects who did not carry any APOE e4 alleles (e4-).  As expected, subjects who were APOE 
e4+ were more likely to be diagnosed with AD compared to subjects who were APOE e4- 
(P<0.01).   
Trajectories of Cholesterol According to Alzheimer’s Disease Status  
   The unadjusted and adjusted trajectories of total cholesterol, HDL cholesterol, and log-
total/HDL ratio according to AD status are presented in Figures 5.7-5.9.  Solid lines represent the 
mean measures of cholesterol according to AD status and the shaded regions represent the point-
wise 95% confidence interval for each measure of cholesterol.  The degree of non-linearity for the 
trajectories as reflected by the estimated EDF of the smoothing term, and the model fit by 
adjusted R2, which is interpreted as the proportion of total variance explained by the model with 
an adjustment for model complexity, are presented in Table 5.9.  According to visual inspection, 
there were no differences in the unadjusted mean trajectories of total cholesterol, HDL 
cholesterol, and log-total/HDL ratio as indicated by the considerable overlap of the 95% 
confidence intervals (Figure 5.7 [unadjusted] – Figure 5.9 [unadjusted]).  Inclusion of 
covariates to the models noticeably reduced the variability in estimated cholesterol trajectories as 
indicated by the 95% confidence intervals for each trajectory; however, trajectories of cholesterol 
in Figures 5.7-5.9 did not substantially change as covariates were added to the models as 
indicated by the consistent EDF values of the smooth terms and little change in the adjusted R2 
for each model (Table 5.9).  This may be due to covariates being included solely as fixed effects 
and not being incorporated into the smoothing term of the model.  
Trajectories of total cholesterol for non-demented subjects and subjects diagnosed with 
AD both followed non-linear trends (Table 5.9).  There were little to no differences in the 
trajectories of total cholesterol between AD and non-demented subjects once the effects of sex, 
educational attainment, smoking history, blood pressure, blood glucose, and history of using 
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cholesterol-lowering medications were controlled for in the models (Figure 5.7, model 1 – 
model 4).  When APOE e4 allele status was included as a covariate (Figure 5.7, model 5), non-
demented and AD subjects exhibited a similar increasing trend in total cholesterol from 30 to 55 
years of age, but AD subjects had consistently higher total cholesterol after 55 years of age 
compared to non-demented subjects.  Subjects diagnosed with AD maintained a consistent level 
of HDL that remained linear even as covariates were added to the models as indicated by the 
EDFs of 1 in Table 5.9.  HDL cholesterol also remained fairly constant from 50 to 75 years of 
age for non-demented subjects, but the overall trend was non-linear due to an increase in HDL 
cholesterol after 75 years of age.  A declining trajectory for log-total/HDL ratio was observed for 
all subjects.  There were little to no differences in the log-total/HDL ratios according to AD status 
from 50 to 70 years of age, but subjects without dementia did exhibit a greater decline in 
total/HDL ratio after 70 years of age.  
Trajectories of Cholesterol According to APOE e4 Allele Status  
The trajectories of total cholesterol, HDL cholesterol, and log-total/HDL ratio according 
to APOE e4 allele status were examined because of the established relationship between APOE 
and AD, the apoE protein’s role in cholesterol metabolism, and the known differences in the 
concentrations of cholesterol according to APOE genotype.  Only the estimated trajectories of 
total cholesterol, HDL cholesterol, and log-total/HDL ratio for the unadjusted and fully adjusted 
models are provided in Figure 5.10 because there were no substantial changes in the EDF for the 
smoothing terms as covariates were added to the models (Table 5.10).  Subjects who did not 
posses an APOE e4 allele (e4-) had consistently lower total cholesterol from midlife to late life 
compared to subjects with one or more e4 alleles (Figure 5.10).  In general, subjects who were 
APOE e4- had slightly higher HDL cholesterol and lower log-total/HDL ratio from midlife to late 
life compared to subjects who possessed one or more APOE e4 alleles (e4+).  All subjects 
exhibited a non-linear decline in log-total/HDL ratio due to an increase in HDL cholesterol with 
advancing age. 
 
 105 
Trajectories of Cholesterol According to Alzheimer’s Disease and APOE e4 Allele Status 
Models stratified according to AD and APOE e4 allele status were used to determine if 
the trajectories of total cholesterol, HDL cholesterol, and log-total/HDL ratio according to AD 
status differed between subjects who were APOE e4+ and those who were APOE e4- (Figure 
5.11; Table 5.11).  The trajectories of cholesterol stratified according to AD status and APOE e4 
allele status did not change substantially as covariates were added to the models, and only the 
unadjusted and fully adjusted models that controlled for sex, education, smoking, average blood 
pressure, average blood glucose, and use of cholesterol lowering medications were used to 
examine the potential interactive effect of AD and APOE e4 allele status on trajectories of 
cholesterol.  
Subjects diagnosed with AD and who were APOE e4+ maintained higher total cholesterol 
from midlife to late life compared to AD e4-, non-demented e4+, and non-demented e4- subjects 
(Figure 5.11, total cholesterol).  This finding suggests that consistently higher total cholesterol 
among subjects diagnosed with AD is due to these subjects being more likely to be APOE e4+.  A 
non-linear increase in HDL cholesterol with age was observed for non-demented e4- subjects, 
whereas subjects who were non-demented and APOE e4+ maintained consistent measures of 
HDL cholesterol with age (Figure 5.11, HDL cholesterol).  The increase in HDL cholesterol was 
most pronounced among subjects diagnosed with AD and who were APOE e4+, but subjects 
diagnosed with AD and were APOE e4- exhibited a slight decrease in HDL cholesterol with age.  
Finally, AD e4+ subjects exhibited a linear decline in log-total/HDL ratio, whereas non-linear 
declines in log-total/HDL ratio were observed for all other groups. 
Trajectories of Cholesterol According to Alzheimer’s Disease Status and Sex 
Models stratified according to AD status and sex were used to determine if the 
trajectories of total cholesterol, HDL cholesterol, and log-total/HDL ratio for men and women 
differed according to AD status (Figure 5.12; Table 5.12).  Based on the unadjusted and adjusted 
models for total cholesterol (Figure 5.12), women had lower total cholesterol compared to men 
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until approximately 50 years of age.  Total cholesterol increased for both men and women during 
midlife, but there was visual evidence for a greater increase in cholesterol among women during 
this period.  Total cholesterol appeared to decline at a similar trajectory for men and women 
following 60 years of age, although women maintained higher total cholesterol compared to men.  
Despite the clear differences in total cholesterol between men and women in the unadjusted and 
adjusted models, there were no dramatic differences in the trajectories of total cholesterol 
between men and women according to AD status.  However, there was visual evidence for 
differences in the trajectories of total cholesterol according to AD status and sex once APOE was 
included as a covariate (Figure 5.12, total cholesterol fully adjusted) and these differences were 
most apparent among men.  Total cholesterol increased for men regardless of AD status, but men 
without dementia exhibited a decline in total cholesterol at a younger age compared to men with 
AD.  Compared to men without dementia, men diagnosed with AD had lower cholesterol during 
midlife, but maintained higher cholesterol following 60 years of age.  A similar trend was 
observed among women, but the apparent differences in total cholesterol according to AD status 
were much less pronounced than in men.  Women diagnosed with AD maintained slightly higher 
total cholesterol after 60 years of age compared to women who did not have dementia, but the 
overall trajectories of total cholesterol were similar for the two groups.  The visually apparent 
differences in the trajectories of total cholesterol between the adjusted and fully adjusted models 
need to be interpreted with some caution because only 23 percent of the final sample (n=568 
subjects) had data for APOE genotype. 
There were obvious differences in the trajectories of HDL cholesterol according to sex, 
with women maintaining higher HDL cholesterol compared to men in the unadjusted, adjusted 
and fully adjusted models.  The trajectories of HDL cholesterol for men and women without 
dementia in the unadjusted and adjusted models exhibited a cubic trend, whereas the trajectories 
for subjects with AD were more linear.  When APOE e4 allele status was included as a covariate, 
there was an increasing trend in HDL cholesterol among women diagnosed with AD, whereas 
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men diagnosed with AD exhibited an accelerated decline at approximately 70 years of age.  The 
visually observed differences between the adjusted and fully adjusted models may be partially 
due to the reduced sample size for the fully adjusted model.   
Despite maintaining considerably higher total cholesterol compared to men, women had a 
lower log-total/HDL cholesterol ratio compared to men due to the higher measures of HDL 
cholesterol.  Based on the adjusted model, there was a decreasing trend for the ratio of total to 
HDL cholesterol among men and women but there were no substantial differences according to 
AD status.  The addition of APOE to the model did not have an apparent effect on trajectories of 
total cholesterol for women.  Men without dementia exhibited an accelerated decline in log-
total/HDL cholesterol ratio at approximately 75 years of age due to an increase in HDL 
cholesterol, whereas the decline in log-total/HDL cholesterol ratio for men with AD followed a 
linear trend.  
    Adjusting for the Effects of Supplemental Estrogen Use:  A total of 133 subjects (3.6%) 
reported having used supplemental estrogen.  Eight men reported using supplemental estrogen, 
but these subjects were excluded from the analysis to avoid confounding results.  There were no 
discernable differences in the trajectories of total cholesterol, HDL cholesterol or log-total/HDL 
ratio according to AD status when supplemental estrogen use was included in the models (Figure 
5.13) compared to the trajectories of total, HDL cholesterol and log-total/HDL ratio for women in 
Figure 5.12.  
Specific Aim Three 
Sample Characteristics 
 A summary of the descriptive characteristics for the final sample according to cognitive 
quartile is provided in Table 5.13.  Subjects in the lowest quartile of cognitive functioning were 
significantly older during the first clinical exam (representing midlife) and upon receiving a 
neuropsychological battery (representing late life) compared to subjects in the highest quartile of 
cognitive functioning.  Also, subjects in the lowest cognitive quartile had significantly lower 
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educational attainment compared to the other groups.  Finally, the lowest cognitive quartile had 
slightly higher average blood glucose levels compared to the other quartiles.  There were no 
differences in history of smoking, blood pressure, use of cholesterol lowering medications or 
APOE e4 allele status.     
Relationship between Subject-Specific Trajectories of Total Cholesterol and Cognition 
 The subject-specific trajectories for total cholesterol were plotted according to cognitive 
quartile and visually examined (Figure 5.14).  There was considerable variability in the subject-
specific trajectories of total cholesterol within each of the cognitive quartiles.  Upon close visual 
examination, subjects in the lowest cognitive quartile appeared to exhibit a slightly greater 
decline in total cholesterol compared to the other quartiles. 
 A subsequent analysis was performed to determine if significant differences in the 
population-average trajectories of total cholesterol according to cognitive quartile could be 
detected.  Subjects in the fourth cognitive quartile had significantly lower total cholesterol 
compared to the second and third quartiles (?̂?=-6.4 mg/dl, SE=2.3 mg/dl, P=0.02).  This 
difference remained significant after controlling for the effects of sex, educational attainment, 
smoking, cholesterol medication use, blood glucose, blood pressure, and APOE e4 allele status 
(Figure 5.15; Table 14).  There were no significant differences in the quadratic trend in total 
cholesterol according to cognitive quartile.     
Conclusion 
In general, the findings from the specific aims were surprising given what has been 
reported in previous studies.  Subjects in the FHS Offspring Cohort diagnosed with dementia had 
higher than expected cognitive performance on the neuropsychological battery, and the utility of 
the three summary scores to differentiate between normal and dementia subjects was lower than 
expected.  This may be due to a sampling bias in which subjects with severe physical or cognitive 
impairments due to dementia would not be healthy enough to receive a neuropsychological 
battery.  The findings from Aim Two and Three were surprising because there was not sufficient 
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evidence to suggest that there are differences in midlife cholesterol according to AD status, but 
older adults with high cognitive functioning had significantly lower cholesterol during midlife 
compared to subjects with low cognition.  The inconsistent findings of Aims Two and Three may 
be due to the peculiar characteristics of FHS participants and cohort differences between the 
Original and Offspring Cohorts.  A thorough summary of the findings from the dissertation 
research, and an interpretation of these findings within the context of prior research, is provided 
in Chapter Six.  
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*Table 5.1: Demographic Characteristics 
 
Characteristic Normal 
(n=619) 
ILM 
(n=214) 
MDI 
(n=399) 
Dementia 
(n=19) 
P-value 
Age (SD) 60.7 (9.2) 59.7 (8.7) 63.5 (9.8) 73.6 (5.6) <0.01 
Education, n (%)     0.02 
< High school 193 (31.1) 68 (31.8) 164 (41.1) 8 (42.1)  
Some college 159 (25.7) 84 (39.2) 103 (25.8) 6 (31.6)  
College degree 267 (43.1) 62 (29.0) 132 (33.1) 5 (26.3)  
Male, n (%) 282 (45.6) 97 (45.3) 197 (49.4) 7 (36.8) 0.50 
 
*Results based on subjects included in the validation set. 
SD = standard deviation, n = number of subjects 
Table 5.2: Differentiating between Normal and Dementia 
Normal and 
dementia 
Composite, 
subtest 
Composite, 
domains 
Learning/memory 
subtests 
AUC (95% CI) 97.2 (93.6-100.0) 97.1 (93.7-100.0) 96.9 (94.0-99.7) 
Cut-off  -0.18 -0.13 -0.19 
Sensitivity 89.5 (66.9-98.7) 89.5 (66.9-98.9) 84.2 (60.4-96.6) 
Specificity  96.8 (95.1-98.0) 92.7 (90.4-94.6) 93.5 (91.3-95.3) 
PPV 45.9 (29.5-63.1) 27.4 (16.9-40.2) 28.6 (17.3-42.2) 
NPV 99.7 (98.8-100.0) 99.7 (98.8-100.0) 99.5 (98.5-99.9) 
Test accuracy 96.6 (94.8-97.8) 92.6 (90.3-94.5) 93.3 (91.0-95.1) 
The optimal cut-off score for each summary score is the point on the receiver operating 
characteristic curve that is closest to (0, 1).   
  
Table 5.3: Differentiating between Normal and ILMTB 
 
Normal and ILMTB Composite, 
subtest 
Composite, 
domains 
Learning/memory 
subtests 
AUC (95% CI) 86.6 (83.9-89.4) 87.4 (84.8-90.1) 89.5 (87.2-91.9) 
Cut-off  0.13 0.14 0.11 
Sensitivity 83.2 (77.5-87.9) 79.9 (73.9-85.1) 84.6 (79.0-89.1) 
Specificity  75.1 (71.5-78.5) 78.7 (75.2-81.4) 78.8 (75.4-82.0) 
PPV 53.6 (48.1-59.1) 56.4 (50.6-62.1) 58.0 (52.3-63.6) 
NPV 92.8 (90.2-94.9) 91.9 (89.2-94.1) 93.7 (91.2-95.6) 
Test accuracy 77.2 (74.2-80.0) 79.0 (76.1-81.7) 80.3 (77.4-83.0) 
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Table 5.4: Differentiating between Normal and MDITB 
 
Normal and MDITB Composite, 
subtest 
Composite, 
domains 
Learning/memory 
subtests 
AUC (95% CI) 90.5 (88.6-92.4) 85.8 (83.4-88.1) 80.0 (77.2-82.7) 
Cut-off  0.02 0.14 0.19 
Sensitivity 79.2 (74.9-83.1) 75.7 (71.2-79.8) 70.9 (66.2-75.3) 
Specificity  85.9 (83.0-88.6) 78.7 (75.2-81.8) 72.9 (69.2-76.3) 
PPV 78.4 (74.1-82.3) 69.6 (65.0-73.9) 62.7 (58.1-67.2) 
NPV 86.5 (83.5-89.1) 83.4 (80.1-86.3) 79.5 (76.0-82.8) 
Test accuracy 83.3 (80.9-85.5) 77.5 (74.8-80.0) 72.1 (69.2-74.8) 
 
Table 5.5: Differentiating between Dementia and ILMTB 
 
Dementia and ILMTB Composite, 
subtest 
Composite, 
domains 
Learning/memory 
subtests 
AUC (95% CI) 89.3 (77.7-100.0) 88.1 (76.0-100.0) 80.7 (67.1-94.3) 
Cut-off  -0.49  -0.62 -0.90 
Sensitivity 84.2 (60.4-96.6) 84.2 (60.4-96.6) 68.4 (43.4-87.4) 
Specificity  93.0 (88.7-96.0) 90.7 (85.9-94.2) 92.5 (88.1-95.7) 
PPV 51.6 (33.1-69.8) 44.4 (27.9-61.9) 44.8 (26.4-64.3) 
NPV 98.5 (95.7-99.7) 98.5 (95.6-99.7) 97.1 (93.7-98.9) 
Test accuracy 92.2 (88.1-95.4) 90.1 (85.6-94.2) 90.6 (86.1-94.0) 
 
Table 5.6: Differentiating between Dementia and MDITB 
 
Dementia and MDITB Composite, 
subtest 
Composite, 
domains 
Learning/memory 
subtests 
AUC (95% CI) 84.2 (71.3-97.1) 85.9 (74.2-97.5) 84.4 (74.0-94.7) 
AUC (95% CI) -0.81 -1.1  -0.89 
Cut-off  78.9 (54.4-93.9) 78.9 (54.4-93.9) 68.4 (43.4-87.4) 
Sensitivity 87.5 (83.8-90.6) 89.2 (85.8-92.1) 92.2 (89.2-94.7) 
Specificity  23.1 (13.5-35.2) 25.9 (15.3-39.0) 29.5 (16.8-45.2) 
PPV 98.9 (97.1-99.7) 98.9 (97.2-99.7) 98.4 (96.5-99.4) 
NPV 87.1 (83.5-90.1) 88.8 (85.3-91.6) 91.1 (88.0-93.7) 
 
Table 5.7: Differentiating between ILMTB and MDITB 
 
ILMTB and MDITB Composite, 
subtest 
Composite, 
domains 
Learning/memory 
subtests 
AUC (95% CI) 65.7 (61.4-69.9) 56.1 (51.6-60.6) 59.7 (55.3-64.2) 
Cut-off  -0.19 -0.40 -0.21 
Sensitivity 58.6 (53.6-63.5) 43.9 (38.9-48.9) 57.6 (52.6-62.5) 
Specificity  65.0 (58.2-71.3) 74.3 (67.9-80.0) 57.9 (51.0-64.6) 
PPV 75.7 (70.6-80.4) 76.1 (70.0-81.4) 71.9 (66.6-76.7) 
NPV 45.7 (40.0-51.5) 41.5 (36.5-46.6) 42.3 (36.6-48.2) 
Test accuracy 60.8 (56.9-64.7) 54.5 (50.4-58.5) 57.7 (53.7-61.7) 
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Table 5.8: Demographic Characteristics according to Alzheimer’s Disease Status 
 
Characteristic No Dementia (n=2102) AD (n=347) P-value 
*Age, midlife (SD) 40.2 (6.7) 42.2 (6.9 <0.01 
**Age, late life (SD) 81.9 (7.6) 78.6 (6.5) <0.01 
Sex, n (%)   <0.01 
Female 1196 (56.9) 232 (66.9)  
Male 906 (43.1) 115 (33.1)  
§Educational attainment, n (%)   0.24 
< High school 1410 (68.9) 222 (65.7)  
> High school 636 (31.1) 116 (34.3)  
Smoking history, n (%)   <0.01 
No 663 (31.5) 160 (46.1)  
Yes 1439 (68.5) 187 (53.9)  
Use of cholesterol lowering medications, n (%)   0.97 
No 1770 (84.2) 293 (84.4)  
Yes 332 (15.8) 54 (15.6)  
Avg. blood glucose, mg/dl (SD) 108.2 (19.0) 105.2 (15.2) 0.01 
Avg. systolic blood pressure, mmHg (SD) 136.5 (15.0) 134.4 (13.4) 0.01 
Avg. diastolic blood pressure, mmHg (SD) 80.1 (8.0) 78.0 (6.5) <0.01 
§§APOE e4 allele status, n (%)   <0.01 
APOE e4- 378 (80.9) 65 (64.4)  
APOE e4+ 89 (19.1) 36 (35.6)  
*Age during the first clinical examination represents midlife 
**Age in which a person was last observed to be cognitively intact represents late life 
§A total of 2384 had data for educational attainment 
§§A total of 568 had data for APOE e4 allele status   
SD = standard deviation and n = number of subjects 
T-tests were used to compare group means for continuous variables (age, blood glucose, and 
blood sugar) and chi-square tests were used to compare group differences for categorical 
variables (sex, education, cholesterol medication use, and APOE e4 allele status). 
Percentages for categorical variables are based on column total.  Value may exceed 100 due to 
rounding. 
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Table 5.9: EDF and Adjusted R2 for Trajectories of Total, HDL and Total/HDL Ratio 
according to Alzheimer’s Disease Status 
 
 Total cholesterol HDL cholesterol Log-total/HDL 
Model EDF Adj. R2 EDF Adj. R2 EDF Adj. R2 
1. Unadjusted (n=2449)  0.09  0.002  0.06 
Non-demented 7.6  5.4  5.7  
AD 6.4  1.7  4.2  
2. Model 1 + gender and 
education (n=2384) 
 0.11  0.11  0.09 
Non-demented 7.6  5.4  5.7  
AD 6.5  1.9  4.1  
3.  Model 2 + smoking (n=2384)  0.11  0.11  0.10 
Non-demented 7.6  5.4  5.7  
AD 6.5  1.9  4.1  
4. Model 3 + blood pressure and 
blood glucose (n=2384) 
 0.13  0.12  0.12 
Non-demented 7.6  5.4  5.7  
AD 6.5  2.0  4.0  
5.  Model 4 + cholesterol 
medications (n=2384) 
 0.17  0.12  0.14 
Non-demented 7.6  5.4  5.7  
AD 6.5  2.0  4.0  
6. Model 6 + APOE e4 allele 
status (n=557) 
 0.19  0.14  0.12 
Non-demented 7.0  3.7  4.3  
AD 5.5  2.1  2.4  
There were 65 subjects who had missing data for educational attainment.  Data for APOE was 
recorded for 568 subjects, but 11 of these subjects had missing data for educational attainment.  
There were no missing data for smoking, blood pressure, blood glucose or use of cholesterol 
lowering medications.   
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Table 5.10: EDF and Adjusted R2 for Trajectories of Total, HDL and Total/HDL Ratio 
according to APOE e4 Allele Status 
 
 Total cholesterol HDL cholesterol Log-total/HDL 
Model EDF Adj. R2 EDF Adj. R2 EDF Adj. R2 
1. Unadjusted (n=568)  0.11  0.003  0.04 
e4- 7.2  3.6  4.4  
e4+ 5.4  2.2  3.1  
2. Model 1 + gender and 
education (n=557) 
 0.12  0.13  0.09 
e4- 7.2  3.3  4.2  
e4+ 5.5  1.9  3.1  
3.  Model 2 + smoking history 
(n=557) 
 0.12  0.13  0.09 
e4- 7.2  3.3  4.3  
e4+ 5.5  1.9  3.1  
4. Model 3 + blood pressure and 
blood glucose (n=557) 
 0.14  0.14  0.11 
e4- 7.2  3.3  4.2  
e4+ 5.5  1.9  3.1  
5.  Model 4 + use of cholesterol 
lowering medications 
(n=557) 
 0.18  0.14  0.12 
e4- 7.2  3.3  4.2  
e4+ 5.5  1.9  3.1  
There were 11 subjects who had missing data for educational attainment.  There were no missing 
observations for smoking history, blood pressure, blood glucose or use of cholesterol lowering 
medications. 
 
 
Table 5.11: EDF and Adjusted R2 for Trajectories of Total, HDL and Total/HDL Ratio 
Stratified by AD and APOE e4 Allele Status 
 
 Total cholesterol HDL cholesterol Log-total/HDL 
Model  EDF Adj. R2 EDF Adj. R2 EDF Adj. R2 
Unadjusted (n=568)  0.12  0.01  0.04 
Non-demented e4- 7.2  3.9  4.4  
Non-demented e4+ 5.4  2.2  3.1  
AD e4- 4.9  1.0  2.3  
AD e4+ 4.3  3.0  1.2  
Adjusted (n=557)  0.19  0.14  0.12 
Non-demented e4- 7.1  3.6  4.2  
Non-demented e4+ 5.4  2.2  3.0  
AD e4- 4.9  1.0  2.3  
AD e4+ 4.3  2.9  1.1  
 
Adjusted model included sex, educational attainment (< high school, > high school), smoking 
history, diastolic and systolic blood pressure, blood glucose and history of cholesterol lowering 
medications.  Of the 568 subjects with APOE data, 11 had missing data for educational 
attainment.   
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Table 5.12: EDF and Adjusted R2 for Trajectories of Total, HDL and Total/HDL Ratio 
Stratified by AD and Sex 
 
 Total cholesterol HDL cholesterol Log-total/HDL 
Model  EDF Adj. R2 EDF Adj. R2 EDF Adj. R2 
Unadjusted (n=2449)  0.14  0.11  0.09 
Non-demented female 7.7  5.7  5.0  
Non-demented male 7.9  4.7  6.3  
AD female 6.5  1.8  3.1  
AD male 5.6  1.0  3.7  
Adjusted (n=2384)  0.19  0.12  0.14 
Non-demented female 7.7  5.7  5.0  
Non-demented male 7.9  4.5  6.3  
AD female 6.6  2.1  3.0  
AD male 5.6  1.0  3.6  
Fully adjusted (n=557)  0.22  0.14  0.12 
Non-demented female 7.1  3.8  3.9  
Non-demented male 6.1  2.9  4.3  
AD female 5.5  1.9  4.3  
AD male 3.9  1.9  1.0  
Adjusted model included educational attainment (< high school, > high school), smoking history, 
diastolic and systolic blood pressure, blood glucose and history of cholesterol lowering 
medications. 
Fully adjusted model includes the covariates from the adjusted model plus APOE e4 allele status. 
There were 65 subjects who had missing data for educational attainment.  Data for APOE was 
recorded for 568 subjects, but 11 of these subjects had missing data for educational attainment. 
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Table 5.13: Demographic Characteristics of Final Sample According to Cognitive Quartile 
 
 Cognitive Quartile 
Characteristic Quartile 1 Quartile 2-3 Quartile 4 P-value 
*Age, midlife (SD) 40.1 (3.3) 39.1 (3.7) 38.1 (3.5) <0.01 
**Age, late life (SD) 67.1 (3.3) 66.3 (3.7) 65.2 (3.4) <0.01 
Sex, n (%)    0.12 
Female 88 (44.4) 192 (50.9) 102 (54.8)  
Male 110 (55.6) 185 (49.1) 84 (45.2)  
Educational attainment, n (%)     <0.01 
< High school 26 (13.1) 11 (2.9) 1 (0.5)  
High school degree 88 (44.4) 137 (36.3) 36 (19.4)  
Some college 52 (26.3) 111 (29.4) 46 (24.7)  
College degree 32 (16.2) 118 (31.3) 103 (55.4)  
Ever smoked, n  (%)    0.43 
No 56 (28.3) 125 (33.2) 55 (29.6)  
Yes 142 (71.7) 252 (66.8) 131 (70.4)  
Use of cholesterol lowering 
medications, n (%) 
   0.82 
No 95 (48.0) 172 (45.6) 89 (47.8)  
Yes 103 (52.0) 205 (54.4) 97 (52.2)  
Avg. blood glucose, mg/dl (SD) 102.2 (20.3) 100.7 (17.9) 97.8 (15.5) 0.05 
Avg. systolic blood pressure, 
mmHg (SD) 
127.6 (11.9) 127.5 (12.0) 125.1 (12.1) 0.06 
Avg. diastolic blood pressure, 
mmHg (SD) 
77.5 (6.6) 77.2 (6.3) 76.6 (6.3) 0.33 
APOE e4 allele status, n (%)    0.11 
APOE e4- 163 (82.3) 281 (74.5) 143 (76.9)  
APOE e4+ 35 (17.7) 96 (25.5) 43 (23.1)  
*Age during first clinical examination represents midlife 
**Age upon receiving neuropsychological battery represents late life 
SD = standard deviation, n = number of subjects 
Analysis of variance was used to compare group means for continuous variables (age, blood 
glucose, and blood pressure) and chi-square tests were used to compare group differences for 
categorical variables (sex, education, cholesterol medication use, and APOE e4 allele status). 
Percentages for categorical variables are based on column total.  Value may exceed 100 due to 
rounding. 
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Table 5.14: Association between Cholesterol Trajectory and Cognitive Quartile 
 
 Estimate (SE) t-value P-value 
Age 0.14 (0.09) 1.5 0.14 
Age^2 -0.09 (0.006) -15.2 < 0.01 
Cognition     
Quartile 2-3 (ref)    
Quartile 1 -1.5 (2.6) -0.56 0.58 
Quartile 4 -5.7 (2.7) -2.1 0.03 
Age*quartile 1 -0.14 (0.13) -1.1 0.29 
Age^2*quartile 1 -0.001 (0.009) -0.16 0.87 
Age*quartile 4 -0.06 (0.14) -0.47 0.64 
Age^2*quartile 4 0.01 (0.009) 1.2 0.23 
Sex    
Female (ref)    
Male -12.1 (2.3) -5.3 < 0.01 
Education    
High school (ref)    
< High school 5.0 (4.3) 1.2 0.24 
Some college 0.08 (2.2) 0.04 0.97 
College degree -2.9 (2.2) -1.3 0.19 
Smoking history    
No (ref)    
Yes  1.1 (1.9) 0.57 0.57 
Cholesterol medications    
No (ref)    
Yes  8.7 (1.8) 4.9 < 0.01 
Blood glucose -0.09 (0.05) -1.7 0.09 
Systolic blood pressure 0.11 (0.11) 1.0 0.30 
Diastolic blood pressure 0.18 (0.20) 0.92 0.36 
APOE e4 allele    
e4- (ref)    
e4+ 0.05 (2.1) 0.03 0.98 
 
Results based on mixed effects regression model controlling for the effects of sex, education, 
smoking, cholesterol medication use, blood glucose, blood pressure and APOE e4 allele status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 118 
 
Figure 5.1: ROC Curves, Normal Cognition and Dementia. 
 
 
 
Figure 5.2: ROC Curves, Normal Cognition and ILMTB  
 
 
 
 
Figure 5.3: ROC Curves, Normal Cognition and MDITB  
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Figure 5.4: ROC Curves, Dementia and ILMTB  
 
 
 
 
Figure 5.5: ROC Curves, Dementia and MDITB  
 
 
 
 
Figure 5.6: ROC Curves, ILMTB and MDITB  
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Figure 5.7: Trajectories of Total Cholesterol Stratified by Alzheimer’s Disease Status 
 
Model 1: adjusted for sex and educational attainment (< high school, > high school) n=2384 
Model 2: model 1 plus smoking  (ever smoker yes, no) n=2384 
Model 3: model 2 plus average blood pressure and average blood glucose n=2384 
Model 4: model 3 plus use of cholesterol lowering medications (ever user yes, no) n=2384 
Model 5: model 4 plus APOE e4 allele status (e4+, e4-) n=557 
 
Figure 5.8: Trajectories of HDL Cholesterol Stratified by Alzheimer’s Disease Status 
 
Model 1: adjusted for sex and educational attainment (< high school, > high school) n=2384 
Model 2: model 1 plus smoking  (ever smoker yes, no) n=2384 
Model 3: model 2 plus average blood pressure and average blood glucose n=2384 
Model 4: model 3 plus use of cholesterol lowering medications (ever user yes, no) n=2384 
Model 5: model 4 plus APOE e4 allele status (e4+, e4-) n=557 
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Figure 5.9: Trajectories of Total/HDL Ratio Stratified by Alzheimer’s Disease Status  
 
Model 1: adjusted for sex and educational attainment (< high school, > high school) n=2384 
Model 2: model 1 plus smoking  (ever smoker yes, no) n=2384 
Model 3: model 2 plus average blood pressure and average blood glucose n=2384 
Model 4: model 3 plus use of cholesterol lowering medications (ever user yes, no) n=2384 
Model 5: model 4 plus APOE e4 allele status (e4+, e4-) n=557 
 
Figure 5.10: Trajectories of Total, HDL and Total/HDL Ratio Stratified by APOE e4 Allele 
Status 
 
Adjusted trajectories control for the effects of sex, educational attainment, smoking, average 
blood pressure, average blood glucose, and use of cholesterol lowering medications.  Unadjusted 
model includes 568 subjects.  Eleven subjects who had missing data for educational attainment 
were excluded from the adjusted models (n=557). 
 
 
 
 
 
 122 
Figure 5.11: Trajectories of Total, HDL, and Total/HDL Ratio Stratified by Alzheimer’s 
Disease and APOE e4 Allele Status 
 
Adjusted trajectories control for the effects of sex, educational attainment, smoking, average 
blood pressure, average blood glucose and use of cholesterol lowering medications.  Adjusted 
models include 557 subjects. 
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Figure 5.12: Trajectories of Total, HDL, and Total/HDL Ratio Stratified by Alzheimer’s 
Disease and Sex 
 
The adjusted models controlled for the effects of educational attainment, smoking, average blood 
pressure, average blood glucose and use of cholesterol lowering medications.  The fully adjusted 
models included APOE e4 allele status plus all of the covariates in the adjusted model.  The 
sample sizes for the unadjusted, adjusted and fully adjusted models were 2449, 2384 and 557 
subjects, respectively.  There were 65 subjects who had missing data for educational attainment.  
Data for APOE was recorded for 568 subjects, but 11 of these subjects had missing data for 
educational attainment. 
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Figure 5.13: Trajectories of Total, HDL and Total/HDL Ratio Among Women Adjusted for 
Supplemental Estrogen use Stratified by Alzheimer’s Disease Status 
 
The adjusted models controlled for the effects of sex, educational attainment, smoking, average 
blood pressure, average blood glucose, use of cholesterol lowering medications and use of 
supplemental estrogen.  The fully adjusted models included APOE e4 allele status plus all of the 
covariates in the adjusted model.  There were 1390 subjects included in the adjusted models.  
There were 337 subjects included in the fully adjusted models. 
 
Figure 5.14: Subject-Specific Trajectories of Total Cholesterol Stratified by  
Cognitive Quartile 
 
  
Subject-specific trajectories of total cholesterol were obtained by combining the fixed and 
random effects for the model that included sex, educational attainment, smoking, cholesterol 
medications, blood glucose, blood pressure, and APOE e4 allele status as covariates.   
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Figure 5.15: Total Cholesterol Trajectories Stratified by Cognitive Quartile 
 
 
Trajectories of total cholesterol adjusted for the effects of sex, educational attainment, smoking, 
cholesterol medications, blood glucose, blood pressure, and APOE e4 allele status. 
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Chapter Six: Discussion and Conclusion 
 
A number of factors have been implicated in pathological changes in cognition later in 
life, and in pathological changes that eventually lead to AD.  Diet represents one dominant set of 
factors, and cholesterol is one particular factor within this domain that has attracted recent 
attention in scholarship. This dissertation has sought to add to this scholarship. 
The research reported in this dissertation, based on longitudinal data taken from the FHS, 
employed a life span approach to promote understanding of the relationship between cholesterol 
levels and cognitive function. A first task (and Specific Aim One) of the research was to 
determine the best way to empirically express cognitive functioning, given that FHS includes 
multiple measures of cognitive function. The resulting metric was later applied (in Specific Aim 
Three) to an analysis of the relationship between life span cholesterol trajectories and cognitive 
function among older adults who had not received a diagnosis of dementia. An intermediate task 
(Specific Aim Two) sought to identify relationships between life span cholesterol trajectories 
(specifically total, HDL, and total/HDL ratio) and AD, recognizing that this pathological 
condition was not addressed in the last Specific Aim. 
 This final chapter of the dissertation offers a critical summary of the findings from 
Specific Aims one through three, which will be presented in turn. A central theme that emerges 
from critical evaluation, not only of the findings but also of the foundational literature, is the 
potential of life course concepts for informing ongoing epidemiological research involving 
cognitive function.  The life course concepts will be covered, and will be followed by specific 
directions for research that may effectively situate this dissertation’s research within a life course 
framework and, consequently, identify areas of ongoing research. 
Discussion of Research Findings 
Defining Midlife and Late Life Based on Total Cholesterol 
 This segment of the research employed a rigorous approach to define age boundaries for 
midlife and late life by visually examining age-related changes in total cholesterol and identifying 
 
 127 
age periods in which there was a prolonged increase in total cholesterol (representing midlife) and 
the ages in which there was a prolonged decline in total cholesterol (representing late life).  Based 
on examination of both the cross-sectional and longitudinal trends, midlife was defined as 
between 30 and 55 years of age for the Original Cohort, and between 30 and 45 years of age for 
the Offspring Cohort.  Late life was defined as 65 and older for the Original Cohort, and 60 years 
and older for the Offspring Cohort.  Findings illuminated potentially significant cohort 
differences in changes to total cholesterol across the life span.  Subsequent research should focus 
on identifying factors that may have contributed to these cohort differences and if these factors 
also contribute to potential cultural differences in life span trajectories of cholesterol and other 
measures of vascular health.   
 This portion of the research also presents a clear challenge to widely accepted notions of 
what constitutes old age, middle age, and other life stages.  Aging research has seemingly taken 
for granted the importance of sufficiently justifying why certain age boundaries for various life 
stages are chosen and the implications that arbitrarily selecting age boundaries may have on 
findings.  A critical evaluation of how age boundaries for midlife, late life, and other life stages 
should be obtained is warranted.   It is commonly recognized, for example, that age 65 represents 
a dominant stage boundary largely as a consequence of policy measures in the U.S. dating back to 
1935 (REF).  These policies, though based on cursory observation of physiological change and 
health status at the time, were essentially derived from consideration of the balance between 
chronological age and economic productivity and need, even though productivity and need are 
not simply a matter of physiological capacity. Once established, a break-point of 65 years 
(‘retirement age’) gathered a certain temporal momentum and has endured as an emerging 
requirement of replication of results within the ‘Scientific Method’ that gained increasing 
credibility through the 20th Century (REF?).  Yet a life course view would suggest that complex 
societal changes, ranging from medical advances to political economic priorities and 
communication/media technologies might well be expected to alter health status at advanced ages 
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along with the potential productivity levels associated with age. In short, the link between 
chronological age and both physiological capacity and economic productivity is likely much 
different today than it was in 1935.   
Specific Aim One 
 Aim One sought to calculate a series of three summary scores for the FHS 
neuropsychological battery and utilize receiver operating characteristic analysis to determine 
which summary score was best able to differentiate between subjects classified as having normal 
cognitive function, test-based impaired learning and memory (ILMTB), test-based multidomain 
impairment (MDITB), and dementia.  The relatively high values for the area under the curve 
(AUC), sensitivity, and specificity indicate that all three summary scores were able to accurately 
differentiate between the four cognitive groups, but significant differences between the three 
summary scores were detected when classifying normal versus dementia, normal versus MDITB, 
and ILMTB versus MDITB.  When compared to the composite subtests summary score, the 
composite domains summary score was not as accurate when differentiating between normal 
versus dementia, and ILMTB versus MDITB, whereas the learning/memory score was less accurate 
when differentiating between normal versus MDITB.  Based on these findings, the composite 
subtests summary score was determined to have the highest utility when differentiating between 
the four cognitive groups and was used as the measure of cognitive functioning for Aim Three. 
 Many population-based cohort studies assess cognitive functioning using a 
neuropsychological battery comprised of a collection of cognitive assessments that are included 
for reasons linked to the specific goals of the study.  But there are considerable differences 
between studies in the number and type of cognitive assessments included in the 
neuropsychological battery, which makes it challenging to compare the results of the subtests 
summary score obtained in Specific Aim One from the FHS neuropsychological battery to 
summary scores obtained from other studies.  A total score for the Consortium to Establish a 
Registry for Alzheimer’s Disease (CERAD) neuropsychological battery has been reported to 
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accurately differentiate between older adults with normal cognition, mild cognitive impairment 
(MCI) and AD (Chandler et al., 2005).  Compared to the results reported by Chandler et al. 
(2005), the composite subtests summary score from Specific Aim One had a similar AUC, 
sensitivity, and specificity when differentiating between normal, cognitively impaired and 
dementia subjects.  This suggests that a summary score that is the sum of the subtests included in 
the neuropsychological battery has similar utility compared to the composite subtest method used 
in Specific Aim One.   
 A total score was not calculated in Specific Aim One because this method does not take 
into account the differential weighting of each assessment within the summary score due to the 
variation in the minimum and maximum possible scores for each assessment.  As a result, a 
subject’s total score may not accurately represent their overall level of cognitive functioning 
because the total score may be highly influenced by performance on only one or two subtests.  
Furthermore, a total score approach does not account for the different scales in which some 
cognitive assessments are scored.  The FHS neuropsychological battery includes the Trail Making 
Test (TMT) A and B, which are timed assessments measured in either minutes or seconds 
(subjects are typically allowed a maximum of five minutes, 300 seconds, to complete each 
assessment).  The relative weight of the TMT A and TMT B scores in a total summary score 
would vary substantially depending on if the time to complete the assessments was measured in 
seconds or minutes.  A potential resolution would be to not include the TMT A and B 
assessments in a total summary score, but these assessments are sensitive to the presence of 
dementia (Rasmusson, Zonderman, Kawas, & Resnick, 1998) and mild cognitive impairment 
(Ashendorf et al., 2008) and not including these assessments would potentially decrease the 
utility of the summary score.       
Limitations: There are important limitations of Specific Aim One that should be 
acknowledged.  First is the low number of participants who had received the neuropsychological 
battery and were diagnosed with dementia.  A total of 1251 subjects in the validation sample 
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completed a neuropsychological battery, but only 19 of these subjects had received a diagnosis of 
dementia.  The low prevalence of dementia is due to the relatively young age of the Offspring 
Cohort.  This limited the ability to detect statistically significant differences between the three 
summary scores when classifying between dementia and the other cognitive groups.  The low 
power was reflected by the wide confidence intervals for area under the curve (AUC), sensitivity, 
specificity, negative predictive value (npv), positive predictive value (ppv) and total accuracy in 
the analyses that included participants with dementia.  The low prevalence of dementia must also 
be taken into consideration when interpreting the ppv and npv for the summary scores because 
these metrics are influenced by disease prevalence (Altman & Bland, 1994).  The ppv of a 
diagnostic measure increases as the prevalence of the disease increases, whereas the npv 
decreases as the prevalence of the disease increases.  This means that in a population were the 
prevalence of a disease is low, a relatively high number of people will be incorrectly classified as 
having the disease compared to the number of people who test positive and truly have the disease.   
 A second limitation is that calculating specificity, sensitivity, ppv, npv and overall 
accuracy of the three summary scores required comparing the classification results from the 
summary scores to those obtained from a predetermined gold standard.  The gold standard for 
classifying participants as MDITB and ILMTB was consistent with the diagnostic criteria for MCI 
established by the National Institute on Aging and Alzheimer’s Association (NIA-AA) 
workgroup (Albert et al., 2011).   The NIA-AA workgroup defines MCI as cognitive performance 
that is >1.5 standard deviations below what a person would be expected to perform based on their 
age and level of education.  The NIA-AA workgroup emphasizes that persons diagnosed with 
MCI are able to maintain their ability to independently perform activities of daily living (ADLs), 
such as paying bills, cooking a meal, or shopping.  While the FHS includes measures for ADLs, 
this criterion was not included in the classification of MDITB and ILMTB because these measures 
were not collected concurrently with the neuropsychological battery.  Not including the ability to 
independently perform activities of daily living in the diagnostic criteria utilized in Aim One 
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raises the possibility that some participants classified as ILMTB or MDITB may have dementia if 
their level of cognitive impairment limited their ability to independently perform ADLs. 
 Finally, the results from the ROC analysis may over-estimate the ability of the summary 
scores to differentiate between the cognitive subgroups because the cognitive assessments used to 
classify participants as normal, MDITB and ILMTB were also used to create the three summary 
scores.  However, biases that may have arisen as a result of utilizing this approach were 
minimized because the summary scores were not used to classify subjects as normal, MDITB, and 
ILMTB. 
Future Research: The findings from this Specific Aim have identified important research 
questions and limitations that need to be addressed by future research.  First, this analysis should 
be replicated using data from a study that has specifically recruited subjects with dementia.  The 
increased number of dementia cases would bias the ppv and npv of the summary scores, but 
would increase the likelihood of detecting significant differences in the classification accuracy of 
the three summary scores.  This would also potentially allow analyses for specific subtypes of 
dementia, such as AD and vascular dementia, to be conducted.  Next, the gold standard criteria 
used to classify participants as normal, ILMTB, and MDITB in this research can be refined by 
including measures of ADLs, repeated measures of cognitive functioning to assess cognitive 
decline, and measures for brain pathology.  Including these measures may improve the ability to 
accurately classify participants as normal, ILMTB and MDITB according to the gold standard.  
Finally, the mini-mental status exam (MMSE; Folstein, Folstein & McHugh, 1975) was not 
included as part of the neuropsychological battery.  The MMSE is commonly used in clinical 
settings to assess cognitive functioning and it would be beneficial to determine if the summary 
scores are better able to differentiate between specific cognitive groups compared to the MMSE.       
  Conclusion: All three summary scores were able to accurately differentiate between the 
normal, ILMTB, MDITB and dementia subgroups, but the findings indicate that the composite 
subtests summary score has the highest utility among the three summary scores.  Based on the 
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results of this Specific Aim, the composite subtests summary score was deemed appropriate as 
the measure of cognitive functioning in aim three.  Furthermore, the study design and methods 
utilized in aim one can be replicated and used by other investigators to create summary scores for 
the neuropsychological batteries employed in other studies. 
Specific Aim Two 
 Specific Aim Two utilized a longitudinal study design to examine the relationship 
between trajectories of total cholesterol, high-density lipoprotein (HDL) cholesterol and 
total/HDL cholesterol ratio from midlife to late life and AD using generalized additive mixed 
models (GAMMs).  The purpose of this Specific Aim was to determine if there were differences 
in the longitudinal trajectories of cholesterol between older adults diagnosed with AD and those 
who do not have dementia. 
    In general, Specific Aim Two findings do not provide strong evidence that there are 
substantial differences in the trajectories of total cholesterol, HDL cholesterol or total/HDL ratio 
from midlife to late life between older adults diagnosed with AD and older adults without 
dementia.  Total cholesterol increased until approximately 60 years of age, which was followed 
by a steady decline with advancing age for older adults with AD, as well as for older adults 
without dementia.  HDL cholesterol increased with age for older adults diagnosed with AD and 
those without dementia.  The increase in HDL followed a linear trend for subjects with AD, 
whereas the increase in HDL cholesterol followed a cubic trend for subjects without dementia.  
Finally, both subjects with AD and subjects without dementia exhibited a steady decline in 
total/HDL cholesterol ratio, which accelerated at approximately 70 years of age. 
 There were slight differences in the trajectories of total, HDL and total/HDL cholesterol 
ratio according to AD status when the effects of sex, educational attainment, smoking history, 
blood pressure, blood glucose and history of using cholesterol-lowering medications were 
 
 133 
controlled for in the adjusted models17.  These differences became more apparent when 
apolipoprotein E (APOE) e4 allele status was added to the adjusted models18.  The overall 
trajectories of cholesterol did not dramatically change once APOE e4 allele status was added as a 
covariate, but older adults diagnosed with AD had higher measures of total cholesterol and HDL 
cholesterol compared to older adults without dementia.  Older adults without dementia had 
slightly higher total/HDL cholesterol ratio, but these subjects exhibited an accelerated decline in 
total/HDL cholesterol ratio following 70 years of age, whereas older adults with AD maintained a 
constant decline.   
 There were substantial differences in the trajectories of total cholesterol, HDL 
cholesterol, and total/HDL cholesterol ratio when stratified according to sex and AD status.  
Women had lower total cholesterol during midlife compared to men, but women exhibited a 
dramatic increase in total cholesterol up until approximately 60 years of age.  Men and women 
exhibited a similar rate of decline in total cholesterol following 60 years of age.  The measures of 
HDL cholesterol remained relatively constant with age for men and women; however, women 
had much higher measures of HDL cholesterol compared to men.  Finally, the ratio of total 
cholesterol to HDL cholesterol declined with age for both men and women, with an accelerated 
rate of decline occurring at approximately 70 years of age.  While there were visually apparent 
differences in total cholesterol, HDL cholesterol and total/HDL cholesterol ratio between men 
and women, there were little to no differences according to AD status for men or women 
according to the adjusted models.  When APOE e4 allele status was included as a covariate (fully 
adjusted model), men who developed AD had lower cholesterol from 30 to 50 years of age and 
maintained higher total cholesterol following 55 years of age compared to men who did not 
develop dementia.  Women who developed AD maintained slightly higher total cholesterol 
                                                        
17 The adjusted model included sex, educational attainment, smoking history, blood pressure, 
blood glucose and history of using cholesterol-lowering medications 
18 The fully adjusted models included APOE e4 allele status plus all of the covariates in the 
adjusted model. 
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following 55 years of age compared to women who did not develop AD.   In the fully adjusted 
model, men who developed AD had higher HDL cholesterol compared to men who did not 
develop AD, but AD subjects exhibited a decline in HDL cholesterol at 70 years of age whereas 
non-demented subjects exhibited a slight increase in HDL cholesterol.  These differences in HDL 
cholesterol among men contributed to an accelerated decline in the total/HDL cholesterol ratio 
among men without dementia whereas men with AD exhibited a steady decline in total/HDL 
cholesterol ratio.  There were no substantial differences in the trajectories of HDL cholesterol or 
total/HDL cholesterol ratio according to AD status among women.   
When the trajectories of total cholesterol were stratified according to AD status and 
APOE e4 allele status, subjects who were diagnosed with AD and carried one or more APOE e4 
alleles had consistently higher cholesterol from midlife to late life compared to non-demented 
subjects who did not carry an APOE e4 allele.  When the trajectories of HDL cholesterol were 
stratified according to AD and APOE e4 allele status, subjects diagnosed with AD and who were 
e4+ exhibited an increase in HDL cholesterol, whereas HDL cholesterol declined for AD e4- 
subjects.  The trajectories of total/HDL cholesterol ratio, according to AD and APOE e4 status, 
followed a similar decreasing trend.  The greatest differences in total/HDL cholesterol ratio were 
observed during midlife, but these differences became less apparent with advancing age.  
There is limited research on the relationship between longitudinal trajectories of 
cholesterol and AD.  A study conducted by Stewart et al. (2007) examined the longitudinal 
trajectories of total cholesterol according to dementia status utilizing data from the Honolulu-Asia 
Aging study.  In this study, men who developed AD exhibited an accelerated decline in total 
cholesterol compared to men who did not develop dementia, whereas the opposite relationship 
was observed among men in the FHS Original Cohort.  Men who did not develop AD in the FHS 
Original Cohort exhibited a greater rate of decline in total cholesterol beginning at 45 to 50 years 
of age compared to men who eventually developed AD.  Furthermore, men who did not develop 
AD had higher cholesterol during midlife and lower cholesterol during late life compared to men 
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who did develop AD.  These findings conflict with findings from previous studies that have 
reported high total cholesterol during midlife (Notkola et al., 1998; Solomon, Kivipelto, et al., 
2009) and low total cholesterol during late life (Reitz et al., 2004; Siest et al., 2000) to be 
associated with AD.  The findings from Specific Aim Two are consistent with a study conducted 
by Lesser et al. (2001) in which older adults with AD had, on average, higher total cholesterol 
and HDL cholesterol compared to older adults without dementia.  Furthermore, a study conducted 
by Solomon et al. (2007) observed that subjects who developed dementia had a significantly 
greater decline in total cholesterol from midlife to late life, but had higher concentrations of total 
cholesterol during midlife and late life compared to older adults without dementia.      
One hypothesis for an age-dependent relationship between peripheral cholesterol and AD 
is that high peripheral cholesterol contributes to an increase in AD neuropathology, which may 
lead to a decline in cholesterol due to a disruption in neurological mechanisms that regulate 
peripheral cholesterol homeostasis (Mielke et al., 2005).  The findings from this Specific Aim do 
not support such a hypothesis19.  Rather, the longitudinal trajectories of total cholesterol 
according to AD status suggest that men in particular with high cholesterol during midlife, who 
are able to reduce their cholesterol later in life, may be less likely to develop AD compared to 
men who do not reduce their cholesterol with advancing age. The use of cholesterol lowering 
medications was controlled for in the analysis and there were no differences in the use of 
cholesterol lowering medications among men according to AD status.  Other factors that may 
lower total cholesterol, such as consuming a low fat diet and regular physical activity, may 
contribute to the apparent decline in cholesterol during midlife among men who do not develop 
AD.  
Limitations:  Certain limitations in this Specific Aim Two need to be acknowledged.  
First, potentially important covariates such as smoking, measures for blood pressure and blood 
                                                        
19 A significant limitation of the hypothesis proposed by Mielke (2005) is the blood brain barrier 
effectively limits the exchange of cholesterol between the periphery and the brain.  
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glucose, and use of cholesterol lowering medications, were not able to be included in the models 
as time-dependent covariates.  A time-dependent covariate means that the value or status of the 
variable changes over time, whereas the vale or status of a time-independent covariate remains 
fixed for the duration of the study, e.g. sex.  Dichotomizing subjects as ever smokers and ever 
medication users, or calculating the averages for blood pressure and blood glucose may, for 
example, oversimplify the potential relationship between these variables and the trajectories of 
cholesterol.  This is a possible explanation for why adjusted R2 values in the models did not 
substantially change as these covariates were added to the models.  An alternative approach that 
was used in the dissertation research was to calculate the total number of clinical examinations 
that a person reported being a smoker or taking cholesterol lowering medications.  This was done 
to account for the duration in which a person was a smoker or took cholesterol-lowering 
medications.  A limitation of this approach, however, was it did not account for differences 
between subjects in the number of times a subject was observed over the course of the study.  To 
clarify, a subject who attended twelve clinical examinations and reported smoking during six 
examinations is likely to be much different compared to a subject who attended seven 
examinations and reported smoking during six examinations.  The difference in the number of 
clinical examinations attended by the two subjects is potentially meaningful because of the higher 
proportion of clinical exams in which the second subject reported smoking.  Additional research 
can address this limitation by including the ratio of clinical exams in which a subject reported 
smoking or using cholesterol-lowering medications as covariates.  A second limitation of treating 
smoking and medication use as time-independent covariates is the age in which a person started 
or stopped these behaviors and the duration of these behaviors are not accounted for in the 
analysis.  This can be addressed by including the age in which a person first reported smoking or 
using cholesterol-lowering medications as covariates in the models. 
Another limitation is that data regarding the use of symptomatic treatments for AD, such 
as Donepezil and Memantine, do not appear to have been collected from subjects of the FHS 
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Original Cohort.  The use of symptomatic treatments for AD may be an important confounding 
variable because there is evidence that acetylcholinesterase inhibitors (AChEI) influence 
cholesterol levels.  In a cross-sectional study of 105 AD patients conducted by Adunsky, Chesnin, 
Ravona, Harats, and Davidson (2004), patients who had been prescribed donepezil (n=35) had 
significantly higher total cholesterol, VLDL, LDL, and triglycerides, but not HDL cholesterol, 
compared to AD patients who had not been prescribed donepezil.  Furthermore, efficacy of 
atorvastatin, a frequently prescribed cholesterol medication commonly known as Lipitor, for the 
treatment of mild to moderate AD has been shown to be higher among patients with total 
cholesterol levels above 220 mg/dl compared to patients with total cholesterol < 200 mg/dl 
(Sparks et al., 2006).  These findings provide evidence that the higher cholesterol among older 
adults who developed AD relative to subjects without dementia may be due to a healthy volunteer 
bias among AD subjects.  Older adults diagnosed with AD who remained in the FHS may have 
been able to do so because of their use of AChEI and other symptomatic treatments for AD, 
which may have altered their lipid profile.   
 Conclusion:  The findings from Specific Aim Two do not provide sufficient evidence that 
the longitudinal trajectories of total cholesterol, HDL cholesterol and total/HDL cholesterol ratio 
differ between older adults with AD and those without dementia.  Immediate attention should be 
placed on conducting research that uses more refined techniques for controlling for the effects of 
smoking and medication use.  These techniques should focus on accounting for the timing and 
duration of smoking and medication use.  Additional research should also focus on quantifying 
the differences in cholesterol according to AD status that were identified in this dissertation 
research using other longitudinal methods such as group based modeling.  Finally, future research 
should focus on generating evidence that provides insight into potential biological mechanisms 
that support cholesterol being an important risk factor for AD and the potential confounding 
effects of symptomatic treatments for AD.  An area of research worth investigating is examining 
if cholesterol outside of the brain is correlated with measures of biomarkers that reflect 
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pathological changes in the brain consistent with AD.  A significant relationship between 
cholesterol and AD biomarkers would provide evidence that there are potential biological 
mechanisms that explain how abnormal concentrations of cholesterol during the life span modify 
the risk for AD.  Plausible biological mechanisms for a relationship between cholesterol and AD 
would justify additional research in this area.  
Specific Aim Three 
 There is considerable heterogeneity in cognitive functioning among older adults who do 
not have dementia and subtle cognitive impairment may be an early warning sign of dementia.  
This, along with evidence for a significant relationship between total cholesterol and cognitive 
functioning among older adults without dementia (Elias, Elias, D'Agostino, Sullivan, & Wolf, 
2005; Henderson, Guthrie, & Dennerstein, 2003; Solomon, Kareholt, et al., 2009), were the 
motivating factors for investigating if there is a visually apparent relationship between a person’s 
unique trajectory of total cholesterol and cognitive functioning during old age.   
 Specific Aim Three utilized a longitudinal study design to examine the relationship 
between subject-specific trajectories of total cholesterol from midlife to late life and cognitive 
functioning among older adults without dementia.  There was not strong visual evidence for a 
relationship between the subject-specific trajectories of total cholesterol from midlife to late life 
and a subject’s level of cognitive functioning during old age.  When the averages of the subject-
specific trajectories for each of the cognitive quartiles were examined, subjects in the fourth 
quartile had significantly lower total cholesterol compared to the second and third quartiles at 55 
years of age.  However, the estimated difference in total cholesterol between the two groups was 
only 5.7 mg/dl and this difference, while statistically significant, is unlikely to have significant 
clinical meaning.  Subjects in the first cognitive quartile also had lower total cholesterol at 55 
years of age compared to the second and third quartiles, but this difference was not statistically 
significant.  Interaction terms between the linear term and cognition, and the quadratic term and 
cognition were included in the mixed effects models to determine if the trajectories of total 
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cholesterol from midlife to late life differed according to cognitive quartile.  Neither of the 
interaction terms were statistically significant indicating that there was not a significant difference 
in the mean trajectories of total cholesterol from midlife to late life according to cognitive 
quartile.            
    The results from this Specific Aim align with a study reporting that high total cholesterol 
during midlife (age 47 - 51) was associated with lower episodic memory and psychomotor speed 
twenty-one years later (Solomon, Kareholt, et al., 2009).  However, another study that utilized 
data from the FHS Original Cohort reported that non-demented older adults, between the ages of 
55 and 88 during the 14th or 15th clinical examination, whose average total cholesterol from the 4th 
through 12th clinical examinations was < 200 mg/dl had lower cognitive functioning compared to 
subjects whose average measures of total cholesterol were between 200 to 239 mg/dl or > 240 
mg/dl (Elias et al., 2005).  Also, Henderson et al. (2003) reported a positive correlation among 
healthy women 52 to 63 years of age between memory function and an increase in total 
cholesterol eight years before memory function was assessed.  Finally, a study of adults 65 years 
of age and older did not report a significant relationship between total cholesterol and memory or 
language (Reitz, Luchsinger, Tang, Manly, & Mayeux, 2005).   
 There are several explanations for the apparent differences in the findings of aim three of 
the dissertation research compared to the findings reported by Elias et al. (2005).  First, there are 
important differences in overall approaches of the two studies.  Based on how the repeated 
measures of total cholesterol were utilized in the analysis, Elias et al. (2005) were able to 
determine if the average measure of total cholesterol during a prolonged period is associated with 
cognitive functioning later in life.  This approach did not allow for potentially important changes 
in the trajectory of total cholesterol to be detected, which was the purpose of the Third Specific 
Aim.  Second, the wide age range of subjects included in the final sample by Elias et al. (2005) 
may have influenced the relationship between total cholesterol and cognition.  The age range of 
subjects during the 4th through 12th clinical examinations was between 30 and 35 years, with the 
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youngest subject during the 4th clinical examination being 34 years of age and the oldest being 69 
years of age.  The findings presented in Chapter Three of this dissertation indicate a strong 
relationship between total cholesterol and chronological age in the FHS Original Cohort, with 
total cholesterol increasing during midlife and declining later in life.  Subjects who were in their 
thirties during the fourth clinical examination likely exhibited an increase in total cholesterol 
during the subsequent nine clinical examinations, whereas total cholesterol likely decreased over 
the same period for subjects in the 50’s and 60’s during the fourth clinical examination.  While 
age was included as a covariate by Elias et al. (2005), this may not have fully accounted for the 
potential confounding effects of age on the relationship between cholesterol and cognition.  A 
third explanation is the unique characteristics of the Offspring and Original Cohorts that may 
contribute to the differences in total cholesterol across the life span.  These characteristics have 
been highlighted in Chapter Three of this dissertation. 
 Limitations:  There are limitations of the research for Specific Aim Three that need to be 
acknowledged.  First, potentially important covariates, such as smoking, use of cholesterol 
lowering medications, blood pressure and blood glucose were included in the models as time-
independent covariates.  Not taking into account the time-dependent nature of these covariates 
may not adequately adjust for the effects that these variables have on the relationship between 
cholesterol and AD.  This is especially relevant for smoking and medication use because the age 
and duration of these behaviors influence vascular health (Celermajer et al., 1993; Dempsey & 
Moore, 1992; Herrington et al., 2002; Young-Xu et al., 2003).  A second limitation is that 
characterizing non-linear trajectories using mixed effects models requires specifying a functional 
form by including quadratic, cubic or higher order polynomial terms in the model.  Imposing a 
predetermined structure on the data may be too restrictive and this was the motivating factor for 
utilizing GAMM in Specific Aim Two.  Despite this limitation, mixed effects models were still 
utilized for Specific Aim Three because the methods that allow for smoothing terms to be applied 
to subject-specific trajectories fall outside the feasible limits of the immediate dissertation 
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research.  Finally, dividing subjects into quartiles according to their cognitive summary score 
does not take into account that some older adults maintain normal functioning in certain cognitive 
domains but may have impairment in other cognitive domains.  This prevented potential 
relationships between the subject-specific trajectories of total cholesterol and specific cognitive 
domains from being detected.  Identifying subjects who are ILMTB, MDITB and normal cognition 
and then examining the subject-specific trajectories of total cholesterol according to these 
cognitive groups can address this limitation. 
 Conclusion:  To summarize, the findings from this Specific Aim do not provide strong 
evidence of a significant relationship between an individual’s unique trajectory for total 
cholesterol from midlife to late life and their level of cognitive functioning during old age.  
Subjects who were in the highest quartile for cognitive functioning had significantly lower total 
cholesterol compared to subjects in the middle two cognitive quartiles.  Additional research is 
needed to clarify the relationship between the longitudinal trajectories of total cholesterol and 
cognitive functioning later in life.  This research should focus on incorporating the duration of 
smoking and cholesterol medication use, as well as the age in which these behaviors started, into 
the analysis as these characteristics may play an important role in the relationship between 
cholesterol and cognitive function. 
The Life Course as a Conceptual Lens 
 The life span perspective is well suited for conducting research that is focused on 
understanding the developmental characteristics of humans as they age, identifying factors that 
may modify physiological, intellectual or other developmental characteristics with advancing age, 
or the relationship between different developmental stages.  This dissertation employed a life 
span perspective by examining trajectories of cholesterol from midlife to late life to determine if 
these trajectories were related to AD and cognitive functioning later in life.  A life span approach 
also supports an age-continuous view to reveal subtle but potentially important time points of 
change that are often obscured by a life stage emphasis.  This approach offers avenues to advance 
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current understanding of the relationship between cholesterol and cognition, but does not prove 
an adequate conceptual framework for examining the true complexity of the interacting factors 
that influence cholesterol levels through the life span and their association with cognitive 
functioning during old age.  A life course view may resolve this shortcoming of the life span 
approach.   
 Simply put, the life course is a person’s life, or life span, in full context (J. F. Watkins, 
1999).  This context refers to the notion that aging is more than the passage of time measured 
chronologically by the accumulation of years.  Rather, aging is reflected by ongoing changes that 
occur within personal (e.g. physical, cognitive and psychological) and social (e.g. family, work 
and education) domains from birth until death (Settersten, 2006).  Many of the significant events 
and transitions that occur within these personal and social domains (e.g. acquiring verbal 
language, puberty, graduating high school, leaving the family home, entering the workforce) are 
highly correlated with chronological age.  This has made chronological age a useful index for 
predicting a person’s physical, cognitive or psychological characteristics, as well as their social 
standing and the roles a person is expected to fill within society (Settersten & Mayer, 1997).  
Furthermore, this use of chronological age has resulted in normative behaviors and characteristics 
associated with distinct life stages that are socially constructed.  This leads to the expectation that 
people move through the life course in a sequential fashion that follows a predictable order and 
questions or concerns are often raised when a person deviates from these social norms (e.g. 
developmental delays during childhood, teenage pregnancy, older adult in a college classroom).  
The variability in the timing and order in which events, experiences and transitions within 
personal and social domains occur are due to the influence that family, education, health, and 
social and cultural factors (e.g. cohort effects) and the complex interactions between these factors 
have on a person’s life course.  These factors provide the context of the life span and introduce 
the socio-cultural influences that shape the life course.  Additional layers of complexity are added 
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to this context when the influences of time (past, present, future), space (the environment in 
which events occur), and the actions of those around us are taken into account.   
 The scholarly pursuit of identifying factors that modify the timing and ordering of the life 
course and the potential implications that mistimed events and transitions have on later life 
outcomes has made the life course an extensively studied area of research.  However, the 
concepts of the life course are valuable tools for developing research questions, designing studies 
and even influencing data collection (Elder et al., 2003; Settersten, 2006).  Engaging the life 
course as a conceptual research framework is the focus of the rest of this chapter.  The remainder 
of this chapter is organized as follows.  First, the core concepts of the life course are presented 
along examples from relevant areas of research.  Next, the application of life course concepts in 
epidemiology is introduced.  These sections are meant to provide sufficient background 
knowledge on life course concepts so that the influence these concepts have for conceptualizing 
future research in AD can be better appreciated.  This chapter concludes by describing how life 
course concepts can be applied to future research that will, hopefully, advance the current 
scientific understanding of AD.  
Concepts of the Life Course 
Every person has their own unique life course that is shaped by (1) endogenous (internal) 
and exogenous (external) factors, (2) early life choices, events and experiences, as well as the 
choices, events and experiences we anticipate happening in the future, (3) the timing in which 
events, experiences, and transitions occur and (4) the interdependence in which people live their 
lives with those around them.  
     Endogenous and Exogenous Factors that Shape the Life Course:  Endogenous factors 
that shape a person’s life course include the genes they inherit from their parents, their physical 
and mental traits, as well as their intelligence, and emotional and personality characteristics.  
Endogenous factors shape a person’s life course by influencing the choices and decisions a person 
makes in response to their environment.  Exogenous factors that shape a person’s life course may 
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be grouped into distinct life domains20.  These domains include: (1) Family, which includes 
personal relationships outside of our immediate and extended family; (2) Place and home, which 
refers to the places/homes that we have lived, as well as personal notions of home; (3) Education, 
which includes formal learning experiences (e.g. high school, college) and informal learning 
experiences (e.g. learning a skill from a family member); (4) Employment, which includes formal 
work experiences (e.g. paying jobs) and informal work experiences (e.g. helping a friend for no 
pay); (5) Recreation and leisure, which are the hobbies and activities we engage in for enjoyment; 
(6) Spirituality, which includes traditional religious activities as well as personal beliefs; (7) 
Historical context, which is the current cultural and social environment that is shaped by 
significant events (e.g. war, economic climate, or political events); and (8) Health, which includes 
personal and family health characteristics, significant health events and health behaviors.  
 Components of Time and Space: The notion that the life course is influenced by events 
and experiences that occurred earlier in life is one of the key constructs of the life course 
perspective.  In some cases the influence of an event or experience on the life course is 
immediately apparent, such as getting married or having a child.  Other times the significance of a 
past event is not recognized until many years later once a person has been able to reflect back on 
their experiences.  The majority of life course scholars emphasize the influence an actual event or 
experience has on a person’s life course, but the memories associated with that event or 
experience often times have far greater implications than the event itself.  This is especially 
relevant for life course research that is interested in outcomes among older adults.  Normative 
declines in memory can make it challenging to recall the specific details of a past experience or 
the details may become altered or exaggerated as a result of a person rehearsing the story in their 
mind. 
                                                        
20 The formal conceptualization of life domains is largely unpublished.  Focus has been given to 
the domains of education, family, work, and historical context and the influence of these domains 
on the life course (Elder, 1994, 1998; Elder, Shanahan, & Clipp, 1994), but less attention has 
been given to leisure (Settersten, 2006), health (Moser & Watkins, 2008; Settersten, 2006) and 
the interdependence of the life domains (Hosier, Downer, Watkins, & Zanjani, 2012a). 
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 The influence of previous events and experiences on the life course provides a link 
between the past and the present, but the present is also linked with the future.  Many of the 
choices and decisions we make in the present are made with the mindset of what we anticipate 
may happen in the future.  This may include a person deciding to start saving for college once 
their child is born in the anticipation that their child will want to attend college or a person 
choosing to complete an advanced directive in case they are unable to express the type of medical 
care they want to receive.  The future time frame of the life course is often times neglected by 
researchers, but recognizing the influence that anticipated events have on the present has 
significant implications for research that is focused on identifying motivating factors for present 
health behaviors.  These implications are elaborated upon in subsequent sections of this chapter. 
 The concept of space is important for the context of the life course because it emphasizes 
the socio-cultural factors that influence a person’s life.  Space refers to the environment in which 
events and experiences take place.  There are several different levels, or zones, of space that 
range from “personal” space all the way to the social and cultural environments in which people 
live their lives.  Social and cultural factors play an important role in shaping the life course 
because these factors can change over time as significant events alter social and cultural norms.  
These changes in social and cultural norms often times manifest as cohort effects. 
 Influence of Timing on the Life Course:  Chronological age by itself has little meaning 
and age alone is typically not accepted as a valid explanation for a behavior or health event.  The 
perceived significance of chronological age is due to the correlation between chronological age 
and important biological, physical, cognitive, behavioral and social characteristics or events.  
Significant educational, career, or family events often times mark the transition from one distinct 
life stage to another.  For example, leaving a parent’s home, graduating from college and entering 
the workforce is a series of life events within the domains of family, education and work that 
signify the transition from young adulthood into adulthood.  The correlation between 
chronological age and events within socially constructed domains has allowed for the life course 
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to be recognized as a collection of distinct and sequential life stages (e.g. childhood, adolescence, 
young adulthood middle age and old age).  The structuring of the life course serves an important 
purpose because it guides members of a society on what role they are expected to play in society, 
as well as plan for significant life events, such as marriage or retirement, which tend to occur 
within a specific age range.   
 The principle of timing proposes that the effect a significant life event has on a persons 
life course depends on the timing in which the event occurs (Elder et al., 2003).  Because many 
social constructs, such as education and work, are structured according to chronological age, a 
person’s life course can be altered if they experience a significant life event at an age that is not 
within the normative age range imposed by their cultural or society.  For example, early entry into 
parenthood often times has dramatic consequences and teenage mothers and fathers complete 
fewer years of education (Pirog-Good, 1993), are more likely to require government assistance 
(Bissell, 2000), and have lower income during adulthood (Moore et al., 1993) compared to those 
who delay parenthood.  
 The effect of timing on the life course is exemplified by the study The Children of the 
Great Depression (Elder, 1974).  In this study, Elder utilized data from the Oakland Growth Study 
and Berkeley Guidance Study to examine the effects that economic deprivation early in life, as a 
consequence of the Great Depression, had on educational attainment, career success and family 
during adulthood and if these effects differed based on the age in which children experienced the 
Great Depression.  The children of the Oakland Growth Study were born during the early 1920’s 
and were able to progress through childhood during the stable economic climate prior to the Great 
Depression, whereas children of the Berkeley Guidance Study were born during the late 1920’s 
and experienced early childhood during the worst period of the Great Depression (Elder, 1998).  
In general, children of the Oakland Growth Study had better outcomes for educational attainment, 
work, and family during adulthood compared to the children of the Berkeley Guidance Study.  
Elder attributed these differences between the Oakland Growth Study and Berkeley Guidance 
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Study to the different life experiences of the two cohorts during the Great Depression. The 
hardships and disadvantages experienced by the participants the Berkeley Guidance Study during 
childhood influenced their life course trajectories in education, career and family through 
adolescence and young adulthood, and caused the trajectories of these domains to be much 
different than those for children born several years earlier. 
 Interdependence of Lives: The notion that a person’s life course is shaped by the choices, 
behaviors and actions of others is an important characteristic of the life course perspective (Elder 
et al., 2003).  The influence of the interdependent nature in which people live their lives on the 
life course is exemplified by examining how children’s health behaviors are often modeled after 
the behavior of their parents.  In a study examining parental smoking history and adolescent 
smoking behavior, adolescents who had one parent who was a current smoker were 2.3 times as 
likely to have ever tried smoking and adolescents with two parents who were current smokers 
were four times as likely to have ever tried smoking compared to adolescents whose parents were 
never smokers (den Exter Blokland, Engels, Hale, Meeus, & Willemsen, 2004).   
 The social implications of the principle of linked lives are apparent by research on the 
relationship between social networks and smoking behavior (Christakis & Fowler, 2008).  
Utilizing data from the FHS, Christakis and Fowler (2008) observed that people whose spouse 
quit smoking decreased that person’s chances of smoking by 67 percent, if a sibling quit smoking 
then that person’s chances of smoking decreased by 25 percent and if a co-worker quit smoking 
then that person’s chances of smoking decreased by 34 percent.  Relationships between social 
networks and social connectedness for self-reported levels of happiness (Fowler & Christakis, 
2008) and obesity (Christakis & Fowler, 2007) have also been observed in the FHS.  
In order to fully appreciate the complexity of the life course, it is necessary to examine the 
interplay between all of the factors that shape the life course.  An example is to identify the 
factors that may influence a person’s career choice as an adult.  The type of career a person 
chooses to pursue is likely to have been influenced by their intellectual capacity, previous 
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educational experiences and family expectations.  A person who exceled in school from an early 
age due to their natural ability to learn or because their parents had the means to provided them 
with resources that fostered educational development will likely have different career aspirations 
compared to a child who struggled early on in school due to delays in intellectual development or 
because their family did not place significant importance on education.  A person’s career choices 
may be further modified based on the current social and economic environment in which they 
live.  For example, college students who graduate during an economic recession may choose to 
attend graduate school to pursue an advanced degree or to receive training in a profession that 
may show promising opportunities for gainful employment. 
The Life Course as a Research Perspective    
As a research perspective, Elder et al. (2003) describes the life course as a conceptual 
framework for creating research questions, developing concepts and designing studies.  
Following Elder’s landmark study The Children of the Great Depression (Elder, 1974), there has 
been a steady increase in the amount of research that has utilized a life course perspective due to 
the growing appreciation for the complex interplay between the domains of people’s lives and the 
influence that social and cultural characteristics have on these relationships.  The majority of 
research has focused on the influence that interactions within socially constructed domains, such 
as family, education and work have on the life course and only recently has the influence of 
health on the life course begun to receive attention by the life course research community.  In one 
of the first studies to utilize a life course perspective to study health, Elder et al. (1994) examined 
the effects that late military deployment to World War II (i.e. deployment after age 33) had on the 
health outcomes of men later in life.  In general, men who were older than 33 years of age upon 
military deployment were at greater risk for poor physical health after returning from war 
compared to men who were deployed at a younger age potentially as a consequence of more 
severe disruptions to work, family and other domains of social support. 
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Life Course Epidemiology: The majority of life course research has been conducted in the 
fields of psychology, sociology, demography and related disciplines, but the life course 
perspective has begun to be utilized by other disciplines.  Epidemiology is one such discipline 
that has adopted a life course perspective to study the potential long-term effects that biological, 
behavioral and psychosocial exposures during gestation, childhood, adolescence, young 
adulthood and across generations have on health outcomes during adulthood (Kuh & Ben-
Shlomo, 2004).  The purpose of life course epidemiology is to examine the cumulative effects 
that prolonged exposures to specific risk factors have on disease risk later in life (Ben-Shlomo & 
Kuh, 2002), the temporal relationship between risk factors (Kuh et al., 2003) and to identify 
critical periods during the life span where interventions can have the greatest impact for 
modifying disease risk (Launer, 2005).  Based on the description of life course epidemiology, it is 
clear that the motivation for applying a life course perspective to epidemiological research is the 
relationship between early life events and health outcomes later in life.  This aspect of the life 
course is not different than the life span framework and if life course epidemiology were only 
interested in examining the relationship between early life exposures and later life outcomes then 
it would be more appropriate to use the term life span epidemiology.  However, the use of the 
term life course is justified for two reasons.  First is the emphasis by life course epidemiology that 
generations are linked by common genetic and social factors and that these commonalities may 
influence health.  Second, life course epidemiology recognizes the dynamic nature of socio-
cultural factors and that secular changes in specific risk factors influence the overall health of a 
population. 
Life Course as a Conceptual Lens for Alzheimer’s Disease Research 
There is strong empirical evidence that the biological cascade of events that may 
ultimately lead to AD is initiated many years or even decades before cognitive decline is 
observed.  This, along with the identification of several midlife risk factors for poor cognition and 
AD later in life, have contributed to the growing interest in a life course approach to study AD 
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(Launer, 2005; Whalley, Dick, & McNeill, 2006).  However, AD research has been focused on 
examining biopsychosocial characteristics during midlife and there has been limited research that 
has examined characteristics earlier in the life span.  Midlife is a critical period for preventing AD 
because the pathological changes to the brain associated with AD are unlikely to have occurred, 
but it is necessary to consider the factors that influence health outcomes during midlife when 
utilizing a life course perspective to study AD.   
Many of the midlife risk factors that have been associated with AD can be linked with 
living in a disadvantaged environment.  Children who grow up in poverty are more likely to 
engage in poor health behaviors (van de Mheen, Stronks, Looman, & Mackenbach, 1998), be 
diagnosed with a chronic disease (Kittleson et al., 2006; van de Mheen et al., 1998), and have 
lower educational attainment (Lawlor et al., 2005) as adults compared to children who grew up in 
families of moderate or high socioeconomic status.  When examined using a life course 
perspective, several pathways that link childhood socioeconomic status (SES) with adult health 
can be identified (S. Cohen, Janicki-Deverts, Chen, & Matthews, 2010).  An example is the 
influence that SES has on the physical environment and how this may modify psychological and 
physical development.  A child born into a family of low SES may live in an overcrowded home 
that is in a neighborhood with poor air and water quality and limited access to education.  These 
disadvantages may cause a child to have developmental delays in language and reading due to 
limited educational opportunities, consume a poor diet because of limited access to healthy foods, 
and not engage in physical activity because their neighborhood is to dangerous to play outside.  
Collectively, these disadvantages increase the risk for poor health as an adult and ultimately 
increase the risk for poor cognitive functioning during old age if the person maintains their 
current behavior.  Compare this to a child who grows up in a family of moderate or high SES who 
may live in a stable home in a neighborhood with good air and water quality and access to quality 
educational opportunities.  These advantages early in life would allow for a child to excel in 
school from an early age and engage in positive health behaviors by modeling the behaviors of 
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their parents.  Collectively, these advantages decrease the risk for poor health as an adult and may 
ultimately decrease the likelihood of having poor cognitive functioning later in life if the person 
maintains their current behaviors.    
The challenge of identifying potential AD risk factors prior to midlife is there are not 
longitudinal studies that have sufficiently examined the physical, behavioral and social 
characteristics of participants beginning in childhood through old age.  An alternative approach 
would be to have participants recall what their physical environment was like as a child and how 
their environment influenced their psychological and physical development.  This approach is not 
realistic because of the difficulty of accurately recalling childhood experiences, especially among 
older adults who may be cognitively impaired.  The FHS provides a unique opportunity to 
conduct life course research on AD because of the multi-generational design of the study.  As 
previously described, the life course principle of linked lives states that people live their lives 
interdependently.  Therefore, examining the social and behavioral characteristics of participants 
of the Original Cohort can provide broad insight into what the physical environment may have 
been like for participants of the FHS Offspring Cohort during childhood.  The influences that 
parental socioeconomic status, health behaviors and health characteristics have on the health 
characteristics of subsequent generations can then be examined by linking data between the 
Original and Offspring Cohorts.  Since a large proportion of the Offspring Cohort was over 60 
years of age upon receiving a neuropsychological battery, the influence that parental 
characteristics have on the cognitive functioning among children who have progressed to old age 
can be examined.  The findings from this research have the potential to provide empirical 
evidence that cognitive functioning during old age is influenced by parental characteristics.   
The majority of life course research has focused on the relationship between early life 
experiences and circumstances and later life outcomes, but it is important to not discount the 
influence that the anticipation of future events has on behavior and decision-making in the 
present.  There is ongoing research that is examining how perceptions of future risk for AD 
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influences present behaviors.  The Risk Evaluation and Education for Alzheimer’s disease 
(REVEAL) Study is an ongoing study in which healthy adults are informed of their APOE 
genotype and are provided with a numerical risk assessment for AD based on their gender, age, 
family history and APOE genotype (Roberts et al., 2005).  The findings from the REVEAL Study 
indicate that adults who learn they carry one or more copies of the APOE e4 allele are more likely 
to start engaging in health behaviors that may reduce their risk for AD later in life, such as 
changes to diet, exercise and medication or vitamin use, compared to adults who learned that they 
did not carry an APOE e4 allele.  This research exemplifies how anticipated future events can 
influence present behavior.   
Engaging a Life Course Approach to the Dissertation Research 
  The principles of the life course perspective can be utilized to create novel research 
questions based on the findings generated by the dissertation research.  One of the most important 
principles of the life course perspective is that the timing in which an event or experience occurs 
may have a significant impact on a person’s life course.  Aims two and three of the dissertation 
research modeled the trajectories of cholesterol according to chronological age, but an alternative 
approach would be to model the trajectories of cholesterol in relation to the age in which AD was 
diagnosed and determine if the trajectories of cholesterol differ before and after a diagnosis of 
AD has been given.  In this approach, the age in which a person was diagnosed with AD is 
subtracted from their age during each observation period.  The age in which a person was 
diagnosed with AD would be zero and the time (in years) prior to AD diagnosis would be 
negative and the time after diagnosis would be positive.  This approach takes into account the 
variability in age at which subjects are diagnosed with AD by setting the time of diagnosis to 
zero.   This method may provide insight to whether a distinct change in the trajectory of 
cholesterol occurs a certain number of years before a subject is diagnosed with AD.  A limitation 
of this approach is that subjects who do not develop AD would be excluded from the analysis and 
therefore the trajectories of cholesterol for AD subjects could not be compared to a control group.   
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 AD risk may also be modified according to the age at which a person is able to begin 
controlling high cholesterol.  The findings from aim two indicate that men who do not develop 
AD have higher total cholesterol during midlife, but exhibit a decline in total cholesterol at a 
younger age compared to men who go on to develop AD.  This suggests that the age at which a 
person is able to reduce their cholesterol influences their risk of developing AD.  If the reduction 
in cholesterol is due to changes in diet, exercise or from using cholesterol-lowering medications, 
then this can provide insight into when interventions that target high cholesterol may have the 
most lasting effects for cognitive functioning later in life. 
 The above examples demonstrate that the concepts of the life course perspective are 
useful tools for conceptualizing future research.  These two examples, however, would still be 
categorized as life span research because neither example took into account the socio-cultural 
context of the life span, which is necessary for a life course study.  A life course study of the 
relationship between cholesterol and AD would need to include data that incorporates the social 
and cultural factors that influence cholesterol levels and cognitive functioning.  These factors may 
include government mandates on displaying nutritional information on restaurant menus, 
regulations on the amount of trans-fats in food, or changes in Food and Drug Administration 
guidelines for cholesterol medications.  These social changes influence the behavior of 
individuals and may contribute to secular changes in cholesterol levels and AD incidence and 
prevalence as a result of overall improved vascular health at the population level.  A challenge to 
a life course study on the relationship between cholesterol and AD is this research requires 
individual level (e.g. age, cholesterol, cognitive function) and population level (e.g. income 
inequality, unemployment rate, access to medical care) data that have been collected 
simultaneously.  Merging population and individual level data can create appropriate data sets to 
examine the influence that social and cultural factors may have on the relationship between 
cholesterol and cognitive functioning during old age.  This area of research could advance the 
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current understanding of AD from a public policy perspective by examining how social and 
cultural characteristics influence the cognitive and vascular health of older adults.  
Conclusion 
 Much of the public’s perception of research is driven by how results are presented by 
large media outlets.  Popular news sources, such as the New York Times and Time Magazine, have 
columns dedicated to summarizing current research on potentially significant discoveries in 
regards to diagnosing and treating various diseases, and things people can incorporate into their 
daily routines to decrease their risk for developing a certain disease or condition.  While 
disseminating current research to the general public via large media outlets is important for 
keeping people informed, it is easy to become confused or misled when results that seemingly 
conflict with prior research are presented.  Therefore, it is important to always consider how the 
public may perceive findings from research and how results fit with the public’s perception of 
health and aging.  This is particularly relevant to this dissertation research because there is a 
strong perception among the general public that cholesterol is detrimental to health because of the 
established relationship between high cholesterol and heart disease.  This makes it necessary to 
critique the dissertation research, and other epidemiological studies that have examined the 
relationship between cholesterol and AD, within the context of the public’s perception towards 
cholesterol, health, and aging.   
This dissertation research presents limited evidence that older adults diagnosed with AD 
maintain higher cholesterol from midlife to late life compared to older adults without dementia, 
and that lower cholesterol during midlife is associated with higher cognition during old age.  
These findings generally support the public health narrative that cholesterol is detrimental to 
health and that controlling cholesterol through dietary changes, exercise, and cholesterol lowering 
medications may decrease the risk for adverse health outcomes during old age.  An informed 
member of the general public may counter with the argument that they have read reports that 
suggest older adults diagnosed with AD have lower cholesterol compared to older adults without 
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dementia and a drop in cholesterol is a risk factor for AD.  This may lead a person to make the 
conclusion that maintaining higher levels of cholesterol protects against AD and may be hesitant 
to lower their cholesterol.  This conflict can be resolved by providing contextual information on 
the aging process and the normative and pathological changes that occur with advancing age.  
Aging is characterized by normative declines in physiological and cognitive domains that, 
collectively, contribute to a prolonged and progressive decline in functioning and quality of life.  
As a person approaches death, however, these declines accelerate in what has been described as a 
terminal drop or terminal decline (Gerstorf et al., 2010; Siegler, 1975).  A plausible explanation 
for the observed relationship between low cholesterol and AD is that AD or symptomatic 
treatments for disease symptoms exacerbate this terminal decline by negatively affecting systems 
involved in cholesterol homeostasis, such as liver function (Giambattistelli et al., 2012; Squitti et 
al., 2007), cholesterol metabolism (Kolsch et al., 2010; Kolsch et al., 2004), and appetite (Ikeda, 
Brown, Holland, Fukuhara, & Hodges, 2002).  Therefore, older adults who exhibit an unintended 
drop in cholesterol may be at a greater risk for AD compared to older adults who intentionally 
lowered their cholesterol through dietary changes, physical exercise, or with cholesterol lowering 
medications.  
This dissertation research focused on the relationships between longitudinal trajectories 
of cholesterol, AD and cognitive functioning later in life.  This research also explored the utility 
of creating summary scores of cognitive functioning that were based on cognitive performance on 
individual subtests of a neuropsychological battery to differentiate between subjects with normal 
cognition, cognitive impairment and dementia. The results from the dissertation research indicate 
that a summary score that provides equal weight to subtests of a neuropsychological battery is 
better able to differentiate between subjects that have been classified as having normal cognition, 
ILMTB, MDITB, and dementia.  There were subtle differences in the longitudinal trajectories of 
total cholesterol, HDL cholesterol and total/HDL ratio from midlife to late life according to AD 
status.  The potential significance of these differences should be interpreted with caution, as they 
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may not be clinically meaningful.  There was not strong visual evidence for a relationship 
between subject-specific trajectories of total cholesterol from midlife to late life and cognition 
later in life, but older adults in the highest quartile for cognitive functioning had slightly lower 
total cholesterol at approximately 55 years of age.   
The results of the dissertation research brought to light important research questions on 
the relationship between longitudinal trajectories of cholesterol, AD and cognitive functioning 
later in life.  Future research should utilize a life course perspective to determine if the timing in 
which a decline in cholesterol occurs is associated with AD and cognitive functioning later in life.  
Furthermore, a life course perspective may also be able to provide insight into if perceptions of 
the future risk of AD and poor cognitive functioning influences present health behaviors.  
Studying the relationship between cholesterol, AD and cognitive functioning may generate 
evidence that can be applied to develop targeted interventions to improve the overall health of 
adults across the life span. 
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